CA2362538A1 - Secreted proteins and polynucleotides encoding them - Google Patents

Secreted proteins and polynucleotides encoding them Download PDF

Info

Publication number
CA2362538A1
CA2362538A1 CA002362538A CA2362538A CA2362538A1 CA 2362538 A1 CA2362538 A1 CA 2362538A1 CA 002362538 A CA002362538 A CA 002362538A CA 2362538 A CA2362538 A CA 2362538A CA 2362538 A1 CA2362538 A1 CA 2362538A1
Authority
CA
Canada
Prior art keywords
seq
nucleotide sequence
nucleotide
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002362538A
Other languages
French (fr)
Inventor
Dario Valenzuela
Olive Yuan
Heidi Hoffmann
Jeff Hall
Peter Rapiejko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphagene Inc
Original Assignee
Alphagene, Inc.
Dario Valenzuela
Olive Yuan
Heidi Hoffmann
Jeff Hall
Peter Rapiejko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphagene, Inc., Dario Valenzuela, Olive Yuan, Heidi Hoffmann, Jeff Hall, Peter Rapiejko filed Critical Alphagene, Inc.
Priority claimed from PCT/US2000/004340 external-priority patent/WO2000049134A1/en
Publication of CA2362538A1 publication Critical patent/CA2362538A1/en
Abandoned legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides secreted proteins and polynucleotides encoding them, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

Description

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
This application is a continuation-in-part of the following applications:
(1) application Ser. No. 09/298,733, filed April 23, 1999; which claims the benefit of provisional application Ser. No. 60/082,961, filed April 24, 1998, now abandoned;
(2) provisional application Ser. No. 60/120,680, filed February 19, 1999;
(3) provisional application Ser. No. 60/149,639, filed August 17, 1999;
(4) provisional application Ser. No. 60/155,686, filed September 23, 1999;
(5) provisional application Ser. No. 60/157,247, filed October 1, 1999;
(6) provisional application Ser. No. 60/167,823, filed November 29, 1999;
(7) provisional application Ser. No. 60/167,822, filed November 29, 1999;
2 0 (8) provisional application Ser. No. 60/XXX,XXX, filed February 15, 2000;
all of which are incorporated by reference herein.

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA
sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO: l from nucleotide 737 to nucleotide 5302;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO: l from nucleotide 782 to nucleotide 5302;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb24_1 deposited with the ATCC under accession number 207113;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 207113;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb24_1 deposited with the ATCC under accession number 207113;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone vb24_1 deposited with the ATCC under accession number 207113;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:2;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment 2 5 comprising eight contiguous amino acids of SEQ ID N0:2;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:l.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:1 from nucleotide 737 to nucleotide 5302; the nucleotide sequence of SEQ ID NO:l from nucleotide 782 to nucleotide 5302; the nucleotide sequence of the full-length protein coding sequence of clone vb24_1 deposited with the ATCC under accession number 207113; or the nucleotide sequence of a mature protein coding sequence of clone vb24_1 deposited with the ATCC under accession number 207113. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 207113. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 756 to amino acid 765 of SEQ ID N0:2.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID NO:1.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID NO: l, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vb24_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:l; and (bb) the nucleotide sequence of the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
NO:l to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1 , but excluding the 2 0 poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 737 to nucleotide 5302, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 737 to nucleotide 5302, to a nucleotide sequence 2 5 corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 737 to nucleotide 5302. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
NO:1 from nucleotide 782 to nucleotide 5302, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:1 from 3 0 nucleotide 782 to nucleotide 5302, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: l from nucleotide 782 to nucleotide 5302.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:2;
(b) a fragment of the amino acid sequence of SEQ ID N0:2, the fragment comprising eight contiguous amino acids of SEQ ID N0:2; and (c) the amino acid sequence encoded by the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 207113;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:2, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 756 to amino acid 765 of SEQ ID N0:2.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 60 to nucleotide 1130;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 156 to nucleotide 1130;
2 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc64_ 1 deposited with the ATCC under accession number 207113;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 30 207113;

(fj a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc64_1 deposited with the ATCC under accession number 207113;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc64_1 deposited with the ATCC under accession number 207113;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:4;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:4;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(I) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:3.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID N0:3 from nucleotide 60 to nucleotide 1130; the nucleotide sequence of SEQ ID N0:3 from nucleotide 156 to nucleotide 1130; the nucleotide sequence of the full-length protein coding sequence of clone vc64_1 deposited with the ATCC under accession number 207113; or the nucleotide sequence of a mature protein coding sequence of clone vc64_1 2 5 deposited with the ATCC under accession number 207113. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 207113. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of 3 0 SEQ ID N0:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 173 to amino acid 182 of SEQ ID N0:4.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:3.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:3, but excluding the poly(A) tail at the 3' end of SEQ ID N0:3; and (ab) the nucleotide sequence of the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and 2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:3, but excluding the poly(A) tail at the 2 5 3' end of SEQ ID N0:3; and (bb) the nucleotide sequence of the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
8 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:3 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:3 from nucleotide 60 to nucleotide 1130, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:3 from nucleotide 60 to nucleotide 1130, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:3 from nucleotide 60 to nucleotide 1130. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:3 from nucleotide 156 to nucleotide 1130, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:3 from nucleotide 156 to nucleotide 1130, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:3 from nucleotide 156 to nucleotide 1130.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:4;
(b) a fragment of the amino acid sequence of SEQ ID N0:4, the fragment comprising eight contiguous amino acids of SEQ ID N0:4; and (c) the amino acid sequence encoded by the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 207113;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such protein comprises the amino acid sequence of SEQ ID N0:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 3 0 of SEQ ID N0:4, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 173 to amino acid 182 of SEQ ID N0:4.
9 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 195 to nucleotide 1298;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 333 to nucleotide 1298;
(d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone vp20_1 deposited with the ATCC under accession number 207113;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp20_1 deposited with the ATCC under accession number 207113;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp20_1 deposited with the ATCC under accession number 207113;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vp20_1 deposited with the ATCC under accession number 207113;
2 0 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:6;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:6;
2 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any 3 0 one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:S.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:S
from nucleotide 195 to nucleotide 1298; the nucleotide sequence of SEQ ID NO:S
from nucleotide 333 to nucleotide 1298; the nucleotide sequence of the full-length protein coding sequence of clone vp20_1 deposited with the ATCC under accession number 207113; or the nucleotide sequence of a mature protein coding sequence of clone vp20_1 deposited with the ATCC under accession number 207113. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp20_1 deposited with the ATCC under accession number 207113. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ >D N0:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 179 to amino acid 188 of SEQ ID N0:6.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID NO:S.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID NO:S, but excluding the poly(A) tail at the 3' end of SEQ ID NO:S; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vp20_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:5, but excluding the poly(A) tail at the 3' end of SEQ ID N0:5; and (bb) the nucleotide sequence of the cDNA insert of clone vp20_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:5 , but excluding the 2 0 poly(A) tail at the 3' end of SEQ ID N0:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:5 from nucleotide 195 to nucleotide 1298, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:5 from nucleotide 195 to nucleotide 1298, to a nucleotide sequence 2 5 corresponding to the 3' end of said sequence of SEQ ID N0:5 from nucleotide 195 to nucleotide 1298. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:5 from nucleotide 333 to nucleotide 1298, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:5 from 3 0 nucleotide 333 to nucleotide 1298, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:5 from nucleotide 333 to nucleotide 1298.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:6;
(b) a fragment of the amino acid sequence of SEQ ID N0:6, the fragment comprising eight contiguous amino acids of SEQ ID N0:6; and (c) the amino acid sequence encoded by the cDNA insert of clone vp20_1 deposited with the ATCC under accession number 207113;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:6, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 179 to amino acid 188 of SEQ ID N0:6.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:7;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 129 to nucleotide 731;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 186 to nucleotide 731;
2 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vq4_1 deposited with the ATCC under accession number 207113;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq4_1 deposited with the ATCC under accession number 30 207113;

(fj a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq4_1 deposited with the ATCC under accession number 207113;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vq4_1 deposited with the ATCC under accession number 207113;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:8;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:8;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:7.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID N0:7 from nucleotide 129 to nucleotide 731; the nucleotide sequence of SEQ ID N0:7 from nucleotide 186 to nucleotide 731; the nucleotide sequence of the full-length protein coding sequence of clone vq4_1 deposited with the ATCC under accession number 207113;
or the nucleotide sequence of a mature protein coding sequence of clone vq4_1 deposited with 2 5 the ATCC under accession number 207113. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vq4_1 deposited with the ATCC under accession number 207113. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological 3 0 activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 95 to amino acid 104 of SEQ ID N0:8.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:7.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:7, but excluding the poly(A) tail at the 3' end of SEQ ID N0:7; and (ab) the nucleotide sequence of the cDNA insert of clone vq4_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and 2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:7, but excluding the poly(A) tail at the 2 5 3' end of SEQ ID N0:7; and (bb) the nucleotide sequence of the cDNA insert of clone vq4_1 deposited with the ATCC under accession number 207113;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:7 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:7 from nucleotide 129 to nucleotide 731, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:7 from nucleotide 129 to nucleotide 731, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:7 from nucleotide 129 to nucleotide 731. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:7 from nucleotide 186 to nucleotide 731, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:7 from nucleotide 186 to nucleotide 731, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:7 from nucleotide 186 to nucleotide 731.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:8;
(b) a fragment of the amino acid sequence of SEQ ID N0:8, the fragment comprising eight contiguous amino acids of SEQ ID N0:8; and (c) the amino acid sequence encoded by the cDNA insert of clone vq4_1 deposited with the ATCC under accession number 207113;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such protein comprises the amino acid sequence of SEQ ID N0:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 3 0 of SEQ ID N0:8, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 95 to amino acid 104 of SEQ ID N0:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 143 to nucleotide 571;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 221 to nucleotide 571;
(d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone vo7_1 deposited with the ATCC under accession number PTA-362;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo7_1 deposited with the ATCC under accession number PTA-362;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo7_1 deposited with the ATCC under accession number PTA-362;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo7_1 deposited with the ATCC under accession number PTA-362;
2 0 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
2 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any 3 0 one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:9.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:9 from nucleotide 143 to nucleotide 571; the nucleotide sequence of SEQ ID N0:9 from nucleotide 221 to nucleotide 571; the nucleotide sequence of the full-length protein coding sequence of clone vo7_1 deposited with the ATCC under accession number PTA-362; or the nucleotide sequence of a mature protein coding sequence of clone vo7_1 deposited with the ATCC under accession number PTA-362. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vo7_1 deposited with the ATCC under accession number PTA-362. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO:10.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:9.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:9, but excluding the poly(A) tail at the 3' end of SEQ ID N0:9; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vo7_1 deposited with the ATCC under accession number PTA-362;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:9, but excluding the poly(A) tail at the 3' end of SEQ ID N0:9; and (bb) the nucleotide sequence of the cDNA insert of clone vo7_1 deposited with the ATCC under accession number PTA-362;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:9 , but excluding the 2 0 poly(A) tail at the 3' end of SEQ ID N0:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:9 from nucleotide 143 to nucleotide 571, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:9 from nucleotide 143 to nucleotide 571, to a nucleotide sequence 2 5 corresponding to the 3' end of said sequence of SEQ ID N0:9 from nucleotide 143 to nucleotide 571. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:9 from nucleotide 221 to nucleotide 571, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:9 from nucleotide 3 0 221 to nucleotide 571, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:9 from nucleotide 221 to nucleotide 571.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:10;
(b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and (c) the amino acid sequence encoded by the cDNA insert of clone vo7_1 deposited with the ATCC under accession number PTA-362;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ
ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO:10.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 NO:11;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:11 from nucleotide 112 to nucleotide 570;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:11 from nucleotide 190 to nucleotide 570;
2 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc65_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc65_1 deposited with the ATCC under accession number 3 0 PTA-361;

(f) a polynucleotide comprising the nucleotide sequence of a mature ' protein coding sequence of clone vc65_1 deposited with the ATCC under accession number PTA-361;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc65_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:12;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:12;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:11.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
NO:11 from nucleotide 112 to nucleotide 570; the nucleotide sequence of SEQ ID
NO:11 from nucleotide 190 to nucleotide 570; the nucleotide sequence of the full-length protein coding sequence of clone vc65_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vc65_1 2 5 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc65_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:12 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment comprising the amino acid ' sequence from amino acid 71 to amino acid 80 of SEQ ID N0:12.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:11.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and (ab) the nucleotide sequence of the cDNA insert of clone vc65_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and (bb) the nucleotide sequence of the cDNA insert of clone vc65_1 deposited with the ATCC under accession number PTA-361;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 112 to nucleotide 570, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 112 to nucleotide 570, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 112 to nucleotide 570. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
NO:11 from nucleotide 190 to nucleotide 570, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:11 from nucleotide 190 to nucleotide 570, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 190 to nucleotide 570.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:12;
(b) a fragment of the amino acid sequence of SEQ ID N0:12, the fragment comprising eight contiguous amino acids of SEQ ID N0:12; and (c) the amino acid sequence encoded by the cDNA insert of clone vc65_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:12, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID N0:12.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13 from nucleotide 4 to nucleotide 261;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13 from nucleotide 124 to nucleotide 261;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc66_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc66_1 deposited with the ATCC under accession number PTA-361;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc66_1 deposited with the ATCC under accession number PTA-361;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc66_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:14;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:14;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:13.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:13 from nucleotide 4 to nucleotide 261; the nucleotide sequence of SEQ ID
N0:13 from nucleotide 124 to nucleotide 261; the nucleotide sequence of the full-length protein coding sequence of clone vc66_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vc66_1 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc66_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID N0:14.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:13.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:13, but excluding the poly(A) tail at the 3' end of SEQ ID N0:13; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vc66_1 deposited with the ATCC under accession number PTA-361;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:13, but excluding the poly(A) tail at the 3' end of SEQ ID N0:13; and (bb) the nucleotide sequence of the cDNA insert of clone vc66_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:13 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:13 from nucleotide 4 to nucleotide 261, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:13 from nucleotide 4 to nucleotide 261, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:13 from nucleotide 4 to nucleotide 261. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:13 from nucleotide 124 to nucleotide 261, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:13 from nucleotide 124 to nucleotide 261, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:13 from nucleotide 124 to nucleotide 261.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:14;
(b) a fragment of the amino acid sequence of SEQ ID N0:14, the fragment comprising eight contiguous amino acids of SEQ ID N0:14; and (c) the amino acid sequence encoded by the cDNA insert of clone vc66_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:14. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:14, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID N0:14.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 135 to nucleotide 1227;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 216 to nucleotide 1227;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc68_1 deposited with the ATCC under accession number PTA-361;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc68_1 deposited with the ATCC under accession number PTA-361;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc68_1 deposited with the ATCC under accession number PTA-361;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc68_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:16;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:16;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25°Io of the length of SEQ ID NO:15.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
NO:15 from nucleotide 135 to nucleotide 1227; the nucleotide sequence of SEQ
ID NO:15 from nucleotide 216 to nucleotide 1227; the nucleotide sequence of the full-length protein coding sequence of clone vc68_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vc68_1 2 5 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc68_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:16 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 160 to amino acid 169 of SEQ ID N0:16.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:15.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and (ab) the nucleotide sequence of the cDNA insert of clone vc68_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and (bb) the nucleotide sequence of the cDNA insert of clone vc68_1 deposited with the ATCC under accession number PTA-361;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:15 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:15 from nucleotide 135 to nucleotide 1227, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:15 from nucleotide 135 to nucleotide 1227, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:15 from nucleotide 135 to nucleotide 1227. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:15 from nucleotide 216 to nucleotide 1227, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:1 S from nucleotide 216 to nucleotide 1227, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:15 from nucleotide 216 to nucleotide 1227.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:16;
(b) a fragment of the amino acid sequence of SEQ ID N0:16, the fragment comprising eight contiguous amino acids of SEQ ID N0:16; and (c) the amino acid sequence encoded by the cDNA insert of clone vc68_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:16, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 160 to amino acid 169 of SEQ ID N0:16.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 79 to nucleotide 2424;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 145 to nucleotide 2424;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vk6_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vk6_1 deposited with the ATCC under accession number PTA-361;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vk6_1 deposited with the ATCC under accession number PTA-361;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vk6_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:18;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:18;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any ' one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:17.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:17 from nucleotide 79 to nucleotide 2424; the nucleotide sequence of SEQ ID
N0:17 from nucleotide 145 to nucleotide 2424; the nucleotide sequence of the full-length protein coding sequence of clone vk6_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vk6_1 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vk6_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 386 to amino acid 395 of SEQ ID N0:18.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:17.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:17, but excluding the poly(A) tail at the 3' end of SEQ ID N0:17; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vk6_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:17, but excluding the poly(A) tail at the 3' end of SEQ ID N0:17; and (bb) the nucleotide sequence of the cDNA insert of clone vk6_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:17 , but 2 0 excluding the poly(A) tail at the 3' end of SEQ ID N0:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:17 from nucleotide 79 to nucleotide 2424, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ >D N0:17 from nucleotide 79 to nucleotide 2424, to a nucleotide 2 5 sequence corresponding to the 3' end of said sequence of SEQ ID N0:17 from nucleotide 79 to nucleotide 2424. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:17 from nucleotide 145 to nucleotide 2424, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:17 from 3 0 nucleotide 145 to nucleotide 2424, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:17 from nucleotide 145 to nucleotide 2424.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:18;
(b) a fragment of the amino acid sequence of SEQ ID N0:18, the fragment comprising eight contiguous amino acids of SEQ ID N0:18; and (c) the amino acid sequence encoded by the cDNA insert of clone vk6_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ LD N0:18, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 386 to amino acid 395 of SEQ ID N0:18.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:19;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 2 to nucleotide 733;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 71 to nucleotide 733;
2 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vo4_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo4_1 deposited with the ATCC under accession number 3 0 PTA-361;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo4_1 deposited with the ATCC under accession number PTA-361;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo4_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:20;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:20;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:19.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:19 from nucleotide 2 to nucleotide 733; the nucleotide sequence of SEQ ID
N0:19 from nucleotide 71 to nucleotide 733; the nucleotide sequence of the full-length protein coding sequence of clone vo4_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vo4_ 1 2 5 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo4_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:20 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID N0:20.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:19.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:19, but excluding the poly(A) tail at the 3' end of SEQ ID N0:19; and (ab) the nucleotide sequence of the cDNA insert of clone vo4_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and 2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:19, but excluding the poly(A) tail at the 2 5 3' end of SEQ ID N0:19; and (bb) the nucleotide sequence of the cDNA insert of clone vo4_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:19 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:19 from nucleotide 2 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:19 from nucleotide 2 to nucleotide 733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:19 from nucleotide 2 to nucleotide 733. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:19 from nucleotide 71 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:19 from nucleotide 71 to nucleotide 733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:19 from nucleotide 71 to nucleotide 733.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:20;
(b) a fragment of the amino acid sequence of SEQ ID N0:20, the fragment comprising eight contiguous amino acids of SEQ ID N0:20; and (c) the amino acid sequence encoded by the cDNA insert of clone vo4_ 1 deposited with the ATCC under accession number PTA-361;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such protein comprises the amino acid sequence of SEQ ID N0:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 3 0 of SEQ ID N0:20, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID N0:20.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21 from nucleotide 151 to nucleotide 1323;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21 from nucleotide 217 to nucleotide 1323;
(d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone vo8_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo8_1 deposited with the ATCC under accession number PTA-361;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo8_1 deposited with the ATCC under accession number PTA-361;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo8_1 deposited with the ATCC under accession number PTA-361;
2 0 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:22;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:22;
2 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any 3 0 one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:21.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:21 from nucleotide 151 to nucleotide 1323; the nucleotide sequence of SEQ
ID N0:21 from nucleotide 217 to nucleotide 1323; the nucleotide sequence of the full-length protein coding sequence of clone vo8_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vo8_1 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo8_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID N0:22.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:21.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:21, but excluding the poly(A) tail at the 3' end of SEQ ID N0:21; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vo8_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:21, but excluding the poly(A) tail at the 3' end of SEQ ID N0:21; and (bb) the nucleotide sequence of the cDNA insert of clone vo8_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:21, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
NO:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:21 , but 2 0 excluding the poly(A) tail at the 3' end of SEQ ID N0:21. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:21 from nucleotide 151 to nucleotide 1323, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:21 from nucleotide 151 to nucleotide 1323, to a nucleotide 2 5 sequence corresponding to the 3' end of said sequence of SEQ ID N0:21 from nucleotide 151 to nucleotide 1323. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:21 from nucleotide 217 to nucleotide 1323, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:21 from 3 0 nucleotide 217 to nucleotide 1323, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:21 from nucleotide 217 to nucleotide 1323.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:22;
(b) a fragment of the amino acid sequence of SEQ ID N0:22, the fragment comprising eight contiguous amino acids of SEQ ID N0:22; and (c) the amino acid sequence encoded by the cDNA insert of clone vo8_ 1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:22. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:22, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID N0:22.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:23;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23 from nucleotide 134 to nucleotide 613;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23 from nucleotide 215 to nucleotide 613;
2 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vol0_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol0_1 deposited with the ATCC under accession number 3 0 PTA-361;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol0_1 deposited with the ATCC under accession number PTA-361;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vol0_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:24;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:24;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:23.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:23 from nucleotide 134 to nucleotide 613; the nucleotide sequence of SEQ ID
N0:23 from nucleotide 215 to nucleotide 613; the nucleotide sequence of the full-length protein coding sequence of clone vol0_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vol0_1 2 5 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol0_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:24 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 75 to amino acid 84 of SEQ ID N0:24.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:23.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:23, but excluding the poly(A) tail at the 3' end of SEQ ID N0:23; and (ab) the nucleotide sequence of the cDNA insert of clone vol0_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:23, but excluding the poly(A) tail at the 3' end of SEQ ID N0:23; and (bb) the nucleotide sequence of the cDNA insert of clone vo 10_ 1 deposited with the ATCC under accession number PTA-361;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:23, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:23 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:23 from nucleotide 134 to nucleotide 613, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:23 from nucleotide 134 to nucleotide 613, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:23 from nucleotide 134 to nucleotide 613. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:23 from nucleotide 215 to nucleotide 613, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:23 from nucleotide 215 to nucleotide 613, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:23 from nucleotide 215 to nucleotide 613.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:24;
(b) a fragment of the amino acid sequence of SEQ ID N0:24, the fragment comprising eight contiguous amino acids of SEQ ID N0:24; and (c) the amino acid sequence encoded by the cDNA insert of clone vol0_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:24. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:24 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:24, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 75 to amino acid 84 of SEQ ID N0:24.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25 from nucleotide 102 to nucleotide 1163;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25 from nucleotide 156 to nucleotide 1163;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vo20_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo20_1 deposited with the ATCC under accession number PTA-361;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo20_1 deposited with the ATCC under accession number PTA-361;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo20_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:26;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:26;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:25.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:25 from nucleotide 102 to nucleotide 1163; the nucleotide sequence of SEQ
ID N0:25 from nucleotide 156 to nucleotide 1163; the nucleotide sequence of the full-length protein coding sequence of clone vo20_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vo20_1 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo20_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 172 to amino acid 181 of SEQ ID N0:26.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:25.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 , in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:25, but excluding the poly(A) tail at the 3' end of SEQ ID N0:25; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vo20_1 deposited with the ATCC under accession number PTA-361;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:25, but excluding the poly(A) tail at the 3' end of SEQ ID N0:25; and (bb) the nucleotide sequence of the cDNA insert of clone vo20_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:25 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:25 from nucleotide 102 to nucleotide 1163, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:25 from nucleotide 102 to nucleotide 1163, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:25 from nucleotide 102 to nucleotide 1163. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:25 from nucleotide 156 to nucleotide 1163, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:25 from nucleotide 156 to nucleotide 1163, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:25 from nucleotide 156 to nucleotide 1163.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:26;
(b) a fragment of the amino acid sequence of SEQ ID N0:26, the fragment comprising eight contiguous amino acids of SEQ ID N0:26; and (c) the amino acid sequence encoded by the cDNA insert of clone vo20_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ 1D N0:26, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 172 to amino acid 181 of SEQ ID N0:26.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27 from nucleotide 67 to nucleotide 702;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27 from nucleotide 157 to nucleotide 702;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vo21_1 deposited with the ATCC under accession number PTA-361;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo21_1 deposited with the ATCC under accession number PTA-361;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo21_1 deposited with the ATCC under accession number PTA-361;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo21_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:28;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:28;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:27.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:27 from nucleotide 67 to nucleotide 702; the nucleotide sequence of SEQ ID
N0:27 from nucleotide 157 to nucleotide 702; the nucleotide sequence of the full-length protein coding sequence of clone vo21_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vo21_1 2 5 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo21_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:28 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID N0:28.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:27.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:27, but excluding the poly(A) tail at the 3' end of SEQ ID N0:27; and (ab) the nucleotide sequence of the cDNA insert of clone vo21_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:27, but excluding the poly(A) tail at the 3' end of SEQ ID N0:27; and (bb) the nucleotide sequence of the cDNA insert of clone vo21_1 deposited with the ATCC under accession number PTA-361;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:27 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:27 from nucleotide 67 to nucleotide 702, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:27 from nucleotide 67 to nucleotide 702, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:27 from nucleotide 67 to nucleotide 702. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:27 from nucleotide 157 to nucleotide 702, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:27 from nucleotide 1~7 to nucleotide 702, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:27 from nucleotide 157 to nucleotide 702.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:28;
(b) a fragment of the amino acid sequence of SEQ ID N0:28, the fragment comprising eight contiguous amino acids of SEQ ID N0:28; and (c) the amino acid sequence encoded by the cDNA insert of clone vo21_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:28. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:28, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID N0:28.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29 from nucleotide 57 to nucleotide 272;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29 from nucleotide 114 to nucleotide 272;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp24_1 deposited with the ATCC under accession number PTA-361;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp24_1 deposited with the ATCC under accession number PTA-361;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp24_1 deposited with the ATCC under accession number PTA-361;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vp24_1 deposited with the ATCC under accession number PTA-361;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:30;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:30;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:29.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:29 from nucleotide 57 to nucleotide 272; the nucleotide sequence of SEQ ID
N0:29 from nucleotide 114 to nucleotide 272; the nucleotide sequence of the full-length protein coding sequence of clone vp24_1 deposited with the ATCC under accession number PTA-361; or the nucleotide sequence of a mature protein coding sequence of clone vp24_1 deposited with the ATCC under accession number PTA-361. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp24_1 deposited with the ATCC under accession number PTA-361. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID N0:30.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:29.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:29, but excluding the poly(A) tail at the 3' end of SEQ ID N0:29; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vp24_1 deposited with the ATCC under accession number PTA-361;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:29, but excluding the poly(A) tail at the 3' end of SEQ ID N0:29; and (bb) the nucleotide sequence of the cDNA insert of clone vp24_1 deposited with the ATCC under accession number PTA-361;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:29 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:29 from nucleotide 57 to nucleotide 272, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:29 from nucleotide 57 to nucleotide 272, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:29 from nucleotide 57 to nucleotide 272. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:29 from nucleotide 114 to nucleotide 272, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:29 from nucleotide 114 to nucleotide 272, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:29 from nucleotide 114 to nucleotide 272.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:30;
(b) a fragment of the amino acid sequence of SEQ ID N0:30, the fragment comprising eight contiguous amino acids of SEQ ID N0:30; and (c) the amino acid sequence encoded by the cDNA insert of clone vp24_1 deposited with the ATCC under accession number PTA-361;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:30. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:30, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID N0:30.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31 from nucleotide 38 to nucleotide 757;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31 from nucleotide 137 to nucleotide 757;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vol7_1 deposited with the ATCC under accession number PTA-366;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol7_1 deposited with the ATCC under accession number PTA-366;

(fj a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol7_1 deposited with the ATCC under accession number PTA-366;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vol7_1 deposited with the ATCC under accession number PTA-366;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:32;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:32;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:31.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:31 from nucleotide 38 to nucleotide 757; the nucleotide sequence of SEQ ID
N0:31 from nucleotide 137 to nucleotide 757; the nucleotide sequence of the full-length protein coding sequence of clone vol7_1 deposited with the ATCC under accession number PTA-366; or the nucleotide sequence of a mature protein coding sequence of clone vol7_1 2 5 deposited with the ATCC under accession number PTA-366. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol7_1 deposited with the ATCC under accession number PTA-366. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:32 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID N0:32.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:31.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:31, but excluding the poly(A) tail at the 3' end of SEQ ID N0:31; and (ab) the nucleotide sequence of the cDNA insert of clone vol7_1 deposited with the ATCC under accession number PTA-366;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:3 l, but excluding the poly(A) tail at the 3' end of SEQ ID N0:31; and (bb) the nucleotide sequence of the cDNA insert of clone vol7_1 deposited with the ATCC under accession number PTA-366;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:31 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:31 from nucleotide 38 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:31 from nucleotide 38 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:31 from nucleotide 38 to nucleotide 757. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:31 from nucleotide 137 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:31 from nucleotide 137 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:31 from nucleotide 137 to nucleotide 757.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:32;
(b) a fragment of the amino acid sequence of SEQ ID N0:32, the fragment comprising eight contiguous amino acids of SEQ ID N0:32; and (c) the amino acid sequence encoded by the cDNA insert of clone vol7_1 deposited with the ATCC under accession number PTA-366;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:32. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:32, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID N0:32.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33 from nucleotide 93 to nucleotide 263;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33 from nucleotide 174 to nucleotide 263;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vq 11 _ 1 deposited with the ATCC
under accession number PTA-367;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql l_1 deposited with the ATCC under accession number PTA-367;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql 1_1 deposited with the ATCC under accession number PTA-367;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vql l_1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:34;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:34;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:33.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:33 from nucleotide 93 to nucleotide 263; the nucleotide sequence of SEQ ID
N0:33 from nucleotide 174 to nucleotide 263; the nucleotide sequence of the full-length protein coding sequence of clone vql 1_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vqll_1 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql 1_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID N0:34.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:33.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:33, but excluding the poly(A) tail at the 3' end of SEQ ID N0:33; and (ab) the nucleotide sequence of the cDNA insert of clone 30 vql l_1 deposited with the ATCC under accession number PTA-367;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:33, but excluding the poly(A) tail at the 3' end of SEQ ID N0:33; and (bb) the nucleotide sequence of the cDNA insert of clone vql l_1 deposited with the ATCC under accession number PTA-367;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:33, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:33 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:33 from nucleotide 93 to nucleotide 263, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:33 from nucleotide 93 to nucleotide 263, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:33 from nucleotide 93 to nucleotide 263. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:33 from nucleotide 174 to nucleotide 263, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:33 from nucleotide 174 to nucleotide 263, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:33 from nucleotide 174 to nucleotide 263.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:34;
(b) a fragment of the amino acid sequence of SEQ ID N0:34, the fragment comprising eight contiguous amino acids of SEQ ID N0:34; and (c) the amino acid sequence encoded by the cDNA insert of clone vql l_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:34. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:34, or a protein comprising a fragment of the amino acid sequence of 5EQ
ID N0:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID N0:34.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35 from nucleotide 43 to nucleotide 1125;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35 from nucleotide 85 to nucleotide 1125;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vq 12_ 1 deposited with the ATCC under accession number PTA-367;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql2_1 deposited with the ATCC under accession number PTA-367;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql2_1 deposited with the ATCC under accession number PTA-367;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vq 12_ 1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:36;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:36;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:35.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:35 from nucleotide 43 to nucleotide 1125; the nucleotide sequence of SEQ ID
N0:35 from nucleotide 85 to nucleotide 1125; the nucleotide sequence of the full-length protein coding sequence of clone vql2_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vql2_1 2 5 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql2_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:36 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID N0:36.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:35.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:35, but excluding the poly(A) tail at the 3' end of SEQ ID N0:35; and (ab) the nucleotide sequence of the cDNA insert of clone vql2_1 deposited with the ATCC under accession number PTA
367;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:35, but excluding the poly(A) tail at the 3' end of SEQ ID N0:35; and (bb) the nucleotide sequence of the cDNA insert of clone vql2_1 deposited with the ATCC under accession number PTA-367;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:35, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:35 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:35 from nucleotide 43 to nucleotide 1125, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:35 from nucleotide 43 to nucleotide 1125, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:35 from nucleotide 43 to nucleotide 1125. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:35 from nucleotide 85 to nucleotide 1125, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:35 from nucleotide 85 to nucleotide 1125, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:35 from nucleotide 85 to nucleotide 1125.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:36;
(b) a fragment of the amino acid sequence of SEQ ID N0:36, the fragment comprising eight contiguous amino acids of SEQ ID N0:36; and (c) the amino acid sequence encoded by the cDNA insert of clone 2 5 vq 12_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:36. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:36, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID N0:36.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37 from nucleotide 32 to nucleotide 904;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37 from nucleotide 77 to nucleotide 904;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vql4_1 deposited with the ATCC under accession number PTA-367;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql4_1 deposited with the ATCC under accession number PTA-367;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql4_1 deposited with the ATCC under accession number PTA-367;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vq 14_1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:38;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:38;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:37.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:37 from nucleotide 32 to nucleotide 904; the nucleotide sequence of SEQ ID
N0:37 from nucleotide 77 to nucleotide 904; the nucleotide sequence of the full-length protein coding sequence of clone vql4_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vql4_1 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql4_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 140 to amino acid 149 of SEQ ID N0:38.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:37.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:37, but excluding the poly(A) tail at the 3' end of SEQ ID N0:37; and (ab) the nucleotide sequence of the cDNA insert of clone 30 vql4_1 deposited with the ATCC under accession number PTA-367;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:37, but excluding the poly(A) tail at the 3' end of SEQ ID N0:37; and (bb) the nucleotide sequence of the cDNA insert of clone vql4_1 deposited with the ATCC under accession number PTA-367;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:37, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:37 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:37 from nucleotide 32 to nucleotide 904, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:37 from nucleotide 32 to nucleotide 904, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:37 from nucleotide 32 to nucleotide 904. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:37 from nucleotide 77 to nucleotide 904, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:37 from nucleotide 77 to nucleotide 904, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:37 from nucleotide 77 to nucleotide 904.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:38;
(b) a fragment of the amino acid sequence of SEQ ID N0:38, the fragment comprising eight contiguous amino acids of SEQ ID N0:38; and (c) the amino acid sequence encoded by the cDNA insert of clone vql4_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:38. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:38, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 140 to amino acid 149 of SEQ ID N0:38.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39 from nucleotide 384 to nucleotide 1193;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39 from nucleotide 642 to nucleotide 1193;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vql5_1 deposited with the ATCC under accession number PTA-367;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql5_1 deposited with the ATCC under accession number PTA-367;

(fj a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql5_1 deposited with the ATCC under accession number PTA-367;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vql5_1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:40;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:40;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:39.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:39 from nucleotide 384 to nucleotide 1193; the nucleotide sequence of SEQ
ID N0:39 from nucleotide 642 to nucleotide 1193; the nucleotide sequence of the full-length protein coding sequence of clone vql5_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vql5_1 2 5 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql5_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:40 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID N0:40.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:39.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:39, but excluding the poly(A) tail at the 3' end of SEQ ID N0:39; and (ab) the nucleotide sequence of the cDNA insert of clone vql5_1 deposited with the ATCC under accession number PTA
367;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:39, but excluding the poly(A) tail at the 3' end of SEQ ID N0:39; and (bb) the nucleotide sequence of the cDNA insert of clone vql5_1 deposited with the ATCC under accession number PTA-367;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:39 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:39 from nucleotide 384 to nucleotide 1193, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:39 from nucleotide 384 to nucleotide 1193, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:39 from nucleotide 384 to nucleotide 1193. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:39 from nucleotide 642 to nucleotide 1193, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:39 from nucleotide 642 to nucleotide 1193, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:39 from nucleotide 642 to nucleotide 1193.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:40;
(b) a fragment of the amino acid sequence of SEQ ID N0:40, the fragment comprising eight contiguous amino acids of SEQ ID N0:40; and (c) the amino acid sequence encoded by the cDNA insert of clone vql5_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:40. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:40 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:40, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID N0:40.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41 from nucleotide 132 to nucleotide 503;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41 from nucleotide 189 to nucleotide 503;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vq 17_ 1 deposited with the ATCC under accession number PTA-367;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql7_1 deposited with the ATCC under accession number PTA-367;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql7_1 deposited with the ATCC under accession number PTA-367;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vql7_1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:42;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:42;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25°l0 of the length of SEQ ID N0:41.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:41 from nucleotide 132 to nucleotide 503; the nucleotide sequence of SEQ ID
N0:41 from nucleotide 189 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone vql7_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vql7_1 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql7_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID N0:42.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:41.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ )D N0:41, but excluding the poly(A) tail at the 3' end of SEQ ID N0:41; and (ab) the nucleotide sequence of the cDNA insert of clone vql7_1 deposited with the ATCC under accession number PTA-367;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:41, but excluding the poly(A) tail at the 3' end of SEQ ID N0:41; and (bb) the nucleotide sequence of the cDNA insert of clone vql7_1 deposited with the ATCC under accession number PTA-367;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:41 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:41 from nucleotide 132 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:41 from nucleotide 132 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:41 from nucleotide 132 to nucleotide 503. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:41 from nucleotide 189 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:41 from nucleotide 189 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:41 from nucleotide 189 to nucleotide 503.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:42;
(b) a fragment of the amino acid sequence of SEQ ID N0:42, the fragment comprising eight contiguous amino acids of SEQ ID N0:42; and (c) the amino acid sequence encoded by the cDNA insert of clone vql7_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:42. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:42, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID N0:42.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43 from nucleotide 69 to nucleotide 401;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43 from nucleotide 138 to nucleotide 401;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vql8_1 deposited with the ATCC under accession number PTA-367;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql8_1 deposited with the ATCC under accession number PTA-367;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq 18_1 deposited with the ATCC under accession number PTA-367;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vq 18_1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:44;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:44 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:44;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:43.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:43 from nucleotide 69 to nucleotide 401; the nucleotide sequence of SEQ ID
N0:43 from nucleotide 138 to nucleotide 401; the nucleotide sequence of the full-length protein coding sequence of clone vql8_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vq 18_ 1 2 5 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql8_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:44 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID N0:44.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:43.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:43, but excluding the poly(A) tail at the 3' end of SEQ ID N0:43; and (ab) the nucleotide sequence of the cDNA insert of clone vql8_1 deposited with the ATCC under accession number PTA
367;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:43, but excluding the poly(A) tail at the 3' end of SEQ ID N0:43; and (bb) the nucleotide sequence of the cDNA insert of clone vql8_1 deposited with the ATCC under accession number PTA-367;
3 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:43 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:43 from nucleotide 69 to nucleotide 401, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:43 from nucleotide 69 to nucleotide 401, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:43 from nucleotide 69 to nucleotide 401. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:43 from nucleotide 138 to nucleotide 401, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:43 from nucleotide 138 to nucleotide 401, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:43 from nucleotide 138 to nucleotide 401.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:44;
(b) a fragment of the amino acid sequence of SEQ ID N0:44, the fragment comprising eight contiguous amino acids of SEQ ID N0:44; and (c) the amino acid sequence encoded by the cDNA insert of clone 2 5 vq 18_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:44 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:44, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID N0:44.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45 from nucleotide 65 to nucleotide 1180;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45 from nucleotide 149 to nucleotide 1180;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vq22_1 deposited with the ATCC under accession number PTA-367;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq22_1 deposited with the ATCC under accession number PTA-367;
(fj a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq22_1 deposited with the ATCC under accession number PTA-367;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vq22_1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:46;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:46;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:45.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:45 from nucleotide 65 to nucleotide 1180; the nucleotide sequence of SEQ ID
N0:45 from nucleotide 149 to nucleotide 1180; the nucleotide sequence of the full-length protein coding sequence of clone vq22_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vq22_1 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq22_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID N0:46.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:45.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ >D N0:45, but excluding the poly(A) tail at the 3' end of SEQ ID N0:45; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vq22_1 deposited with the ATCC under accession number PTA-367;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:45, but excluding the poly(A) tail at the 3' end of SEQ ID N0:45; and (bb) the nucleotide sequence of the cDNA insert of clone vq22_1 deposited with the ATCC under accession number PTA-367;
25 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:45, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:45 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:45 from nucleotide 65 to nucleotide 1180, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:45 from nucleotide 65 to nucleotide 1180, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:45 from nucleotide 65 to nucleotide 1180. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:45 from nucleotide 149 to nucleotide 1180, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:45 from nucleotide 149 to nucleotide 1180, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:45 from nucleotide 149 to nucleotide 1180.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:46;
(b) a fragment of the amino acid sequence of SEQ ID N0:46, the fragment comprising eight contiguous amino acids of SEQ ID N0:46; and (c) the amino acid sequence encoded by the cDNA insert of clone vq22_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:46, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID N0:46.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47 from nucleotide 18 to nucleotide 1409;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47 from nucleotide 60 to nucleotide 1409;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vr3_1 deposited with the ATCC under accession number PTA-367;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;

(fj a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vr3_1 deposited with the ATCC under accession number PTA-367;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:48;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:48;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:47.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:47 from nucleotide 18 to nucleotide 1409; the nucleotide sequence of SEQ ID
N0:47 from nucleotide 60 to nucleotide 1409; the nucleotide sequence of the full-length protein coding sequence of clone vr3_1 deposited with the ATCC under accession number PTA-367; or the nucleotide sequence of a mature protein coding sequence of clone vr3_1 2 5 deposited with the ATCC under accession number PTA-367. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:48 3 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 227 to amino acid 236 of SEQ ID N0:48.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:47.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:47, but excluding the poly(A) tail at the 3' end of SEQ ID N0:47; and (ab) the nucleotide sequence of the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and 2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:47, but excluding the poly(A) tail at the 2 5 3' end of SEQ ID N0:47; and (bb) the nucleotide sequence of the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:47 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:47 from nucleotide 18 to nucleotide 1409, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:47 from nucleotide 18 to nucleotide 1409, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:47 from nucleotide 18 to nucleotide 1409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:47 from nucleotide 60 to nucleotide 1409, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:47 from nucleotide 60 to nucleotide 1409, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:47 from nucleotide 60 to nucleotide 1409.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:48;
(b) a fragment of the amino acid sequence of SEQ ID N0:48, the fragment comprising eight contiguous amino acids of SEQ ID N0:48; and (c) the amino acid sequence encoded by the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such protein comprises the amino acid sequence of SEQ ID N0:48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 3 0 of SEQ ID N0:48, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 227 to amino acid 236 of SEQ ID N0:48.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49 from nucleotide 690 to nucleotide 2570;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49 from nucleotide 765 to nucleotide 2570;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49 from nucleotide 1286 to nucleotide 2895;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb26_1 deposited with the ATCC under accession number PTA-501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb26_1 deposited with the ATCC under accession number PTA-501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb26_1 deposited with the ATCC under accession number PTA-501;
2 0 (h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vb26_1 deposited with the ATCC under accession number PTA-501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:50;
(j) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:50;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein 3 0 of (i) or (j) above ;
(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID N0:49.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:49 from nucleotide 690 to nucleotide 2570; the nucleotide sequence of SEQ
ID N0:49 from nucleotide 765 to nucleotide 2570; the nucleotide sequence of SEQ ID
N0:49 from nucleotide 1286 to nucleotide 2895; the nucleotide sequence of SEQ ID N0:49 from nucleotide 1286 to nucleotide 2570; the nucleotide sequence of SEQ ID N0:49 from nucleotide 981 to nucleotide 1282; the nucleotide sequence of the full-length protein coding sequence of clone vb26_1 deposited with the ATCC under accession number PTA-501; or the nucleotide sequence of a mature protein coding sequence of clone vb26_1 deposited with the ATCC under accession number PTA-501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vb26_1 deposited with the ATCC under accession number PTA-501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:50 from amino acid 112 to amino acid 197. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
NO:50 having biological activity, the fragment preferably comprising eight (more preferably 2 0 twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ >D N0:50 having biological activity, the fragment comprising an amino acid sequence selected from the group comprising the sequence from amino acid 308 to amino acid 317 of SEQ ID NO:50, the sequence from amino acid 112 to amino acid 197 of SEQ ID
2 5 N0:50, the sequence from amino acid 200 to amino acid 627 of SEQ ID N0:50, and the sequence from amino acid 364 to amino acid 373 of SEQ ID N0:50.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:49.
Further embodiments of the invention provide isolated polynucleotides produced 3 0 according to a process selected from the group consisting of:
(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:49, but excluding the poly(A) tail at the 3' end of SEQ ID N0:49; and (ab) the nucleotide sequence of the cDNA insert of clone vb26_1 deposited with the ATCC under accession number PTA-501;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:49, but excluding the poly(A) tail at the 3' end of SEQ ID N0:49; and 2 0 (bb) the nucleotide sequence of the cDNA insert of clone vb26_1 deposited with the ATCC under accession number PTA-501;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
2 5 (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:49, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
3 0 N0:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:49 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:49 from nucleotide 690 to nucleotide 2570, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:49 from nucleotide 690 to nucleotide 2570, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:49 from nucleotide 690 to nucleotide 2570. Also preferably the polynucleotide isolated according to the above process comprises a nuc,~eotide sequence corresponding to the cDNA sequence of SEQ ID
N0:49 from nucleotide 765 to nucleotide 2570, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:49 from nucleotide 765 to nucleotide 2570, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:49 from nucleotide 765 to nucleotide 2570. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:49 from nucleotide 1286 to nucleotide 2895, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:49 from nucleotide 1286 to nucleotide 2895, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID
N0:49 from nucleotide 1286 to nucleotide 2895.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:50;
(b) the amino acid sequence of SEQ ID N0:50 from amino acid 112 to amino acid 197;
(c) a fragment of the amino acid sequence of SEQ ID N0:50, the fragment comprising eight contiguous amino acids of SEQ ID N0:50; and 2 5 (d) the amino acid sequence encoded by the cDNA insert of clone vb26_1 deposited with the ATCC under accession number PTA-501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:50 or the amino acid sequence of SEQ ID N0:50 from amino acid 112 to amino acid 197. In further preferred 3 0 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:50, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:50 having biological activity, the fragment comprising an amino acid sequence selected from the group comprising the sequence from amino acid 308 to amino acid 317 of SEQ ID N0:50, the sequence from amino acid 112 to amino acid 197 of SEQ ID
N0:50, the sequence from amino acid 200 to amino acid 627 of SEQ ID N0:50, and the sequence from amino acid 364 to amino acid 373 of SEQ ID N0:50.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51 from nucleotide 105 to nucleotide 1724;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51 from nucleotide 186 to nucleotide 1724;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc70_1 deposited with the ATCC under accession number PTA-1074;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc70_1 deposited with the ATCC under accession number 2 0 PTA-1074;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc70_1 deposited with the ATCC under accession number PTA-1074;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc70_1 deposited with the ATCC under accession number PTA-1074;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:52;
(i) a polynucleotide encoding a protein comprising a fragment of the 3 0 amino acid sequence of SEQ ID N0:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:52;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:51.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:51 from nucleotide 105 to nucleotide 1724; the nucleotide sequence of SEQ
ID NO:51 from nucleotide 186 to nucleotide 1724; the nucleotide sequence of the full-length protein coding sequence of clone vc70_1 deposited with the ATCC under accession number PTA-1074; or the nucleotide sequence of a mature protein coding sequence of clone vc70_1 deposited with the ATCC under accession number PTA-1074. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc70_1 deposited with the ATCC under accession number PTA-1074. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:52 2 0 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 265 to amino acid 274 of SEQ ID N0:52.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:51.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID N0:51, but excluding the poly(A) tail at the 3' end of SEQ ID N0:51; and (ab) the nucleotide sequence of the cDNA insert of clone vc70_1 deposited with the ATCC under accession number PTA-1074;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:51, but excluding the poly(A) tail at the 3' end of SEQ ID N0:51; and (bb) the nucleotide sequence of the cDNA insert of clone vc70_1 deposited with the ATCC under accession number PTA-1074;
2 0 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 5 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:51, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:51 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 3 0 corresponding to the cDNA sequence of SEQ ID N0:51 from nucleotide 105 to nucleotide 1724, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:51 from nucleotide 105 to nucleotide 1724, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:51 from nucleotide 105 to nucleotide 1724. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:51 from nucleotide 186 to nucleotide 1724, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:51 from nucleotide 186 to nucleotide 1724, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:51 from nucleotide 186 to nucleotide 1724.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:52;
(b) a fragment of the amino acid sequence of SEQ ID N0:52, the fragment comprising eight contiguous amino acids of SEQ ID N0:52; and (c) the amino acid sequence encoded by the cDNA insert of clone vc70_1 deposited with the ATCC under accession number PTA-1074;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:52. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:52 having biological activity, the fragment preferably 2 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ >D N0:52, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 265 to amino acid 274 of SEQ ID N0:52.
In one embodiment, the present invention provides a composition comprising an 2 5 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53 from nucleotide 3 to nucleotide 239;
3 0 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vo28_1 deposited with the ATCC under accession number PTA-1074;

(d) a polynucleotide encoding the full-length protein encoded by the ' cDNA insert of clone vo28_1 deposited with the ATCC under accession number PTA-1074;
(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo28_1 deposited with the ATCC under accession number PTA-1074;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo28_1 deposited with the ATCC under accession number PTA-1074;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:54;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:54;
(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any 2 0 one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID N0:53.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
2 5 N0:53 from nucleotide 3 to nucleotide 239; the nucleotide sequence of the full-length protein coding sequence of clone vo28_1 deposited with the ATCC under accession number PTA-1074; or the nucleotide sequence of a mature protein coding sequence of clone vo28_1 deposited with the ATCC under accession number PTA-1074. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein 3 0 encoded by the cDNA insert of clone vo28_1 deposited with the ATCC under accession number PTA-1074. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID N0:54.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:53.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:53, but excluding the poly(A) tail at the 3' end of SEQ ID N0:53; and (ab) the nucleotide sequence of the cDNA insert of clone vo28_1 deposited with the ATCC under accession number PTA-1074;
(ii) hybridizing said probes) to human genomic DNA in 2 0 conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:53, but excluding the poly(A) tail at the 3' end of SEQ ID N0:53; and 3 0 (bb) the nucleotide sequence of the cDNA insert of clone vo28_1 deposited with the ATCC under accession number PTA-1074;

(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:53 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:53 from nucleotide 3 to nucleotide 239, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:53 from nucleotide 3 to nucleotide 239, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:53 from nucleotide 3 to nucleotide 239.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:54;
2 0 (b) a fragment of the amino acid sequence of SEQ ID N0:54, the fragment comprising eight contiguous amino acids of SEQ ID N0:54; and (c) the amino acid sequence encoded by the cDNA insert of clone vo28_1 deposited with the ATCC under accession number PTA-1074;
the protein being substantially free from other mammalian proteins. Preferably such 2 5 protein comprises the amino acid sequence of SEQ ID N0:54. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:54, or a protein comprising a fragment of the amino acid sequence of SEQ
3 0 ID N0:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID N0:54.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55 from nucleotide 49 to nucleotide 1452;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55 from nucleotide 109 to nucleotide 1452;
(d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone vo29_1 deposited with the ATCC under accession number PTA-1074;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo29_1 deposited with the ATCC under accession number PTA-1074;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo29_ 1 deposited with the ATCC under accession number PTA-1074;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo29_1 deposited with the ATCC under accession number PTA-2 0 1074;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:56;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:56 having biological activity, the fragment 2 5 comprising eight contiguous amino acids of SEQ ID N0:56;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:55 from nucleotide 49 to nucleotide 1452; the nucleotide sequence of SEQ ID
NO:55 from nucleotide 109 to nucleotide 1452; the nucleotide sequence of the full-length protein coding sequence of clone vo29_1 deposited with the ATCC under accession number PTA-1074; or the nucleotide sequence of a mature protein coding sequence of clone vo29_1 deposited with the ATCC under accession number PTA-1074. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo29_1 deposited with the ATCC under accession number PTA-1074. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID N0:56.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID NO:55.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ff~ NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vo29_1 deposited with the ATCC under accession number PTA-1074;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:55, but excluding the poly(A) tail at the 3' end of SEQ ID N0:55; and (bb) the nucleotide sequence of the cDNA insert of clone vo29_1 deposited with the ATCC under accession number PTA-1074;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a 2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:55 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:55. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 5 corresponding to the cDNA sequence of SEQ ID N0:55 from nucleotide 49 to nucleotide 1452, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:55 from nucleotide 49 to nucleotide 1452, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:55 from nucleotide 49 to nucleotide 1452. Also preferably the polynucleotide isolated according to the above 3 0 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:55 from nucleotide 109 to nucleotide 1452, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:55 from nucleotide 109 to nucleotide 1452, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:55 from nucleotide 109 to nucleotide 1452.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:56;
(b) a fragment of the amino acid sequence of SEQ ID N0:56, the fragment comprising eight contiguous amino acids of SEQ ID N0:56; and (c) the amino acid sequence encoded by the cDNA insert of clone vo29_1 deposited with the ATCC under accession number PTA-1074;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:56, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID N0:56.
In one embodiment, the present invention provides a composition comprising an 2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57 from nucleotide 48 to nucleotide 866;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57 from nucleotide 114 to nucleotide 866;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vo30_1 deposited with the ATCC under accession number PTA-1074;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-1074;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo30_1 deposited with the ATCC under accession number PTA-1074;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vo30_1 deposited with the ATCC under accession number PTA-1074;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:58;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:58 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:58;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 2 0 25% of the length of SEQ ID N0:57.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:57 from nucleotide 48 to nucleotide 866; the nucleotide sequence of SEQ ID
N0:57 from nucleotide 114 to nucleotide 866; the nucleotide sequence of the full-length protein coding sequence of clone vo30_1 deposited with the ATCC under accession number.PTA-1074; or the nucleotide sequence of a mature protein coding sequence of clone vo30_1 deposited with the ATCC under accession number PTA-1074. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-1074. In further preferred embodiments, the present invention provides a polynucleotide 3 0 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to amino acid 140 of SEQ ID N0:58.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:57.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:57, but excluding the poly(A) tail at the 3' end of SEQ ID N0:57; and (ab) the nucleotide sequence of the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-1074;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the 2 0 probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group 2 5 consisting of:
(ba) SEQ ID N0:57, but excluding the poly(A) tail at the 3' end of SEQ ID N0:57; and (bb) the nucleotide sequence of the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-3 0 1074;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:57, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:57 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:57. Also preferably the ~polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:57 from nucleotide 48 to nucleotide 866, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:57 from nucleotide 48 to nucleotide 866, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:57 from nucleotide 48 to nucleotide 866. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:57 from nucleotide 114 to nucleotide 866, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:57 from nucleotide 114 to nucleotide 866, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:57 from nucleotide 114 to nucleotide 866.
In other embodiments, the present invention provides a composition comprising a 2 0 protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:58;
(b) a fragment of the amino acid sequence of SEQ ID N0:58, the fragment comprising eight contiguous amino acids of SEQ ID N0:58; and 2 5 (c) the amino acid sequence encoded by the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-1074;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:58. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino 3 0 acid sequence of SEQ ID N0:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:58, or a protein comprising a fragment of the amino acid sequence of SEQ

ID N0:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to amino acid 140 of SEQ ID N0:58.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59 from nucleotide 235 to nucleotide 510;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59 from nucleotide 316 to nucleotide 510;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp25_1 deposited with the ATCC under accession number PTA-1074;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA-1074;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp25_1 deposited with the ATCC under accession number PTA-1074;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vp25_1 deposited with the ATCC under accession number PTA-1074;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:60;
2 5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:60 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:60;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
3 0 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:59.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:59 from nucleotide 235 to nucleotide 510; the nucleotide sequence of SEQ ID
N0:59 from nucleotide 316 to nucleotide 510; the nucleotide sequence of the full-length protein coding sequence of clone vp25_1 deposited with the ATCC under accession number PTA-1074; or the nucleotide sequence of a mature protein coding sequence of clone vp25_1 deposited with the ATCC under accession number PTA-1074. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA-1074. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:60 having biological activity, the fragment comprising the amino acid 2 0 sequence from amino acid 41 to amino acid 50 of SEQ ID N0:60.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:59.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
2 5 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:59, but excluding the poly(A) tail at the 3 0 3' end of SEQ ID N0:59; and (ab) the nucleotide sequence of the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA-1074;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ >D N0:59, but excluding the poly(A) tail at the 3' end of SEQ ID N0:59; and (bb) the nucleotide sequence of the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA
1074;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and 2 0 (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:59, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:59 , but 2 5 excluding the poly(A) tail at the 3' end of SEQ ID N0:59. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:59 from nucleotide 235 to nucleotide 510, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:59 from nucleotide 235 to nucleotide 510, to a nucleotide 3 0 sequence corresponding to the 3' end of said sequence of SEQ ID N0:59 from nucleotide 235 to nucleotide 510. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

N0:59 from nucleotide 316 to nucleotide 510, and extending contiguously from a ' nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:59 from nucleotide 316 to nucleotide 510, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:59 from nucleotide 316 to nucleotide 510.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:60;
(b) a fragment of the amino acid sequence of SEQ ID N0:60, the fragment comprising eight contiguous amino acids of SEQ ID N0:60; and (c) the amino acid sequence encoded by the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA-1074;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:60, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:60 having biological activity, the fragment comprising the amino acid sequence 2 0 from amino acid 41 to amino acid 50 of SEQ ID N0:60.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61;
2 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61 from nucleotide 177 to nucleotide 1626;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61 from nucleotide 219 to nucleotide 1626;
(d) a polynucleotide comprising the nucleotide sequence of the full-3 0 length protein coding sequence of clone vq25_1 deposited with the ATCC
under accession number PTA-1074;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq25_1 deposited with the ATCC under accession number PTA-1074;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq25_1 deposited with the ATCC under accession number PTA-1074;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vq25_1 deposited with the ATCC under accession number PTA-1074;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:62;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:62;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any 2 0 one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25°10 of the length of SEQ ID N0:61.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
2 5 N0:61 from nucleotide 177 to nucleotide 1626; the nucleotide sequence of SEQ ID N0:61 from nucleotide 219 to nucleotide 1626; the nucleotide sequence of the full-length protein coding sequence of clone vq25_1 deposited with the ATCC under accession number PTA-1074; or the nucleotide sequence of a mature protein coding sequence of clone vq25_1 deposited with the ATCC under accession number PTA-1074. In other preferred 3 0 embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq25_1 deposited with the ATCC under accession number PTA-1074. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID N0:62.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:61.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:61, but excluding the poly(A) tail at the 3' end of SEQ ID N0:61; and (ab) the nucleotide sequence of the cDNA insert of clone vq25_1 deposited with the ATCC under accession number PTA-1074;
2 0 (ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and 2 5 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:61, but excluding the poly(A) tail at the 3 0 3' end of SEQ ID N0:61; and (bb) the nucleotide sequence of the cDNA insert of clone vq25_1 deposited with the ATCC under accession number PTA-1074;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:61, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:61 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:61 from nucleotide 177 to nucleotide 1626, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:61 from nucleotide 177 to nucleotide 1626, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:61 from nucleotide 177 to nucleotide 1626. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:61 from nucleotide 219 to nucleotide 1626, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:61 from nucleotide 219 to nucleotide 1626, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:61 from nucleotide 219 to nucleotide 1626.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:62;
(b) a fragment of the amino acid sequence of SEQ ID N0:62, the fragment comprising eight contiguous amino acids of SEQ ID N0:62; and (c) the amino acid sequence encoded by the cDNA insert of clone 3 0 vq25_1 deposited with the ATCC under accession number PTA-1074;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:62. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:62, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID N0:62.
In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.
Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the genes) corresponding to the polynucleotide sequences disclosed herein.
Processes are also provided for producing a protein, which comprise:
(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and (b) purifying the protein from the culture.
The protein produced according to such methods is also provided by the present invention.
Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which 2 0 specifically reacts with such protein are also provided by the present invention.
Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures lA and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
Clone"vb24 1"
A polynucleotide of the present invention has been identified as clone "vb24 1 ".
vb24_1 was isolated from a human fetal brain cDNA library and was identified as encoding 2 0 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb24_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb24_1 protein").
The nucleotide sequence of vb24_1 as presently determined is reported in SEQ
ID
NO:l, and includes a poly(A) tail. What applicants presently believe to be the proper 2 5 reading frame and the predicted amino acid sequence of the vb24_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ )D N0:2. Amino acids 3 to 15 of SEQ ID N0:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted 3 0 leader/signal sequence not be separated from the remainder of the vb24_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb24_1 should be approximately 6033 bp.

The nucleotide sequence disclosed herein for vb24_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb24_1 demonstrated at least some similarity with sequences identified as AB005299 (Homo sapiens BAI 3 mRNA, complete cds), ABO11122 (Homo sapiens mRNA for KIAA0550 protein, complete cds), N50991 (yy94e07.s1 Homo sapiens cDNA clone 281220 3'), and Q77404 (Human genome fragment (Preferred);
standard;
DNA). The predicted amino acid sequence disclosed herein for vb24_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX
search protocol. The predicted vb24_1 protein demonstrated at least some similarity to sequences identified as AB005299 (BAI 3 [Homo sapiens]) and W37412 (Human G-protein coupled receptor HIBCD07). Based upon sequence similarity, vb24_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII
computer program predicts eight potential transmembrane domains within the vb24 1 protein sequence, centered around amino acids 16, 888, 923, 952, 993, 1030, 1100, and 1138 of SEQ ID N0:2, respectively. The vb24_1 protein shares significant amino acid sequence similarity with GenBank Accession Number AB005299 (BAI 3 [Homo sapiens]), which is a splice variant of GenBank Accession Number ABOl 1122 (HIAA0550 protein [Homo sapiens]), and shares amino acid similarity with other members of the BAI/secretin protein families. The members of the BAI/secretin protein families are G-protein-coupled 2 0 receptors. The TopPredII profiles for some members of the BAI/secretin protein families are strikingly similar to that of vb24_1, with one transmembrane domain predicted at the N-terminus (approximately within the first 20 amino acids) and multiple transmembrane domains near the C-terminus. The N-terminal transmembrane domains of the BAI/secretin protein family members are described as leader/signal sequences, consistent with the first transmembrane domain in the predicted vb24_1 protein being a leader/signal sequence.
Clone "vc64 1"
A polynucleotide of the present invention has been identified as clone "vc64 1 ".
vc64_1 was isolated from a human fetal brain cDNA library and was identified as encoding 3 0 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc64_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc64_1 protein") The nucleotide sequence of vc64_1 as presently determined is reported in SEQ
ID
N0:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc64_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:4. Amino acids 20 to 32 of SEQ 1D N0:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 33. Due to the hydrophobic nature of the predicted leader/signal sequence, the TopPredII computer program predicts that is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc64_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc64_1 should be approximately 2022 bp.
The nucleotide sequence disclosed herein for vc64_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc64_1 demonstrated at least some similarity with sequences identified as AI217133 (qf47c10.x1 Soares testis NHT Homo sapiens cDNA clone IMAGE:1753170 3', mRNA sequence), T19353 (Human gene signature HUMGS00377;
standard; cDNA to mRNA), and 249239 (A.thaliana mRNA for putative dTDP-glucose 4-6-dehydratases). The predicted amino acid sequence disclosed herein for vc64_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the 2 0 BLASTX search protocol. The predicted vc64_1 protein demonstrated at least some similarity to sequences identified as 898529 (dTDP-glucose dehydratase encoded by the acbB gene), U40800 (similar to thymidine diphosphoglucose 4,6-dehydratase [Caenorhabditis elegans)), and the dehydratases of many disparate species. The hydratase protein family is very diverse with proteins ranging in length from less than 300 to more than 400 amino acids. The vc64_1 protein appears to be an alternatively spliced variant of certain hydratases, and the existence of splice variants is also consistent with the diversity of the hydratase family. Based upon sequence similarity, vc64_1 proteins and each similar protein or peptide may share at least some activity.
vc64_1 protein was expressed in a COS cell expression system, and an expressed 3 0 protein band of approximately 5 kDa was detected in conditioned medium using SDS
polyacrylamide gel electrophoresis.

Clone"vp20 1"
A polynucleotide of the present invention has been identified as clone "vp20_1".
vp20_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp20_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp20_1 protein").
The nucleotide sequence of vp20_1 as presently determined is reported in SEQ
ID
NO:S, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp20_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:6. Amino acids 34 to 46 of SEQ ID N0:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp20_ 1 protein.
Another potential vp20_1 reading frame and predicted amino acid sequence is encoded by basepairs 910 to 1293 of SEQ ID NO:S and is reported as SEQ ID
N0:88.
Amino acids 9 to 21 of SEQ ID N0:88 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of this predicted leader/signal sequence, it is likely to act as a transmembrane 2 0 domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:88.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp20_1 should be approximately 1916 bp.
The nucleotide sequence disclosed herein for vp20_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp20_1 demonstrated at least some similarity with sequences identified as AA044732 (zk67e09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA
clone 487912 3', mRNA sequence) and AA044769 (zk67e09.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487912 5', mRNA sequence). Based upon sequence 3 0 similarity, vp20_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vp20_1 protein sequence, one centered around amino acid 60 and another around amino acid 87 of SEQ ID N0:6. The TopPredII
computer program also predicts one additional potential transmembrane domain within the protein of SEQ ID N0:88, centered around amino acid 80 of SEQ ID N0:88. The nucleotide sequence of the vp20_1 clone indicates that it may contain one or more MIR
repeat sequences.
Clone"vq4 1"
A polynucleotide of the present invention has been identified as clone "vq4_1".
vq4_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vq4_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq4_1 protein").
The nucleotide sequence of vq4_1 as presently determined is reported in SEQ ID
N0:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq4_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:8. Amino acids 7 to 19 of SEQ ID N0:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted 2 0 leader/signal sequence not be separated from the remainder of the vq4_1 protein.
Were the 'G' residue at position 336 of SEQ ID N0:7 to be deleted, two alternative overlapping vq4_1 reading frames and predicted amino acid sequences would result: the first alternative amino acid sequence is encoded by SEQ ID N0:7 from nucleotide 129 to what would then be nucleotide 359, and is reported in SEQ ID N0:89; the second 2 5 alternative amino acid sequence is encoded by SEQ ID N0:7 from nucleotide 275 to what would then be nucleotide 730, and is reported in SEQ ID N0:90.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vq4_1 should be approximately 831 bp.
The nucleotide sequence disclosed herein for vq4_1 was searched against the 3 0 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq4_1 demonstrated at least some similarity with sequences identified as M75099 . (Human rapamycin- and FK506-binding protein, complete cds), N36303 (yx99e09.r1 Homo sapiens cDNA clone 269896 5' similar to SW:FKB3 MOUSE
P45878 FK506-BINDING PROTEIN PRECURSOR), and T18037 (Human FKBP-13 immunophilin cDNA; standard; cDNA). The predicted amino acid sequence disclosed herein for vq4_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq4_1 protein demonstrated at least some similarity to sequences identified as M75099 (rapamycin- and FK506-binding protein [Homo sapiens]) and 828980 (hRFKBP). Based upon sequence similarity, vq4_1 proteins and each similar protein or peptide may share at least some activity.
The TopPredII
computer program predicts two potential transmembrane domains within the vq4_ 1 protein sequence, one centered around amino acid 14 and another around amino acid 164 of SEQ
ID N0:8.
Clone"vo7 1"
A polynucleotide of the present invention has been identified as clone "vo7 1 ".
vo7_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo7_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo7_1 protein").
The nucleotide sequence of vo7_1 as presently determined is reported in SEQ ID
2 0 N0:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo7_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino acids 14 to 26 of SEQ ID NO:10 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted 2 5 leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo7_1 protein.
If a nucleotide were added to the nucleotide sequence of SEQ ID N0:9 between residue 477 and residue 484, and if a purine residue were added to the nucleotide sequence of SEQ ID N0:9 between residue 896 and residue 900, another potential vo7_1 reading 3 0 frame and predicted amino acid sequence encoded by what would then be basepairs 143 to 1336 of SEQ ID N0:9 is reported in SEQ ID N0:91. Amino acids 14 to 26 of SEQ ID
N0:91 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID
N0:91.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vo7_1 should be approximately 1740 bp.
The nucleotide sequence disclosed herein for vo7_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo7_1 demonstrated at least some similarity with sequences identified as L04733 (Homo Sapiens kinesin light chain mRNA, complete cds) and W07481 (za96d09.r1 Soares fetal lung NbHLI9W Homo sapiens cDNA clone 300401 5' similar to gb L04733 KINESIN LIGHT CHAIN (HUMAN); mRNA sequence). The predicted amino acid sequence disclosed herein for vo7_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
The predicted vo7_1 protein demonstrated at least some similarity to sequences identified as L04733 (kinesin light chain [Homo sapiens]). Movement of membrane-bounded organelles to intracellular destinations requires properly oriented microtubules and force-generating enzymes, such as the microtubule-stimulated ATPase kinesin.
(See Cyr et al., 1991, Proc. Natl. Acad. Sci. USA 88(22): 10114-10118, which is incorporated by 2 0 reference herein). Based upon sequence similarity, vo7_1 proteins and each similar protein or peptide may share at least some activity.
Clone "vc65 1"
A polynucleotide of the present invention has been identified as clone "vc65 1".
2 5 vc65_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc65_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc65_1 protein").
The nucleotide sequence of vc65_1 as presently determined is reported in SEQ
ID
3 0 NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc65_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:12. Amino acids 14 to 26 of SEQ ID N0:12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc65_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc65_1 should be approximately 826 bp.
The nucleotide sequence disclosed herein for vc65_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vc65_1 demonstrated at least some similarity with sequences identified as AA506313 (nh45c03.s1 NCI CGAP_Pr5 Homo sapiens cDNA clone IMAGE:955300 similar to TR:G685170 6685170 ADHERIN; mRNA sequence) and T22080 (Human gene signature HUMGS03624). Based upon sequence similarity, vc65_1 proteins and each similar protein or peptide may share at least some activity.
Clone "vc66 1"
A polynucleotide of the present invention has been identified as clone "vc66 1 ".
vc66_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc66_1 is a full-length clone, including the entire coding 2 0 sequence of a secreted protein (also referred to herein as "vc66_1 protein") The nucleotide sequence of vc66_1 as presently determined is reported in SEQ
ID
N0:13, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc66_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:14. Amino acids 28 to 40 2 5 of SEQ ID N0:14 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 41. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc66_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 3 0 vc66_ 1 should be approximately 1652 bp.
The nucleotide sequence disclosed herein for vc66_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vc66_1 demonstrated at least some similarity with sequences identified as AA291293 (zsl8dll.sl NCI CGAP_GCBl Homo sapiens cDNA clone IMAGE 685557 3', mRNA sequence). Based upon sequence similarity, vc66_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vc66_1 indicates that it may contain a LIMAS repeat region.
Clone"vc68 1"
A polynucleotide of the present invention has been identified as clone "vc68 1 ".
vc68_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc68_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc68_1 protein") The nucleotide sequence of vc68_1 as presently determined is reported in SEQ
ID
N0:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc68_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:16. Amino acids 15 to 27 of SEQ ID N0:16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted 2 0 leader/signal sequence not be separated from the remainder of the vc68_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc68_1 should be approximately 2652 bp.
The nucleotide sequence disclosed herein for vc68_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc68_1 demonstrated at least some similarity with sequences identified as AI147732 (qb47e06.x1 NCI CGAP_Brn23 Homo sapiens cDNA clone IMAGE 1703266 3' similar to WP F55C5.2 CE11152 GLYCEROPHOSPHORYLDIESTER PHOSPHODIESTERASE LIKE; mRNA sequence), AC003108 (Human Chromosome 16 BAC clone CIT987SK-327024, complete sequence), 3 0 and T26462 (Human gene signature HUMGS08704). The predicted amino acid sequence disclosed herein for vc68_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc68_ 1 protein demonstrated at least some similarity to sequences identified as AC00310 (Unknown gene product [Homo sapiens]) and W89783 (Staphylococcus aureus protein SEQ ID
#5231).
Based upon sequence similarity, vc68_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vc68_1 protein sequence centered around amino acid 38 of SEQ ID N0:16. The nucleotide sequence of vc68_1 indicates that it may contain an Alu repetitive element.
Clone "vk6 1"
A polynucleotide of the present invention has been identified as clone "vk6_1 ".
vk6_1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vk6_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vk6_1 protein").
The nucleotide sequence of vk6_1 as presently determined is reported in SEQ ID
N0:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vk6_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:18. Amino acids
10 to 22 of SEQ ID N0:18 are a predicted leader/signal sequence, with the predicted mature amino 2 0 acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vk6_1 protein.
If nine nucleotides encoding the amino acid sequence Met-Ile-Phe were inserted between nucleotide 678 and nucleotide 679 of SEQ ID N0:17, another potential vk6_1 2 5 reading frame and predicted amino acid sequence, encoded by what would then be basepairs 79 to 2427 of SEQ ID N0:17, is reported in SEQ ID N0:92.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vk6_1 should be approximately 4899 bp.
The nucleotide sequence disclosed herein for vk6_1 was searched against the 3 0 GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vk6_1 demonstrated at least some similarity with sequences identified as AC006208 (Homo Sapiens 3p21.1-9 PAC RPCI4-793P23 (Roswell Park Cancer Institute Human PAC Library) complete sequence), AI127070 (qb97e10.x1 Soares fetal heart NbHHI9W Homo sapiens cDNA clone IMAGE 1708074 3', mRNA sequence), U28369 (Homo sapiens semaphorin V mRNA, complete cds), and V35367 (Human semaphorin encoding cDNA). The predicted amino acid sequence disclosed herein for vk6_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vk6_1 protein demonstrated at least some similarity to sequences identified as U28369 (semaphorin V [Homo sapiens]) and W63748 (Human semaphorin). The vk6_1 amino acid sequence also demonstrated significant similarities to the semaphorin and collapsin proteins of many species. "The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules." (Kolodkin et al., 1993, Cell 75(7): 1389-99, which is incorporated by reference herein). Based upon sequence similarity, vk6_1 proteins and each similar protein or peptide may share at least some activity. Motif analysis detects an ATP/GTP-binding site motif A (P-loop) around residue 747 of SEQ ID N0:18. The TopPredII
computer program predicts two additional potential transmembrane domains within the vk6_1 protein sequence, one centered around amino acid 140 and another around amino acid 336 of SEQ
ID N0:18.
Clone "vo4 1 "
2 0 A polynucleotide of the present invention has been identified as clone "vo4 1 ".
vo4_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo4_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo4_1 protein").
The nucleotide sequence of vo4_1 as presently determined is reported in SEQ ID
N0:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo4_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:20. Amino acids
11 to 23 of SEQ ID N0:20 are a predicted leader/signal sequence, with the predicted mature amino 3 0 acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo4_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vo4_1 should be approximately 2383 bp.
The nucleotide sequence disclosed herein for vo4_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo4_1 demonstrated at least some similarity with sequences identified as AA613523 (nq22dOl .s 1 NCI CGAP_Co 10 Homo Sapiens cDNA clone IMAGE:1144609, mRNA sequence), E 12646 (cDNA encoding cell growth inhibiting factor), and Q60729 (Human brain Expressed Sequence Tag EST00852). The predicted amino acid sequence disclosed herein for vo4_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo4_1 protein demonstrated at least some similarity to sequences identified as W74956 (Human secreted protein encoded by gene 77 clone HOEAS24) and 292825 (C13C4.5 [Caeno-rhabditis elegans]). Based upon sequence similarity, vo4._1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four additional potential transmembrane domains within the vo4 1 protein sequence, centeres around amino acids 69, 114, 169, and 207 of SEQ ID
N0:20, respectively.
Clone"vo8 1"
2 0 A polynucleotide of the present invention has been identified as clone "vo8 1".
vo8_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo8_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo8_1 protein").
The nucleotide sequence of vo8_1 as presently determined is reported in SEQ ID
N0:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo8_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:22. Amino acids 10 to 22 of SEQ ID N0:22 are a predicted leader/signal sequence, with the predicted mature amino 3 0 acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo8_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vo8_1 should be approximately 3243 bp.
The nucleotide sequence disclosed herein for vo8_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vo8_1 demonstrated at least some similarity with sequences identified as AF007138 (Homo sapiens clone 23631 mRNA sequence), AI204925 (an02a08.x 1 Stratagene schizo brain S 11 Homo sapiens cDNA clone IMAGE
1684406 3' similar to TR Q92597 Q92597 RTP, COMPLETE CDS; mRNA sequence), and Q59200 (Human brain Expressed Sequence Tag EST00134). The predicted amino acid sequence disclosed herein for vo8_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo8_1 protein demonstrated at least some similarity to sequences identified as AF045564 (development-related protein [Rattus norvegicus]). Based upon sequence similarity, vo8_1 proteins and each similar protein or peptide may share at least some activity.
Clone"vol0 1"
A polynucleotide of the present invention has been identified as clone "vol0 1 ".
vol0_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the 2 0 amino acid sequence of the encoded protein. vo 10_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo 10_ 1 protein").
The nucleotide sequence of vol0_1 as presently determined is reported in SEQ
ID
N0:23, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vol0_1 protein corresponding 2 5 to the foregoing nucleotide sequence is reported in SEQ ID N0:24. Amino acids 15 to 27 of SEQ ID N0:24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vol0_1 protein.
3 0 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vol0_1 should be approximately 1048 bp.

The nucleotide sequence disclosed herein for vol0_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol0_1 demonstrated at least some similarity with sequences identified as AI193090 (qe69e08.x1 Soares_fetal_lung NbHLI9W Homo Sapiens cDNA
clone IMAGE:1744262 3' similar to WP:F45G2.10 CE16053; mRNA sequence) and T 19307 (Human gene signature HUMGS00329). The predicted amino acid sequence disclosed herein for vol0_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vol0_1 protein demonstrated at least some similarity to sequences identified as 293382 (F45G2.10 [Caenorhabditis elegans]). Based upon sequence similarity, vol0_1 proteins and each similar protein or peptide may share at least some activity.
Clone"vo20 1"
A polynucleotide of the present invention has been identified as clone "vo20 1".
vo20_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo20_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo20_ 1 protein").
The nucleotide sequence of vo20_1 as presently determined is reported in SEQ
ID
2 0 N0:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo20_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:26. Amino acids 6 to 18 of SEQ ID N0:26 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted 2 5 leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo20_1 protein.
If a nucleotide residue was deleted from the sequence beginning at nucleotide and ending at nucleotide 774 of SEQ ID N0:25, another potential vo20_1 reading frame and predicted amino acid sequence, encoded by what would then be basepairs 102 to 932 3 0 of SEQ ID N0:25, is reported in SEQ ID N0:93.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vo20_1 should be approximately 2067 bp.

The nucleotide sequence disclosed herein for vo20_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo20_1 demonstrated at least some similarity with sequences identified as AA452380 (zx29bl l.rl Soares total fetus Nb2HF8 9w Homo sapiens cDNA
clone 787869 5', mRNA sequence), L13291 Human ADP-ribosylarginine hydrolase mRNA, complete cds), and V05140 (cDNA encoding human ADP-ribosylarginine hydrolase). The predicted amino acid sequence disclosed herein for vo20_ 1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX
search protocol. The predicted vo20_1 protein demonstrated at least some similarity to sequences identified as L13291 (ADP-ribosylarginine hydrolase [Homo sapiensJ) and W46493 (Human ADP-ribosylarginine hydrolase). Based upon sequence similarity, vo20_1 proteins and each similar protein or peptide may share at least some activity. The predicted vo20_1 protein demonstrated at least some similarity to ADP-ribosylarginine hydrolases from other species as well, which catalyze the reverse reaction of mono-ADP-ribosylation. "ADP-ribosylarginine hydrolases specifically cleave the alpha-anomer, leading to release of ADP-ribose and regeneration of the free guanidino group of arginine" (Moss et al., 1997, Adv. Exp. Med. Biol. 419: 25-33, which is incorporated by reference herein). Moss et al. also proport that there might be a cell surface version of the hydrolase. The TopPredII computer program predicts two additional 2 0 potential transmembrane domains within the vo20_1 protein sequence, one centered around amino acid 176 and another around amino acid 314 of SEQ ID N0:26.
Clone "vo21 1"
A polynucleotide of the present invention has been identified as clone "vo21 1 ".
vo21_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo21_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo21_1 protein").
The nucleotide sequence of vo21_1 as presently determined is reported in SEQ
ID
3 0 N0:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo21_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:28. Amino acids 18 to 30 of SEQ ID N0:28 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 31. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo21_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vo21_1 should be approximately 2560 bp.
The nucleotide sequence disclosed herein for vo21_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No significant sequence similarities were identified.
Motif analysis revealed a cytochrome C motif around residue 3 of SEQ ID N0:28. The TopPredII computer program predicts an additional potential transmembrane domain within the vo21_1 protein sequence centered around amino acid 193 of SEQ ID
N0:28.
The nucleotide sequence of vo21_1 indicates that it may contain an Alu repetitive element.
Clone "vp24 1 "
A polynucleotide of the present invention has been identified as clone "vp24_1 ".
vp24_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp24_1 is a full-length clone, including the 2 0 entire coding sequence of a secreted protein (also referred to herein as "vp24_1 protein").
The nucleotide sequence of vp24_1 as presently determined is reported in SEQ
ID
N0:29, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp24_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:30. Amino acids 7 to 19 2 5 of SEQ ID N0:30 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp24_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 3 0 vp24_1 should be approximately 1536 bp.
The nucleotide sequence disclosed herein for vp24_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp24_1 demonstrated at least some similarity with sequences identified as AA947280 (ok20a12.s1 Soares NSF F8 9W_OT PA P S1 Homo Sapiens cDNA clone IMAGE 1508350 3', mRNA sequence). Based upon sequence similarity, vp24_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vp24_1 protein sequence centered around amino acid 55 of SEQ ID
N0:30.
Clone "vol7 1"
A polynucleotide of the present invention has been identified as clone "vo 17 1 ".
vol7_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vol7_1 is a full-length clone, including the entire coding sequence of a protein (also referred to herein as "vol7_1 protein") The nucleotide sequence of vol7_1 as presently determined is reported in SEQ
ID
N0:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vol7_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:32. Amino acids 21 to 33 of SEQ ID N0:32 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 34.
Another potential vol7_1 reading frame and predicted amino acid sequence, encoded by basepairs 2530 to 2691 of SEQ ID N0:31, is reported in SEQ ID
N0:94.
Amino acids 2 to 14 of SEQ ID N0:94 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain 2 5 should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:94.
Another potential vol7_1 reading frame and predicted amino acid sequence, encoded by basepairs 402 to 785 of SEQ ID N0:31, is reported in SEQ ID N0:95.
Amino acids 32 to 44 of SEQ ID N0:95 are a possible leader/signal sequence, with the predicted 3 0 mature amino acid sequence beginning at amino acid 45. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:95.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vol7_1 should be approximately 2755 bp.
The nucleotide sequence disclosed herein for vol7_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol7_1 demonstrated at least some similarity with sequences identified as AF020762 (Homo sapiens clone 1400 unknown protein mRNA, partial cds), N91173 (zb12c08.s1 Soares fetal lung NbHLI9W Homo sapiens cDNA clone 301838 3', mRNA sequence), and Q60597 (Human brain Expressed Sequence Tag EST02608). The predicted amino acid sequence disclosed herein for vol7_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
The predicted vol7_1 protein demonstrated at least some similarity to sequences identified as AF020762 (unknown protein [Homo sapiens]) and AF022770 (peripherial benzodiazepine receptor associated protein [Mus musculus]). Benzodiazepine receptors are responsible for the manifestation of peripheral-type benzodiazepine recognition sites and are most likely to comprise binding domains for benzodiazepines and isoquinoline carboxamides. These integral membrane protein receptors play a role in the transport of porphyrins and heme and have a mitochondria) subcellular localization. Based upon 2 0 sequence similarity, vol7_1 proteins and each similar protein or peptide may share at least some activity.
Clone "v lq 1 1"
A polynucleotide of the present invention has been identified as clone "vql l_1 ".
2 5 vql l_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql l_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vql l_1 protein").
The nucleotide sequence of vql 1_1 as presently determined is reported in SEQ
ID
3 0 N0:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vql l_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ 117 N0:34. Amino acids 15 to 27 of SEQ ID N0:34 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql l_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vql 1_1 should be approximately 1177 bp.
The nucleotide sequence disclosed herein for vql l_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vql l_1 demonstrated at least some similarity with sequences identified as 839062 (yd08g1l.sl Homo sapiens cDNA clone 25117 3'). Based upon sequence similarity, vql 1_1 proteins and each similar protein or peptide may share at least some activity.
Clone "v lq 2 1"
A polynucleotide of the present invention has been identified as clone "vq 12_ 1 ".
vq 12_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vql2_1 protein") 2 0 The nucleotide sequence of vq 12_ 1 as presently determined is reported in SEQ ID
N0:35, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vql2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:36. Amino acids 2 to 14 of SEQ ID N0:36 are a predicted leader/signal sequence, with the predicted mature amino 2 5 acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql2_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vq 12_ 1 should be approximately 1435 bp.
30 The nucleotide sequence disclosed herein for vql2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vql2_1 demonstrated at least some similarity with sequences identified as AI479299 (tm56hOl.x1 NCI CGAP Kidll Homo sapiens cDNA clone IMAGE:2162161 3', mRNA sequence). Based upon sequence similarity, vql2_1 proteins and each similar protein or peptide may share at least some activity. Motifs analysis detects a glycoprotein hormones beta chain signature centered approximately around amino acid 192 of SEQ ID N0:36.
Clone "v lq 4 1 "
A polynucleotide of the present invention has been identified as clone "vq 14_ 1 ".
vql4_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql4_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vql4_1 protein") The nucleotide sequence of vql4_1 as presently determined is reported in SEQ
ID
N0:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vql4_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:38. Amino acids 3 to 15 of SEQ ID N0:38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted 2 0 leader/signal sequence not be separated from the remainder of the vq 14_1 protein.
If two nucleotides were inserted between nucleotide 651 and nucleotide 657 of SEQ
ID N0:37, another potential vql4_1 reading frame and predicted amino acid sequence, encoded by what would then be basepairs 32 to 712 of SEQ ID N0:37, is reported in SEQ
ID N0:96. Amino acids 3 to 15 of SEQ ID N0:96 are a predicted leader/signal sequence, 2 5 with the predicted mature amino acid sequence beginning at amino acid 16.
Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:96.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 3 0 vql4_1 should be approximately 1183 bp.
The nucleotide sequence disclosed herein for vql4_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql4_1 demonstrated at least some similarity with sequences identified as AI291113 (qm10d12.x1 NCI CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1881431 3' similar to contains LTRl.t3 TAR1 repetitive element; mRNA
sequence) and T80413 (Tylactone synthase gene cluster). Based upon sequence similarity, vql4_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts 7 additional potential transmembrane domains within the vql4_1 protein sequence, centered around amino acids 59, 108, 137, 176, 220, 240, and 250 of SEQ ID N0:38, respectively. The protein of SEQ ID N0:96 is also predicted to have 4 additional potential transmembrane domains, centered around amino acids 59, 108, 137, and 176 of SEQ ID N0:96, respectively.
Clone "vql5 1"
A polynucleotide of the present invention has been identified as clone "vql5_1".
vql5_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql5_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vql5_1 protein").
The nucleotide sequence of vql5_1 as presently determined is reported in SEQ
ID
N 039, and includes a poly(A) tail. What applicants presently believe to be the proper 2 0 reading frame and the predicted amino acid sequence of the vql5_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:40. Amino acids 74 to 86 of SEQ ID N0:40 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 87. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted 2 5 leader/signal sequence not be separated from the remainder of the vq 15_1 protein.
Another potential vql5_1 reading frame and predicted amino acid sequence, encoded by basepairs 18 to 353 of SEQ ID N0:39, is reported in SEQ ID N0:97.
Amino acids 24 to 36 of SEQ ID N0:97 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 37. Due to the hydrophobic nature 3 0 of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:97.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vql5_1 should be approximately 1519 bp.
The nucleotide sequence disclosed herein for vql5_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql5_1 demonstrated at least some similarity with sequences identified as AA573785 (nk07e12.s1 NCI CGAP_Co2 Homo sapiens cDNA clone IMAGE 1012846, mRNA sequence), AF115384 (Homo sapiens LR8 (LR8) mRNA, complete cds), and T20820 (Human gene signature HUMGS02069). The predicted amino acid sequence disclosed herein for vql5_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vql5_1 protein demonstrated at least some similarity to sequences identified as AF11538 (LR8 [Homo sapiens]) and W75125 (Human secreted protein encoded by gene 69 clone HPEBD70). LR8 is a protein of unknown function, "expressed by a subpopulation of human lung fibroblasts by differential display" (Lurton et al., 1999, Am J
Respir Cell Mol Biol 20(2): 327-31, which is incorporated by reference herein). Based upon sequence similarity, vql5_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vql5_1 protein sequence, one centered around amino acid 138 and another around amino acid 218 of SEQ ID N0:40.
Clone "vql7 1"
A polynucleotide of the present invention has been identified as clone "vql7_1 ".
vql7_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid 2 5 sequence of the encoded protein. vq 17_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vql7_1 protein").
The nucleotide sequence of vql7_1 as presently determined is reported in SEQ
ID
N0:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vql7_1 protein corresponding 3 0 to the foregoing nucleotide sequence is reported in SEQ ID N0:42. Amino acids 7 to 19 of SEQ ID N0:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql7_1 protein.
Another potential vql7_1 reading frame and predicted amino acid sequence, encoded by basepairs 1947 to 2342 of SEQ ID N0:41, is reported in SEQ ID
N0:98.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vql7_1 should be approximately 2869 bp.
The nucleotide sequence disclosed herein for vql7_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql7_1 demonstrated at least some similarity with sequences identified as AA225412 (nc24f07.s1 NCI CGAP_Prl Homo Sapiens cDNA clone IMAGE:1009093, mRNA sequence) and T20503 (Human gene signature HUMGS01709).
Based upon sequence similarity, vql7_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vql7_1 protein sequence centered around amino acid 65 of SEQ ID N0:42. The TopPredII computer program predicts two potential transmembrane domains within the protein sequence of SEQ ID N0:98, one centered around amino acid 66 and another around amino acid 79 of SEQ ID N0:98.
Clone "v lq 8 1"
2 0 A polynucleotide of the present invention has been identified as clone "vq 18_1 ".
vq 18_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql8_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq 18_ 1 protein") 2 5 The nucleotide sequence of vq 18_1 as presently determined is reported in SEQ ID
N0:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vql8_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:44. Amino acids 11 to 23 of SEQ ID N0:44 are a predicted leader/signal sequence, with the predicted mature amino 3 0 acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql8_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vq 18_ 1 should be approximately 687 bp.
The nucleotide sequence disclosed herein for vql8_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql8_1 demonstrated at least some similarity with sequences identified as 847882 (yj62dll.rl Soares breast 2NbHBst Homo sapiens cDNA clone IMAGE 153333 5', mRNA sequence). Based upon sequence similarity, vql8_1 proteins and each similar protein or peptide may share at least some activity. The vql8_1 protein appears to be one member of a family of proteins produced by alternative splicing (see, for example, the yd51_1 protein of International Application No. PCT/US99/10843, which is incorporated by reference herein).
Clone "v 2q 2 1 "
A polynucleotide of the present invention has been identified as clone "vq22_1".
vq22_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vq22_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq22_1 protein").
The nucleotide sequence of vq22_1 as presently determined is reported in SEQ
ID
2 0 N0:45, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq22_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:46. Amino acids 16 to 28 of SEQ ID N0:46 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 29. Due to the hydrophobic nature of the predicted 2 5 leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq22_1 protein.
If the following changes were made to the nucleotide sequence of SEQ ID N0:45 - deletion of nucleotides 1096 and 1097; deletion of one nucleotide from the group of nucleotides 1142, 1143, and 1144; deletion of one nucleotide from the group of nucleotides 3 0 1159, 1160, and 1161; deletion of one nucleotide from the group of nucleotides 1187, 1188, and 1189; and insertion of a "G" residue between nucleotide 1204 and nucleotide 1207 -another potential reading frame would be createdfrom what would then be nucleotides 65 to 1327, with a predicted amino acid sequence reported as SEQ ID N0:99. Amino acids 16 to 28 of SEQ ID N0:99 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 29. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:99.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vq22_1 should be approximately 1653 bp.
The nucleotide sequence disclosed herein for vq22_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vq22_1 demonstrated at least some similarity with sequences identified as AA716162 (zg63fOl.s1 Soares fetal_heart_NbHHI9W Homo sapiens cDNA
clone IMAGE:398041 3', mRNA sequence) and T26470 (Human gene signature HUMGS08712). The predicted amino acid sequence disclosed herein for vq22_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq22_1 protein demonstrated at least some similarity to sequences identified as U58748 (similar to potential transmembrane domains in S. cerevisiae nuclear division RFTl protein (SP P38206) [Caenorhabditis elegans]).
Based upon sequence similarity, vq22_1 proteins and each similar protein or peptide may 2 0 share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within both the vq22_1 protein sequence and the amino acid sequence of the protein of SEQ ID N0:99, centered around amino acids 96, 126, 181, and 343, respectively, of SEQ ID N0:46 and of SEQ ID N0:99.
2 5 Clone "vr3 1 "
A polynucleotide of the present invention has been identified as clone "vr3_1 ".
vr3_1 was isolated from a human adult muscle cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vr3_1 is a full-length clone, including the 3 0 entire coding sequence of a secreted protein (also referred to herein as "vr3_1 protein") The nucleotide sequence of vr3_1 as presently determined is reported in SEQ ID
N0:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vr3_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:48. Amino acids 2 to 14 of SEQ ID N0:48 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vr3_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vr3_1 should be approximately 3133 bp.
The nucleotide sequence disclosed herein for vr3_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vr3_1 demonstrated at least some similarity with sequences identified as AI302099 (qn57g 10.x 1 NCI CGAP_Kids Homo sapiens cDNA clone IMAGE 1902402 3' similar to gb M14058 COMPLEMENT C1R COMPONENT
PRECURSOR (HUMAN); mRNA sequence) and M14058 (Human complement Clr mRNA, complete cds). The predicted amino acid sequence disclosed herein for vr3_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vr3_1 protein demonstrated at least some similarity to sequences identified as M14058 (human complement Clr [Homo sapiens]).
C 1 r is a zymogen of a serine protease that is involved in the activation of the first 2 0 component of the classical pathway of the complement system (Leytus et al., 1986, Biochemistry 25 (17): 4855-4863, which is incorporated by reference herein).
Based upon sequence similarity, vr3_1 proteins and each similar protein or peptide may share at least some activity. Motifs analysis detects a serine proteases, trypsin family, active site around residue 407 of SEQ ID N0:48. Hidden Markov Model analysis detects a CUB domain 2 5 from residue 16 to residue 137 of SEQ ID N0:48, and a trypsin profile from residue 222 to residue 456 of SEQ ID N0:48. The nucleotide sequence of vr3_1 indicates that it may contain an Alu repetitive element.
Clone"vb26 1"
3 0 A polynucleotide of the present invention has been identified as clone "vb26 1 ".
vb26_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb26_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb26_1 protein").
The nucleotide sequence of vb26_1 as presently determined is reported in SEQ
ID
N0:49, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb26_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:50. Amino acids 13 to 25 of SEQ ID N0:50 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb26_1 protein.
The nucleotide and amino acid sequences of vb26_1 are related to those of clone vc8_1, described in U.S. application Ser. No. 09/298,733. Clone vb26 1 contains the entire coding sequence of clone vc8_1, and has an additional three nucleotides at nucleotides 1283 to 1285 of SEQ ID N0:49.
The EcoRIlNotI restriction fragment obtainable from the deposit containing clone vb26_1 should be approximately 2974 bp.
The nucleotide' sequence disclosed herein for vb26_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vb26_1 demonstrated at least some similarity with sequences 2 0 identified as AI807015 (wf37b05.x 1 Soares NFL_T GBC_S 1 Homo Sapiens cDNA
clone IMAGE:2357745 3' similar to SW:NDC1 RABIT Q28615 RENAL SODIUM/
DICARBOXYLATE COTRANSPORTER; mRNA sequence), U26209 (Human renal sodium/dicarboxylate cotransporter (NADC1) mRNA, complete cds), and V27580 (Human hepatocyte nuclear factor 4 isoform gamma DNA). The predicted amino acid sequence disclosed herein for vb26_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vb26_1 protein demonstrated at least some similarity to sequences identified as U87318 (NaDC-[Xenopus laevis]) and W98815 (H. pylori GHPO 1401 protein). Human renal sodium/dicarboxylate cotransporter (NADC1) displays remarkably wide substrate 3 0 selectivity, covering endogenous substrates such as cyclic nucleotides, a prostaglandin and uric acid, and a variety of drugs with different structures (e.g. antibiotics, a nonsteroidal anti-inflammatory drug, diuretics, an antineoplastic drug, and a uricosuric drug); this protein is a multispecific organic anion transporter at the basolateral membrane of the proximal tubule (Sekine et al., 1997, J. Biol. Chem. 272 (30): 18526-9, which is incorporated by reference herein). Based upon sequence similarity, vb26_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts 11 probable transmembrane domains within the vb26_1 protein sequence, centered around amino acids 46, 61, 132, 282, 323, 385, 423, 508, 529, 556, and 598 of SEQ ID N0:50, respectively, and an additional two putative transmernbrane domains centered around residues 91 and 472 of SEQ ID N0:50.
Clone "vc70 1"
A polynucleotide of the present invention has been identified as clone "vc70 1 ".
vc70_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc70_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc70_1 protein").
The nucleotide sequence of vc70_1 as presently determined is reported in SEQ
ID
N0:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc70_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:52. Amino acids 15 to 27 2 0 of SEQ ID N0:52 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc70_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc70_1 should be approximately 2187 bp.
The nucleotide sequence disclosed herein for vc70_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc70_1 demonstrated at least some similarity with sequences identified as AI423223 (tf26fOl.x1 NCI CGAP_Brn23 Homo sapiens cDNA clone 3 0 IMAGE:2097337 3', mRNA sequence) and X33812 (Coding sequence for human secreted protein cb96_10). The predicted amino acid sequence disclosed herein for vc70_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc70_1 protein demonstrated at least some similarity to sequences identified as Y05319 (Human secreted protein cb96_10).
Based upon sequence similarity, vc70_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts eight additional potential transmembrane domains within the vc70_1 protein sequence, centered around amino acids 58, 110, 153, 204, 316, 373, 420, and 502 of SEQ ID N0:52, respectively. The vc70_1 protein appears to be a splice variant of the cb96_10 protein, with the vc70_1 protein having an additional 73 amino acids at the N-terminal end containing a signal sequence and an additional transmembrane domain.
Clone "vo28 1 "
A polynucleotide of the present invention has been identified as clone "vo28 1 ".
vo28_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo28_1 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "vo28_1 protein") The nucleotide sequence of vo28_1 as presently determined is reported in SEQ
ID
N0:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo28_1 protein corresponding 2 0 to the foregoing nucleotide sequence is reported in SEQ ID N0:54.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vo28_1 should be approximately 2056 bp.
The nucleotide sequence disclosed herein for vo28_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vo28_1 demonstrated at least some similarity with sequences identified as F22780 (HSPD07683 HM3 Homo Sapiens cDNA clone LL44B 10, mRNA
sequence). Based upon sequence similarity, vo28_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vo28_1 indicates that it may contain an Alu repetitive element.

Clone"vo29 1"
A polynucleotide of the present invention has been identified as clone "vo29 1 ".
vo29_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo29_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo29_1 protein").
The nucleotide sequence of vo29_1 as presently determined is reported in SEQ
ID
N0:55, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo29_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:56. Amino acids 8 to 20 of SEQ ID N0:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21; amino acids 5 to 17 of SEQ ID N0:56 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 18; and amino acids 11 to 23 of SEQ ID
N0:56 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 24. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the protein of SEQ ID N0:56.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 2 0 vo29_1 should be approximately 1803 bp.
The nucleotide sequence disclosed herein for vo29_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo29_1 demonstrated at least some similarity with sequences identified as AI433801 (th81f07.x1 Soares NhHMPu_S1 Homo sapiens cDNA clone 2 5 IMAGE:2125093 3' similar to SW:YMNO YEAST Q03103 HYPOTHETICAL 65.0 KD
PROTEIN IN COX 14 5'REGION PRECURSOR; mRNA sequence), AR018794 (Sequence 76 from patent US 5783182), and X19751 (Mammalian Erol DNA). The predicted amino acid sequence disclosed herein for vo29_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo29_1 3 0 protein demonstrated at least some similarity to sequences identified as (unknown protein [Arabidopsis thaliana)), W99801 (Mammalian Erol protein), and Y03632 (Hypoxia-regulated gene RTP241 product). Erol regulates the oxidation potential of the endoplasmic reticulum, and may be used to increase disulfide bond formation in proteins during their production and/or purification. Based upon sequence similarity, vo29_1 proteins and each similar protein or peptide may share at least some activity.
Motifs analysis detects an EF-hand calcium binding domain centered around amino acid 159 of SEQ ID N0:56.
Clone"vo30 1"
A polynucleotide of the present invention has been identified as clone "vo30_1".
vo30_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo30_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo30_1 protein").
The nucleotide sequence of vo30_1 as presently determined is reported in SEQ
ID
N0:57, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo30_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:58. Amino acids 10 to 22 of SEQ ID N0:58 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted 2 0 leader/signal sequence not be separated from the remainder of the vo30_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vo30_1 should be approximately 1356 bp.
The nucleotide sequence disclosed herein for vo30_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTNBLASTX and FASTA search protocols. vo30_1 demonstrated at least some similarity with sequences identified as AA397685 (zt87d03.r1 Soares testis NHT Homo sapiens cDNA clone IMAGE 729317 5', mRNA sequence) and AI983410 (wu19c10.x1 Soares Dieckgraefe colon NHCD Homo sapiens cDNA clone IMAGE:990757 3' similar to contains TARl.t3 TAR1 repetitive element; mRNA sequence). Based upon sequence similarity, vo30_1 3 0 proteins and each similar protein or peptide may share at least some activity. Motifs analysis detects an ATP/GTP binding site motif A (P-loop) centered around amino acid 38 of SEQ ID N0:58.

Clone "v 2p 5 1 "
A polynucleotide of the present invention has been identified as clone "vp25_1 ".
vp25_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp25_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp25_1 protein").
The nucleotide sequence of vp25_1 as presently determined is reported in SEQ
ID
N0:59, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp25_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:60. Amino acids 15 to 27 of SEQ ID N0:60 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp25_1 protein.
Another potential reading frame, encoded by nucleotides 1362 to 1622 of SEQ ID
N0:59, is reported as the amino acid sequence of SEQ ID NO:100. Amino acids 5 to 17 of SEQ ID NO:100 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted 2 0 leader/signal sequence not be separated from the remainder of the protein of SEQ ID
NO:100.
Another potential reading frame, encoded by nucleotides 2560 to 2820 of SEQ ID
N0:59, is reported as the amino acid sequence of SEQ ID NO:101. Amino acids 21 to 33 of SEQ ID NO:101 are a predicted leader/signal sequence, with the predicted mature amino 2 5 acid sequence beginning at amino acid 34. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID
NO:101.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 3 0 vp25_ 1 should be approximately 2989 bp.
The nucleotide sequence disclosed herein for vp25_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp25_1 demonstrated at least some similarity with sequences identified as AA481107 (aa29dOl.r1 NCI CGAP_GCB 1 Homo Sapiens cDNA clone IMAGE:814657 5', mRNA sequence), AF146793 (Mus musculus protein B gene, partial cds; and CLOCK (Clock), PFT27 (pFT27), and HSAR (HSAR) genes, complete cds), AI081234 (oy67a03.x1 NCI CGAP_CLL1 Homo sapiens cDNA clone IMAGE 1670860 3' similar to SW PF27_MOUSE P52875 TRANSMEMBRANE PROTEIN PFT27;
contains MSRl.tl MSR1 repetitive element), and X37441 (Human secreted protein cDNA
fragment containing gene 55). The predicted amino acid sequence disclosed herein for vp25_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vp25_1 protein demonstrated at least some similarity to sequences identified as AF14679 (PFT27 [Mus musculus]) and (Human secreted protein fragment #2 encoded from gene 55). Based upon sequence similarity, vp25_1 proteins and each similar protein or peptide may share at least some activity. The vp25_1 protein and the proteins of database entries AF14679 and appear to be members of a family of proteins produced as splice variants. The nucleotide sequence of vp25_1 indicates that it may contain an Alu repetitive element.
Clone"vq25 1"
A polynucleotide of the present invention has been identified as clone "vq25_1 ".
2 0 vq25_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vq25_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq25_1 protein").
The nucleotide sequence of vq25_1 as presently determined is reported in SEQ
ID
N0:61, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq25_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:62. Amino acids 2 to 14 of SEQ ID N0:62 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15; amino acids 4 to 16 of SEQ ID N0:62 are also 3 0 a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 17. Due to the hydrophobic nature of these predicted leader/signal sequence, each is likely to act as a transmembrane domain should it not be separated from the remainder of the vq25_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vq25_1 should be approximately 2048 bp.
The nucleotide sequence disclosed herein for vq25_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq25_1 demonstrated at least some similarity with sequences identified as AC007026 (Homo sapiens clone DJ0751 G 11, complete sequence), (oz77hOl .x 1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone IMAGE
1681393 3' similar to SW CTCF_HUMAN P49711 TRANSCRIPTIONAL REPRESSOR
CTCF; mRNA sequence), AW003280 (wq64h08.x1 NCI CGAP_GC6 Homo sapiens cDNA clone IMAGE:2476095 3' similar to TR:Q60694 Q60694 REl-SILENCING
TRANSCRIPTION FACTOR; mRNA sequence), and X00648 (Human secreted protein gene 38 clone HODCV74). The predicted amino acid sequence disclosed herein for vq25_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq25_1 protein demonstrated at least some similarity to sequences identified as AC00487 (zinc finger-like; similar to P52742 (PID g 1731411 ) [Homo sapiens]) and 899364 (Human REST protein DNA binding domain). Based upon sequence similarity, vq25_1 proteins and each similar protein or 2 0 peptide may share at least some activity. Motifs analysis detects three Zinc-finger, C2H2-type, domains centered around amino acids 149, 359, and 387 of SEQ ID N0:62, respectively. Hidden markov model analysis detects eight of these Zinc-forger, C2H2-type, domains approximately at amino acids 91 to 113, 119 to 141, 147 to 169, 301 to 323, 329 to 351, 357 to 379, 385 to 407, and 413 to 435 of SEQ ID N0:62, respectively.
Deposit of Clones Clones vb24_l, vc64_1, vp20_1, and vq4_1 were deposited on February 17, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty 3 0 and were given the accession number 207113, from which each clone comprising a particular polynucleotide is obtainable.

Clone vo7_1 was deposited on July 15, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number PTA-362, from which the vo7_1 clone comprising a particular polynucleotide is obtainable.
Clones vc65_1, vc66_l, vc68_1, vk6_1, vo4_l, vo8_l, vol0_l, vo20_1, vo21_l, and vp24_ 1 were deposited on July 15, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number PTA-361, from which each clone comprising a particular polynucleotide is obtainable.
Clone vol7_1 was deposited on July 15, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number PTA-366, from which the vol7_1 clone comprising a particular polynucleotide is obtainable.
Clones vql l_1, vql2_1, vql4_1, vql5_1, vql7_l, vql8_1, vq22_1, and vr3_1 were deposited on July 15, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number PTA-367, from which each clone comprising a particular polynucleotide is obtainable.
Clone vb26_1 was deposited on August 11, 1999 with the ATCC (American Type 2 0 Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number PTA-501. (Note that due to a typographical error, the deposit of clone vb26_ 1 under the accession number PTA-501 was initially recorded at the ATCC as a deposit of clone "YB26_ 1 ".) Clones vc70_1, vo28_1, vo29_l, vo30_1, vp25_1, and vq25_1 were deposited on December 21, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number PTA-1074, from which each clone comprising a particular polynucleotide is obtainable.
3 0 All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. ~ 1.808(b), and the term of the deposit will comply with 37 C.F.R. ~ 1.806.

Each clone has been transfected into separate bacterial cells (E. coli) in these composite deposits. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures lA and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al., 1991, Nucleic Acids Res. 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et al., 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the CIaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.
Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided 2 0 herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
Clone Probe Sequence vb24_1 SEQ ID N0:63 vc64_1 SEQ ID N0:64 vp20_1 SEQ ID N0:65 vq4_1 SEQ ID N0:66 vo7_1 SEQ ID N0:67 3 0 vc65_1 SEQ ID N0:68 vc66_1 SEQ ID N0:69 vc68_1 SEQ ID N0:70 vk6_ 1 SEQ ID N0:71 vo4_ 1 SEQ ID N0:72 vo8_ 1 SEQ ID N0:73 vol0 _1 SEQ ID N0:74 vo20 _1 SEQ ID N0:75 vo21 _1 SEQ ID N0:76 vp24 _1 SEQ ID N0:77 vol7 _1 SEQ ID N0:78 vq 11 _ 1 SEQ ID N0:79 vql2_1 SEQ ID N0:80 vql4 _1 SEQ ID N0:81 vql5 _1 SEQ ID N0:82 vql7 _1 SEQ ID N0:83 vql8 _1 SEQ ID N0:84 vq22_1 SEQ ID N0:85 vr3_ SEQ ID N0:86 vb26_ 1 SEQ ID N0:87 In preferred probes/primers, the second nucleotide position is occupied by a biotinylated 2 0 phosphoaramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramadite) (Glen Research, cat. no.

1953)).
The design of the oligonucleotide probe should preferably follow these parameters:
2 5 (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
(b) It should be designed to have a T~, of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).
The oligonucleotide should preferably be labeled with y-32P ATP (specific activity 6000 3 0 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used.
Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 ~.~1 of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 pg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 pg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.
Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.
The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCI/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 pg/ml of yeast RNA, and 10 mM EDTA
(approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL. The filter is then preferably 2 0 incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1 % SDS at room temperature with gentle shaking for 15 minutes.
A third wash with O.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to 2 5 visualize the positives on the X-ray film. Other known hybridization methods can also be employed.
The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.
3 0 Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R.S.
McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker"
sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.
The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature forms) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with the ATCC) in a suitable mammalian cell or other host cell. The sequences) of the mature forms j of the protein may also be determinable from the amino acid sequence of the full-length form.
The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are 2 0 derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed 2 5 herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.
3 0 The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes in situ. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address http://www.ncbi.nlm.nih.gov/UniGene/, in order to identify "UniGene clusters"
of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.
Organisms that have enhanced, reduced, or modified expression of the genes) corresponding to the polynucleotide sequences disclosed herein are provided.
The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morns, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al., 1997, Biochem.
Mol. Med.
62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1-39;
all of which are incorporated by reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide molecules having some 2 0 complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression of the mRNA ("RNA intereference" or "RNAi"; Fire et al., 1998, Nature 391 (6669): 806-811; Montgomery et al., 1998, Proc. Natl.
Acad. Sci.
USA 95 (26): 15502-15507; and Sharp, 1999, Genes Dev. 13 (2): 139-141; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the 2 5 genes) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European 3 0 Patent No. 0 649 464 B 1, incorporated by reference herein). In addition, organisms are provided in which the genes) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding genes) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al., 1993, Proc. Natl. Acad. Sci. USA
90(16):
7431-7435; Clark et al., 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al., 1988, Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153;
5,614, 396;
5,616,491; and 5,679,523; all of which are incorporated by reference herein).
These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein products) of the corresponding gene(s).
Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with 2 0 known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmsmbrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).
2 5 Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90%
or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid 3 0 sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.
In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266:
460-480;
Altschul et al., 1990, Basic local alignment search tool, Journal of Molecular Biology 215:
403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, Nature Genetics 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, Proc.
Natl. Acad. Sci.
USA 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST
version 2.0 executable programs for several UNIX platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite -- BLASTP, BLASTN, BLASTX, 2 0 TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including 2 5 zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any 3 0 combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSLJM62, but other amino acid comparison matrices such as PAM can be utilized.
Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90%
identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papio papio, Papio hamadryas, Cercopitheccas aethiops, Cebus capucinus, Aotus trivirgatus, Sanguinus Oedipus, 2 0 Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela visors, Canis familiaris, Oryctolagus cuniculus, Bos taurus, Ovis aries, Sus scrofa, and Equcas caballus, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuanez, 1988, 2 5 Ann. Rev. Genet. 22: 323-351; O'Brien et al., 1993, Nature Genetics 3:103-112; Johansson et al., 1995, Genomics 25: 682-690; Lyons et al., 1997, Nature Genetics 15: 47-56;
O'Brien et al., 1997, Trends in Genetics 13(10): 393-399; Carver and Stubbs, 1997, Genome Research 7:1123-1137; all of which are incorporated by reference herein).
The invention also encompasses allelic variants of the disclosed polynucleotides or 3 0 proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60%

sequence identity (more preferably, at least 75% identity; most preferably at least 90°Io identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.
The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.
The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

StringencyPolynucleotideHybridHybridization TemperatureWash ConditionHybrid Lengthand Temperature (bP)~ Bufferr and Buffed A DNA:DNA z 50 65C; lxSSC -or- 65C; 0.3xSSC
42C; lxSSC, 50% formamide B DNA:DNA <50 TB*; lxSSC TB*; lxSSC

C DNA:RNA z 50 67C; lxSSC -or- 67C; 0.3xSSC
45C; lxSSC, 50% formamide D DNA:RNA <50 TD*; IxSSC TD*; lxSSC

E RNA:RNA z 50 70C; IxSSC -or- 70C; 0.3xSSC
50C; lxSSC, 50% formamide F RNA:RNA <50 TF*; lxSSC TF*; IxSSC

G DI~TA:DNA z 50 65C; 4xSSC -or- 65C; lxSSC
42C; 4xSSC, 50% formamide 1 H DNA:DNA <50 TH*; 4xSSC TH*; 4xSSC
O

I DI~TA:RNA Z 50 67C; 4xSSC -or- 67C; lxSSC
45C; 4xSSC, 50% formamide J DNA:RNA <50 T,*; 4xSSC T,*; 4xSSC

K RNA:RNA s 50 70C; 4xSSC -or- 67C; lxSSC
50C; 4xSSC, 50% formamide L RNA:RNA <50 TL*; 2xSSC T~*; 2xSSC

M DNA:DNA s 50 50C; 4xSSC -or- 50C; 2xSSC
40C; 6xSSC, 50% formamide N DNA:DNA <50 T,,*; 6xSSC TN*; 6xSSC

O DNA:RNA s 50 55C; 4xSSC-or- 55C; 2xSSC
42C; 6xSSC, 50% formamide P DNA:RNA <50 TP*; 6xSSC Tp*; 6xSSC

Q RNA:RNA z 50 60C; 4xSSC -or- 60C; 2xSSC
45C; 6xSSC, 50% formamide 2 R RNA:RNA <50 TR*; 4xSSC TR*; 4xSSC
O

$: The hybrid length is that anticipated for the hybridized regions) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be 2 5 determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.
': SSPE (lxSSPE is 0.15M NaCI, lOmM NaH2P04, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (lxSSC is 0.15M NaCI and l5rru'vI sodium citrate) in the hybridization and wash buffers;
washes are performed for 15 minutes after hybridization is complete.
3 0 *TB - TR: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C
less than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equations. For hybrids less than 18 base pairs in length, Tm(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, Tm(°C) = 81.5 + 16.6(log,o[Na+]) + 0.41 (%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na'] is the concentration of sodium ions in the hybridization buffer ((Na'] for lxSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 1 l, and Current Protocols in Molecular Biology, 1995, F.M.
Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.
Preferably, each such hybridizing polynucleotide has a length that is at least 25%(rnore preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90%
or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
The isolated polynucleotide endcoing the protein of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 ( 1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an 2 0 expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster 2 5 Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Co1o205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.
Alternatively, it may be possible to produce the protein in lower eukaryotes such 3 0 as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac~ kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No 1555 ( 1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."
The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column 2 0 containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl~ or Cibacrom blue Sepharose~; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
2 5 Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and 3 0 Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope.

One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).
Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."
The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
The protein may also be produced by known conventional chemical synthesis.
Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or 2 0 immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.
The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA
2 5 sequences can be made by those skilled in the art using known techniques.
Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence.
For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, 3 0 replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S.
Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.
USES AND BIOLOGICAL ACTIVITY
The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
Research Uses and Utilities The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular 2 0 stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA
sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers 2 5 for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes 3 0 a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al., 1993, Cell75: 791-803 and in Rossi et al., 1997, Proc. Natl. Acad. Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.
The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction.
Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.
Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning:
2 0 A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F.
Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.
Nutritional Uses 2 5 Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid 3 0 preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RBS, DA1, 123, T1165, HT2, CTLL2, TF-l, Mo7e and CMK.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.
Kruisbeek, D.H.
Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. i 37:3494-3500, 1986;
Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992;
2 0 Bowman et al., J. Immunol. 152: 1756-1761, 1994.
Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in:
Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology.
J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto.
1994; and 2 5 Measurement of mouse and human Interferon 'y, Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto.
1994.
Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine 3 0 Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A.
80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto.
1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986;
Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K.
J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In Current Protocols in Immunology. J.E.e.a.
Coligan eds.
Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.
Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in:
Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H.
Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans);
Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J.
Immun.
11:405-41 l, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol.
140:508-512, 1988.
Immune Stimulati~ or Suppressin Activi A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies 2 5 and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, 3 0 bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems.
Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.
Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both.
Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from 2 0 immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.
Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing 2 5 high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys 3 0 the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-l, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.
The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans.
Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl.
Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to 2 0 determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.
Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production 2 5 of cytokines and autoantibodies involved in the pathology of the diseases.
Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T
cell activation and prevent production of autoantibodies or T cell-derived cytokines which may 3 0 be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRLllprllpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).
Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy.
Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B
lymphocyte antigens systemically.
Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune 2 0 responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.
2 5 In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, 3 0 the tumor cell can be transfected to express a combination of peptides.
For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.
The presence of the peptide of the present invention having the activity of a B
lymphocyte antigens) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II
molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II
molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I a chain protein and ~i2 microglobulin protein or an MHC class II a chain protein and an MHC class II ~3 chain protein to thereby express MHC
class I or MHC class II proteins on the cell surface. Expression of the appropriate class I
or class II MHC in conjunction with a peptide having the activity of a B
lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B
lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific 2 0 immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, 2 5 those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.
Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Hernnann et al., Proc. Natl.
Acad. Sci.
USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982;
Handa et 3 0 al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986;
Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl.
Acad. Sci. USA
78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J.

Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986;
Bowmanet al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988;
Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J.
Immunol.
153:3079-3092, 1994.
Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in:
Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function:
In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology.
J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto.
1994.
Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.
Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol.
137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J.
Immunol. 149:3778-3783, 1992.
Dendritic cell-dependent assays (which will identify, among others, proteins 2 0 expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961 965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989;
Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.
Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate 3 0 lymphocyte homeostasis) include, without limitation, those described in:
Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993;
Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991;

Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.
Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.
Hematopoiesis Re ulatin~ Activity A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and 2 0 consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders 2 5 (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinur~ia), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.
3 0 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.
Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.
Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994;
Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, LK. and Briddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994;
Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic Cells.
R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc.., New York, NY.
1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 163-179, 2 0 Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.
Tissue Growth Activity 2 5 A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
A protein of the present invention, which induces cartilage and/or bone growth in 3 0 circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.
A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in 2 0 repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or 2 5 ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include 3 0 an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.
The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue.
More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome.
Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.
Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.
It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of 2 0 fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.
A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
2 5 A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
The activity of a protein of the invention may, among other means, be measured by the following methods:
3 0 Assays for tissue generation activity include, without limitation, those described in:
International Patent Publication No. W095/16035 (bone, cartilage, tendon);
International Patent Publication No. W095/05846 (nerve, neuronal); International Patent Publication No.
W091/07491 (skin, endothelium ).
Assays for wound healing activity include, without limitation, those described in:
Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J.
Invest.
Dermatol 71:382-84 (1978).
Activin/Inhibin Activity A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-~i group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary.
See, for example, 2 0 United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.
The activity of a protein of the invention may, among other means, be measured by the following methods:
2 5 Assays for activin/inhibin activity include, without limitation, those described in:
Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985;
Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.
3 0 Chemotactic/Chemokinetic Activity A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.
Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion 2 0 include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub.
Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748;
Gruber et al.
2 5 J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:
1762-1768, 1994.
Hemostatic and Thrombolytic ActivitX
A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation 3 0 disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.
Receptor/Li~and Activity A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions.
Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
2 0 A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for receptor-ligand activity include without limitation those 2 5 described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M.
Kruisbeek, D.H.
Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987;
Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp.
Med.
3 0 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994;
Stitt et al., Cell 80:661-670, 1995.

Anti-Inflammatory Activity Proteins of the present invention may also exhibit anti-inflammatory activity.
The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.
Cadherin/Tumor Invasion Sup~pressor ActivitX
Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin 2 0 expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis.
Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.
The cadherin superfamily includes well over forty members, each with a distinct pattern of 2 5 expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin 3 0 so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.
E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types.
Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.
Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.
Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately 2 0 expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.
Fragments of proteins of the present invention with cadherin activity, preferably a 2 5 polypeptide comprising a decapeptide of the cadherin recognition site, and poly-nucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects.
Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer 3 0 patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.
Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995;
Miyaki et al.
Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A
protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.
Other Activities A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms;
effecting the 2 0 fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);
effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent 2 5 behaviors; providing analgesic effects or other pain reducing effects;
promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for 3 0 example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING
A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable Garner.
Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the Garner will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-l, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNFO, TNFl, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic 2 0 factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic ~ or anti-thrombotic factor, or anti-inflammatory agent.
A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical 2 5 compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
The pharmaceutical composition of the invention may be in the form of a complex of the proteins) of present invention along with protein or peptide antigens.
The protein and/or peptide antigen will deliver a stimulatory signal to both B and T
lymphocytes. B
3 0 lymphocytes will respond to antigen through their surface immunoglobulin receptor. T
lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigens) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.
The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable earners, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution.
Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like.
Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No.
4,501,728; U.S.
Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.
As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient 2 0 to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in 2 5 the therapeutic effect, whether administered in combination, serially or simultaneously.
In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination 3 0 with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.
Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection.
Intravenous administration to the patient is preferred.
When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95%
protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain 2 0 physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.
2 5 When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A
preferred pharmaceutical 3 0 composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response.
Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 pg to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 qg to about 1 mg) of protein of the present invention per kg body weight.
The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the 2 0 range of 12 to 24 hours of continuous intravenous administration.
Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the 2 5 term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein. Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.
3 0 Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, Monoclonal antibodies: principles and practice, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in Current Protocols in Immunology, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons).
Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods.
Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, supra; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in Current Protocols in Immunology, Unit 2.8, Greene Publishing Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S.
Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild et al., 1996, Nature Biotechnology 14: 845-851; Mendez et al., 1997, Nature Genetics 15: 146-156 (erratum Nature Genetics 16: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide 2 0 immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P.
Merrifield, J.
Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, et al., FEBS Lett. 211, ( 1987).
2 5 Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic 3 0 cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device.
When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair.
Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.
The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation.
Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, 2 0 tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides.
Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be 2 5 comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.
Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic 3 0 acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.
A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, polyethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and polyvinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-a and TGF-~3), and insulin-like growth factor (IGF).
2 0 The therapeutic compositions are also presently valuable for veterinary applications.
Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.
The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various 2 5 factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical 3 0 composition. For example, the addition of other known growth factors, such as IGF I
(insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.
Polynucleotides of the present invention can also be used for gene therapy.
Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells.
Treated cells can then be introduced in vivo for therapeutic purposes.
Patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING
<110> Valenzuela, Dario Yuan, Olive Hoffman, Heidi Hall, Jeff Rapiejko, Peter <120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
<130> GI 6918X
<140>
<141>
<160> 101 <170> PatentIn Ver. 2.0 <210> 1 <211> 5948 <212> DNA
<213> Homo sapiens <400> 1 cgactgcgcg ccggcgcgca cacccgagac agagctttac tatctcgctc cctctcgcgc 60 ctccctcctc gctgggcatt caaacagctt tccgacatca ccagccaagg atttttttcc 120 ccgctctcct tagtcgccgt ccgtccatca gtacctgcag gggggaggag gaggagggag 180 gaaagcggaa agaggaaaaa gcataagctt gagccttccg atccgaccac gaatactcct 240 gtaataaacc caccgcccca acaaatctgc catagcagcc gccgccgccg ccggtcactt 300 ctcgtctcag ctctttcttt gcttcttggt ttgttggggg tagcttttat gaaacaaatc 360 tttgctatta agccacttac attttggggg gttccttaga gtctcccttg ggggggcttc 420 tccctccctt tagcccccct cggtttggag gtt,ggattca gttggatacg gcgcaaggtt 480 ctgggctcct gctggctttt ttttcctctc tctcatcgac ccccctttgg ttcccacccc 540 ccaccttttg cttttcgtat gtatgcattt ttaaaaataa atcctgattt tggaagctga 600 gccggggaaa atgggcaacg gtgattggga ccgaagggga gtctctccgt cactgttgct 660 gggacgcgtg cctgtgctgg tgtcttagag caagagcctc cctgagcttt cggagtggaa 720 ggccaaatga cataggatga aggctgttcg taacctgctg atttatatat tttccaccta 780 tctcctggtt atgtttggat ttaatgctgc ccaagacttc tggtgttcaa ctttggtgaa 840 gggagtcatt tatggatcgt attctgtaag tgaaatgttt cctaaaaact ttacaaactg 900 cacttggacg ctggaaaatc cagatccaac caaatatagc atttacctga aattttccaa 960 aaaggacctt agctgctcta acttttcact cctggcttat cagtttgatc atttttccca 1020 tgaaaaaata aaggatcttt taagaaagaa tcattctata atgcaactct gcaattccaa 1080 gaatgctttc gtttttctac agtatgataa aaattttatt caaatacgtc gagtatttcc 1140 aactaatttc ccaggattac agaaaaaagg ggaagaagat cagaaatctt tttttgagtt 1200 tttggtattg aacaaggtca gcccaagcca gtttggttgc catgtattat gtacttggtt 1260 ggagagctgc ttaaaatcag aaaatgggag aacagaatca tgtgggatca tgtatacaaa 1320 atgcacctgc cctcagcatt tgggagagtg ggggatcgac gaccagtcgc tgattttgtt 1380 aaataacgtg gtgttacccc tgaatgagca gacagagggc tgcctgaccc aggagctgca 1440 aaccacccaa gtctgcaatc ttaccaggga ggccaagcga ccacccaaag aagaatttgg 1500 aatgatggga gatcatacaa ttaaaagtca gcgacctcga tctgttcatg aaaaaagggt 1560 ccctcaggaa caagctgatg ctgctaaatt tatggcacaa actggtgaat ctggtgtgga 1620 agagtggtcc cagtggagca catgttcggt tacttgtggt caagggtcgc aggtgcgaac 1680 cagaacttgt gtatcacctt acgggacaca ctgcagcggc ccattaagag aatcaagggt 1740 ttgcaataac actgccctct gtccagtaca cggagtatgg gaggaatggt caccatggag 1800 tttatgttca tttacatgtg gtcgaggcca aagaacaaga acaaggtcat gcacacctcc 1860 tcagtatgga ggaaggccgt gtgaaggacc tgaaacacat cataagcctt gtaatattgc 1920 tctttgccca gttgatggac agtggcaaga gtggagttcg tggagccagt gctcagtaac 1980 gtgctcgaat gggactcagc agagaagccg gcagtgcact gcagctgccc atggaggctc 2040 cgaatgcaga gggccatggg cagaaagcag agagtgctat aaccctgaat gtacagccaa 2100 tggtcaatgg aatcagtggg gtcattggag tggttgttcc aagtcctgtg atggcggctg 2160 ggaaaggcga ataaggacct gtcagggtgc agtgataaca gggcagcaat gtgaaggaac 2220 gggcgaagaa gtgagaagat gcagtgagca gcgatgccct gcaccttatg aaatatgccc 2280 tgaggattat ctgatgtcga tggtgtggaa aagaactcca gcaggcgact tggcattcaa 2340 tcaatgtccc ctgaatgcca caggcaccac tagcagacgc tgctctctca gtcttcatgg 2400 agtggccttc tgggaacagc cgagctttgc aagatgcata tcaaatgagt acagacactt 2460 gcagcattca attaaagagc accttgctaa ggggcagcga atgctggcag gtgatggaat 2520 gtcccaggtg accaagacac tgttggattt aactcagaga aaaaatttct atgcaggcga 2580 tcttctgatg tctgtggaga tcctgagaaa tgtgacagac acatttaaaa gggcaagtta 2640 catccctgca tctgatggtg tccagaactt ctttcaaata gttagcaacc ttctagatga 2700 agaaaacaag gaaaaatggg aagatgcaca acagatttat ccagggtcaa tagagttaat 2760 gcaggtgatt gaagatttta tacacattgt tggaatgggg atgatggact ttcagaattc 2820 atacttaatg actggaaatg tagtggctag tattcagaag cttcctgcag cctctgttct 2880 aacagacatc aactttccaa tgaaaggacg gaagggaatg gttgactggg caagaaactc 2940 agaagatagg gtagtaattc caaaaagcat tttcactccg gtgtcatcaa aagaattaga 3000 tgaatcatct gtatttgttc ttggcgcagt cctatacaaa aacttagatc taattttgcc 3060 cactttgaga aattatactg tcattaattc caaaatcatc gtggtcacaa taaggcctga 3120 acccaaaaca accgattcgt ttctggagat agaactagct catttggcta atggtacttt 3180 gaatccctat tgtgtattgt gggatgactc caaaacgaac gagtctttgg gaacgtggtc 3240 cacccaggga tgtaaaactg tgcttaccga tgcatcccat acgaaatgct tatgtgatcg 3300 tctctctacc ttcgccattt tggctcagca acctagagaa ataatcatgg aatcctctgg 3.360 cacaccttca gttaccctaa tagtaggcag tggtctttct tgcttggcct tgattaccct 3420 agcagttgtc tatgcagcat tatggaggta catacgctct gagagatcca taatactaat 3480 taacttctgc ctgtctatca tctcatccaa tatcctcata ctggttggac agactcagac 3540 acataataag agtatctgca caaccaccac tgcatttttg cactttttct tcctggcttc 3600 attctgttgg gttttgactg aggcgtggca atcatatatg gctgtaactg gaaaaattag 3660 gacacggctt ataagaaaac gctttttgtg ccttggatgg ggtttaccag cattagtagt 3720 ggccacatca gtaggcttca ccagaacaaa aggatatggc actgatcact actgctggct 3780 ctctcttgaa ggaggactac tctatgcttt tgtgggacct gcagccgctg ttgtcctggt 3840 caacatggtg attggcattt tggtatttaa taaacttgtt tccagagatg gaatcctaga 3900 taaaaagctc aaacacagag ccggtcagat gagtgagcct catagcggtt tgacgctcaa 3960 atgtgccaag tgtggagtag tttcaacaac agctttgtca gccaccaccg ccagtaacgc 4020 catggcgtct ctttggagct cctgtgtggt gttgcccctt ctggctttga cgtggatgtc 4080 tgcggttctg gccatgacag ataaacgctc catattgttt caaatacttt ttgctgtgtt 4140 tgattcattg caaggctttg ttatagtcat ggtccactgc attcttcgga gagaggttca 4200 ggatgcattt agatgccgat tgagaaactg tcaggatccc atcaatgcag attcttcgag 4260 ttcgtttcct aatgggcatg ctcaaatcat gacagacttt gaaaaggatg tagacattgc 4320 ctgtcgatca gttcttcata aggatattgg tccttgccga gcagccacaa taacaggaac 4380 actttctagg atttctctaa atgatgatga agaagaaaag ggaacaaacc ctgaagggct 4440 aagctattca acattgcctg gaaatgtcat ttccaaagtc atcatccagc aacccacagg 4500 tttgcacatg cccatgagta tgaatgagct tagcaatcca tgtttgaaaa aagaaaatag 4560 tgaattgcgg agaactgtgt acttatgtac ggatgataat ttgagagggg ctgacatgga 4620 catagtccat cctcaagaaa gaatgatgga aagtgactat attgtgatgc ccagaagttc 4680 tgtaaataac cagccttcaa tgaaagaaga aagcaaaatg aatattggca tggaaacctt 4740 gccacatgaa aggctattgc actacaaagt aaaccctgaa ttcaatatga atccccctgt 4800 aatggaccag ttcaatatga acttagagca acatctcgca ccccaggaac atatgcagaa 4860 tttgcccttt gaacctcgca cagctgtgaa gaatttcatg gcctctgagt tggatgataa 4920 tgcaggacta tcaagaagtg aaactggatc aacgatatca atgagttctt tagagagaag 4980 aaaatcacga tattcagacc ttgactttga gaaggtcatg catacaagga agaggcatat 5040 ggaactattt caagaactaa atcagaaatt tcaaactttg gacagatttc gggatatacc 5100 aaatacaagc agtatggaaa accccgcacc aaacaagaat ccatgggaca ctttcaaaaa 5160 ccccagtgaa tacccgcatt acaccacaat caatgtctta gacacagagg caaaggatgc 5220 tttggaactg aggccagcag agtgggagaa gtgtctgaat ttgcctctgg atgtgcaaga 5280 gggtgacttt caaacagaag tttaaaaaaa tcaaaatgga ctaaggtaga gacaaaactt 5340 tattgcactg acacttaaga cttgggaagc ctgacatttc tatctggaca gtgtgactat 5400 cttatgtcag gaccttcatg tgccaaacgt cagtggtgtt ttcatatggt aacttctcac 5460 tagtcaggct agtggagaga tgaccaggtg tacagttctg accatcctgt gttgtaagta 5520 cccgtggaat ggatttgtaa ggtaatcttt atagataaac ctcaagcaac gattcatgtt 5580 gtaaccgctt catatggttt agttttcaaa aaacttcacc atgaagcaca atgtatatat 5640 ttatgcagtt tttaaagttt ataacagtct gtttggccat tactacactt tttactttat 5700 agagtggtcc cagtggagca catgttcggt tacttgtggt caagggtcgc aggtgcga aatataaaagcaaagttt tt tcattaaat ttgttgagctacattcttcattgc5760 g gaatgt tttaaatgcaataaagtaat atctcactt gaataatatatttcacatctttat5820 a ttatat tattgcagttttctctagaa gctctgaga ctctgctgcagctgtgtataaaat5880 a agcttt atttaaaatgttgtatggtg aaataaact tgtctacatatcaaaaaaaaaaaaaaaa5940 t tt aaaaaaaa 5948 <210> 2 <211> 1522 <212> PRT

<213> HomoSapiens <400> 2 Met Lys ValArgAsnLeuLeuIleTyrIlePheSerThrTyrLeu Ala Leu Val PheGlyPheAsnAlaAlaGlnAspPheTrpCysSerThr Met Leu Val GlyValIleTyrGlySerTyrSerValSerGluMetPhe Lys Pro Lys PheThrAsnCysThrTrpThrLeuGluAsnProAspPro Asn Thr Lys SerIleTyrLeuLysPheSerLysLysAspLeuSerCys Tyr Ser Asn SerLeuLeuAlaTyrGlnPheAspHisPheSerHisGlu Phe Lys Ile AspLeuLeuArgLysAsnHisSerIleMetGlnLeuCys Lys Asn Ser AsnAlaPheValPheLeuGlnTyrAspLysAsnPheIle Lys Gln Ile ArgValPheProThrAsnPheProGlyLeuGlnLysLys Arg Gly Glu AspGlnLysSerPhePheGluPheLeuValLeuAsnLys Glu Val Ser SerGlnPheGlyCysHisValLeuCysThrTrpLeuGlu Pro Ser Cys LysSerGluAsnGlyArgThrGluSerCysGlyIleMet Leu Tyr Thr CysThrCysProGlnHisLeuGlyGluTrpGlyIleAsp Lys Asp Gln LeuIleLeuLeuAsnAsnValValLeuProLeuAsnGlu Ser Gln Thr GlyCysLeuThrGlnGluLeuGlnThrThrGlnValCys Glu Asn Leu ArgGluAlaLysArgProProLysGluGluPheGlyMet Thr Met Gly Asp His Thr Ile Lys Ser Gln Arg Pro Arg Ser Val His Glu Lys Arg Val Pro Gln Glu Gln Ala Asp Ala Ala Lys Phe Met Ala Gln Thr Gly Glu Ser Gly Val Glu Glu Trp Ser Gln Trp Ser Thr Cys Ser Val Thr Cys Gly Gln Gly Ser Gln Val Arg Thr Arg Thr Cys Val Ser Pro Tyr Gly Thr His Cys Ser Gly Pro Leu Arg Glu Ser Arg Val Cys Asn Asn Thr Ala Leu Cys Pro Val His Gly Val Trp Glu Glu Trp Ser Pro Trp Ser Leu Cys Ser Phe Thr Cys Gly Arg Gly Gln Arg Thr Arg Thr Arg Ser Cys Thr Pro Pro Gln Tyr Gly Gly Arg Pro Cys Glu Gly Pro Glu Thr His His Lys Pro Cys Asn Ile Ala Leu Cys Pro Val Asp Gly Gln Trp Gln Glu Trp Ser Ser Trp Ser Gln Cys Ser Val Thr Cys Ser Asn Gly Thr Gln Gln Arg Ser Arg Gln Cys Thr Ala Ala Ala His Gly Gly Ser Glu Cys Arg Gly Pro Trp Ala Glu Ser Arg Glu Cys Tyr Asn Pro Glu Cys Thr Ala Asn Gly Gln Trp Asn Gln Trp Gly His Trp Ser Gly Cys Ser Lys Ser Cys Asp Gly Gly Trp Glu Arg Arg Ile Arg Thr Cys Gln Gly Ala Val Ile Thr Gly Gln Gln Cys Glu Gly Thr Gly Glu Glu Val Arg Arg Cys Ser Glu Gln Arg Cys Pro Ala Pro Tyr Glu Ile Cys Pro Glu Asp Tyr Leu Met Ser Met Val Trp Lys Arg Thr Pro Ala Gly Asp Leu Ala Phe Asn Gln Cys Pro Leu Asn Ala Thr Gly Thr Thr Ser Arg Arg Cys Ser Leu Ser Leu His Gly Val Ala Phe Trp Glu Gln Pro Ser Phe Ala Arg Cys Ile Ser Asn Glu Tyr Arg His Leu Gln His Ser Ile Lys Glu His Leu Ala Lys Gly Gln Arg Met Leu Ala Gly Asp Gly Met Ser Gln Val Thr Lys Thr Leu Leu Asp Leu Thr Gln Arg Lys Asn Phe Tyr Ala Gly Asp Leu Leu Met Ser Val Glu Ile Leu Arg Asn Val Thr Asp Thr Phe Lys Arg Ala Ser Tyr Ile Pro Ala Ser Asp Gly Val Gln Asn Phe Phe Gln Ile Val Ser Asn Leu Leu Asp Glu Glu Asn Lys Glu Lys Trp Glu Asp Ala Gln Gln Ile Tyr Pro Gly Ser Ile Glu Leu Met Gln Val Ile Glu Asp Phe Ile His Ile Val Gly Met Gly Met Met Asp Phe Gln Asn Ser Tyr Leu Met Thr Gly Asn Val Val Ala Ser Ile Gln Lys Leu Pro Ala Ala Ser Val Leu Thr Asp Ile Asn Phe Pro Met Lys Gly Arg Lys Gly Met Val Asp Trp Ala Arg Asn Ser Glu Asp Arg Val Val Ile Pro Lys Ser Ile Phe Thr Pro Val Ser Ser Lys Glu Leu Asp Glu Ser Ser Val Phe Val Leu Gly Ala Val Leu Tyr Lys Asn Leu Asp Leu Ile Leu Pro Thr Leu Arg Asn Tyr Thr Val Ile Asn Ser Lys Ile Ile Val Val Thr Ile Arg Pro Glu Pro Lys Thr Thr Asp Ser Phe Leu Glu Ile Glu Leu Ala His Leu Ala Asn Gly Thr Leu Asn Pro Tyr Cys Val Leu Trp Asp Asp Ser Lys Thr Asn Glu Ser Leu Gly Thr Trp Ser Thr Gln Gly Cys Lys Thr Val Leu Thr Asp Ala Ser His Thr Lys Cys Leu Cys Asp Arg Leu Ser Thr Phe Ala Ile Leu Ala Gln Gln Pro Arg Glu Ile Ile Met Glu Ser Ser Gly Thr Pro Ser Val Thr Leu Ile Val Gly Ser Gly Leu Ser Cys Leu Ala Leu Ile Thr Leu Ala Val Val Tyr Ala Ala Leu Trp Arg Tyr Ile Arg Ser Glu Arg Ser Ile Ile Leu Ile Asn Phe Cys Leu Ser Ile Ile Ser Ser Asn Ile Leu Ile Leu Val Gly Gln Thr Gln Thr His Asn Lys Ser Ile Cys Thr Thr Thr Thr Ala Phe Leu His Phe Phe Phe Leu Ala Ser Phe Cys Trp Val Leu Thr Glu Ala Trp Gln Ser Tyr Met Ala Val Thr Gly Lys Ile Arg Thr Arg Leu Ile Arg Lys Arg Phe Leu Cys Leu Gly Trp Gly Leu Pro Ala Leu Val Val Ala Thr Ser Val Gly Phe Thr Arg Thr Lys Gly Tyr Gly Thr Asp His Tyr Cys Trp Leu Ser Leu Glu Gly Gly Leu Leu Tyr Ala Phe Val Gly Pro Ala Ala Ala Val Val Leu Val Asn Met Val Ile Gly Ile Leu Val Phe Asn Lys Leu Val Ser Arg Asp Gly Ile Leu Asp Lys Lys Leu Lys His Arg Ala Gly Gln Met Ser Glu Pro His Ser Gly Leu Thr Leu Lys Cys Ala Lys Cys Gly Val Val Ser Thr Thr Ala Leu Ser Ala Thr Thr Ala Ser Asn Ala Met Ala Ser Leu Trp Ser Ser Cys Val Val Leu Pro Leu Leu Ala Leu Thr Trp Met Ser Ala Val Leu Ala Met Thr Asp Lys Arg Ser Ile Leu Phe Gln Ile Leu Phe Ala Val Phe Asp Ser Leu Gln Gly Phe Val Ile Val Met Val His Cys Ile Leu Arg Arg Glu Val Gln Asp Ala Phe Arg Cys Arg Leu Arg Asn Cys Gln Asp Pro Ile Asn Ala Asp Ser Ser Ser Ser Phe Pro Asn Gly His Ala Gln Ile Met Thr Asp Phe Glu Lys Asp Val Asp Ile Ala Cys Arg Ser Val Leu His Lys Asp Ile Gly Pro Cys Arg Ala Ala Thr Ile Thr Gly Thr Leu Ser Arg Ile Ser Leu Asn Asp Asp Glu Glu Glu Lys Gly Thr Asn Pro Glu Gly Leu Ser Tyr Ser Thr Leu Pro Gly Asn Val Ile Ser Lys Val Ile Ile Gln Gln Pro Thr Gly Leu His Met Pro Met Ser Met Asn Glu Leu Ser Asn Pro Cys Leu Lys Lys Glu Asn Ser Glu Leu Arg Arg Thr Val Tyr Leu Cys Thr Asp Asp Asn Leu Arg Gly Ala Asp Met Asp Ile Val His Pro Gln Glu Arg Met Met Glu Ser Asp Tyr Ile Val Met Pro Arg Ser Ser Val Asn Asn Gln Pro Ser Met Lys Glu Glu Ser Lys Met Asn Ile Gly Met Glu Thr Leu Pro His Glu Arg Leu Leu His Tyr Lys Val Asn Pro Glu Phe Asn Met Asn Pro Pro Val Met Asp Gln Phe Asn Met Asn Leu Glu Gln His Leu Ala Pro Gln Glu His Met Gln Asn Leu Pro Phe Glu Pro Arg Thr Ala Val Lys Asn Phe Met Ala Ser Glu Leu Asp Asp Asn Ala Gly Leu Ser Arg Ser Glu Thr Gly Ser Thr Ile Ser Met Ser Ser Leu Glu Arg Arg Lys Ser Arg Tyr Ser Asp Leu Asp Phe Glu Lys Val Met His Thr Arg Lys Arg His Met Glu Leu Phe Gln Glu Leu Asn Gln Lys Phe Gln Thr Leu Asp Arg Phe Arg Asp Ile Pro Asn Thr Ser Ser Met Glu Asn Pro Ala Pro Asn Lys Asn Pro Trp Asp Thr Phe Lys Asn Pro Ser Glu Tyr Pro His Tyr Thr Thr Ile Asn Val Leu Asp Thr Glu Ala Lys Asp Ala Leu Glu Leu Arg Pro Ala Glu Trp Glu Lys Cys Leu Asn Leu Pro Leu Asp Val Gln Glu Gly Asp Phe Gln Thr Glu Val <210> 3 <211> 1955 <212> DNA
<213> Homo Sapiens <400> 3 gattgtgcag caggcgggcc cccgcgcggc agggccctgg acccgcgcgg ctcccgggga 60 tggtgagcaa ggcgctgctg cgcctcgtgt ctgccgtcaa ccgcaggagg atgaagctgc 120 tgctgggcat cgccttgctg gcctacgtcg cctctgtttg gggcaacttc gttaatatga 180 ggtctatcca ggaaaatggt gaactaaaaa ttgaaagcaa gattgaagag atggttgaac 240 cactaagaga gaaaatcaga gatttagaaa aaagctttac ccagaaatac ccaccagtaa 300 agtttttatc agaaaaggat cggaaaagaa ttttgataac aggaggcgca gggttcgtgg 360 gctcccatct aactgacaaa ctcatgatgg acggccacga ggtgaccgtg gtggacaatt 420 tcttcacggg caggaagaga aacgtggagc actggatcgg acatgagaac ttcgagttga 480 ttaaccacga cgtggtggag cccctctaca tcgaggttga ccagatatac catctggcat 540 ctccagcctc ccctccaaac tacatgtata atcctatcaa gacattaaag accaatacga 600 ttgggacatt aaacatgttg gggctggcaa aacgagtcgg tgcccgtctg ctcctggcct 660 ccacatcgga ggtgtatgga gatcctgaag tccaccctca aagtgaggat tactggggcc 720 acgtgaatcc aataggacct cgggcctgct acgatgaagg caaacgtgtt gcagagacca 780 tgtgctatgc ctacatgaag caggaaggcg tggaagtgcg agtggccaga atcttcaaca 840 cctttgggcc acgcatgcac atgaacgatg ggcgagtagt cagcaacttc atcctgcagg 900 cgctccaggg ggagccactc acggtatacg gatccgggtc tcagacaagg gcgttccagt 960 acgtcagcga tctagtgaat ggcctcgtgg ctctcatgaa cagcaacgtc agcagcccgg 1020 tcaacctggg gaacccagaa gaacacacaa tcctagaatt tgctcagtta attaaaaacc 1080 ttgttggtcc cgctggagga aggtttaaac aaagcaattc actacttccg taaagaactc 1140 gagtaccagg caaataatca gtacatcccc aaaccaaagc ctgccagaat aaagaaagga 1200 cggactcgcc acagctgaac tcctcacttt taggacacaa gactaccatt gtacacttga 1260 tgggatgtat ttttggcttt tttttgttgt cgtttaaaga aagactttaa caggtgtcat 1320 gaagaacaaa ctggaatttc attctgaagc ttgctttaat gaaatggatg tgcctaaaag 1380 ctcccctcaa aaaactgcag attttgcctt gcactttttg aatctctctt tttatgtaaa 1440 atagcgtaga tgcatctctg cgtattttca agttttttta tcttgctgtg agagcatatg 1500 ttgtgactgt cgttgacagt tttatttact ggtttctttg tgaagctgaa aaggaacatt 1560 aagcgggaca aaaaatgccg attttattta taaaagtggg tacttaataa atgagtcgtt 1620 atactatgca taaagaaaaa tcctagcagt attgtcaggt ggtggtgcgc cggcattgat 1680 tttagggcag ataaaagaat tctgtgtgag agctttatgt ttctctttta attcagagtt 1740 tttccaaggt ctacttttga gttgcaaact tgactttgaa atattcctgt tggtcatgat 1800 caaggatatt tgaaatcact actgtgtttt gctgcgtatc tggggcgggg gcaggttggg 1860 gggcacaaag ttaacatatt cttggttaac catggttaaa tatgctattt taataaaata 1920 ttgaaactca ccaaaaaaaa aaaaaaaaaa aaaaa 1955 <210> 4 <211> 357 <212> PRT
<213> Homo sapiens <400> 4 Met Val Ser Lys Ala Leu Leu Arg Leu Val Ser Ala Val Asn Arg Arg Arg Met Lys Leu Leu Leu Gly Ile Ala Leu Leu Ala Tyr Val Ala Ser Val Trp Gly Asn Phe Val Asn Met Arg Ser Ile Gln Glu Asn Gly Glu Leu Lys Ile Glu Ser Lys Ile Glu Glu Met Val Glu Pro Leu Arg Glu Lys Ile Arg Asp Leu Glu Lys Ser Phe Thr Gln Lys Tyr Pro Pro Val g Lys Phe Leu Ser Glu Lys Asp Arg Lys Arg Ile Leu Ile Thr Gly Gly Ala Gly Phe Val Gly Ser His Leu Thr Asp Lys Leu Met Met Asp Gly His Glu Val Thr Val Val Asp Asn Phe Phe Thr Gly Arg Lys Arg Asn Val Glu His Trp Ile Gly His Glu Asn Phe Glu Leu Ile Asn His Asp Val Val Glu Pro Leu Tyr Ile Glu Val Asp Gln Ile Tyr His Leu Ala Ser Pro Ala Ser Pro Pro Asn Tyr Met Tyr Asn Pro Ile Lys Thr Leu Lys Thr Asn Thr Ile Gly Thr Leu Asn Met Leu Gly Leu Ala Lys Arg Val Gly Ala Arg Leu Leu Leu Ala Ser Thr Ser Glu Val Tyr Gly Asp Pro Glu Val His Pro Gln Ser Glu Asp Tyr Trp Gly His Val Asn Pro Ile Gly Pro Arg Ala Cys Tyr Asp Glu Gly Lys Arg Val Ala Glu Thr Met Cys Tyr Ala Tyr Met Lys Gln Glu Gly Val Glu Val Arg Val Ala Arg Ile Phe Asn Thr Phe Gly Pro Arg Met His Met Asn Asp Gly Arg Val Val Ser Asn Phe Ile Leu Gln Ala Leu Gln Gly Glu Pro Leu Thr Val Tyr Gly Ser Gly Ser Gln Thr Arg Ala Phe Gln Tyr Val Ser Asp Leu Val Asn Gly Leu Val Ala Leu Met Asn Ser Asn Val Ser Ser Pro Val Asn Leu Gly Asn Pro Glu Glu His Thr Ile Leu Glu Phe Ala Gln Leu Ile Lys Asn Leu Val Gly Pro Ala Gly Gly Arg Phe Lys Gln Ser Asn Ser Leu Leu Pro <210> 5 <211> 1874 <212> DNA

<213> Homo sapiens <400> 5 aaattctcca tgaagtgtac tatgttccat cattccttcc caaagccacc ggaagcattc 60 cttctaggaa aggtggagtc ggtagtgaga agccggaggt gagaagaccc ctaagcggat 120 ggattcattc attttctgaa tttcctatgt gaggacagta ttagagccca gtgaggcttt 180 gagaggcccc aaagatgagc gccaacagca gcagagtggg ccagcttctc ttgcagggtt 240 cagcgtgcat taggtggaag caggatgtgg aaggggctat ctaccaccta gccaactgcc 300 tcttactcct gggcttcatg gggggcagtg gggtgtatgg atgcttctat ctttttggct 360 tcctgagtgc aggttacctg tgctgcgtgc tgtggggctg gttcagtgcc tgtggcctgg 420 acattgttct ttggagcttc ctgctggctg tggtctgcct gctccagctg gcacacctgg 480 tataccgcct gcgtgaggac accctccctg aggagtttga cctcctctac aagacgctgt 540 gcctgccctt gcaggtgccc ctacagacat acaaggagat tgttcactgc tgtgaggagc 600 aggtcttaac tctggccact gaacagacct atgctgtgga gggtgagaca cccatcaacc 660 gcctgtccct gctgctctct ggccgggttc gtgtgagcca ggatgggcag tttctgcact 720 acatctttcc ataccagttc atggactctc ctgagtggga atcactacag ccttctgagg 780 agggggtgtt ccaggtcact ctgactgctg agacctcatg tagctacatt tcctggcccc 840 ggaaaagtct ccatcttctt ctgaccaaag agcgatacat ctcctgcctc ttctcggctc 900 tgctgggata tgacatctcg gagaagctct acactctcaa tgacaagctc tttgctaagt 960 ttgggctgcg ctttgacatc cgccttccca gcctctacca tgtcctgggt cccactgctg 1020 cagatgctgg accagagtcc gagaagggtg atgaggaagt ctgtgagcca gctgtgtccc 1080 ctcctcaggc cacacccacc tctctccagc aaacaccccc ttgttctacc cctccagcta 1140 ccaccaactt tcctgcacct cctacccggg ccaggttgtc caggccagac agtggcatac 1200 tgggtgagga ctccaccagt ctggtgctgg aggattttga ggaggtgtca ggatcagaat 1260 cgtttatgga ttataggagt gatggggagt acatgaggtg aagggagaac taacatgggc 1320 acagccaccg gctcaggatc ctatcttcta gaattcctct ccagagctac tctcaagtta 1380 tatccagggg acaggcccct ttggctccaa cccacacgcc tgaactttaa ggatcattgg 1440 actatcttct ctgtggccag cgcagctctc ttctgtgttc acagaatggc cactgatagg 1500 cacgcctctt ttcccaccca ctggaaggct cacaggcaag gtgagagagg acacagaagg 1560 tgccaacact gtcgctacag taaggacctg aagtgacttt gagaaattca ccctcacaaa 1620 ccttccttca ggagcaggca ttggtagtgc agaggcacag attccgtcct ttaccagctg 1680 cagaatcttg ggcaagttac atagcctctg tgagcctcat cggtaaacag tgggggttat 1740 gaaacccacc tcacagggtt gttgtgagga tccaatgagt tgatttaggt aagcacctag 1800 cacatgccat ggcaccaagt aagcactcaa taaatcactc aactccttta aaaaaaaaaa 1860 aaaaaaaaaa aaaa 1874 <210> 6 <211> 368 <212> PRT
<213> Homo Sapiens <400> 6 Met Ser Ala Asn Ser Ser Arg Val Gly Gln Leu Leu Leu Gln Gly Ser Ala Cys Ile Arg Trp Lys Gln Asp Val Glu Gly Ala Ile Tyr His Leu Ala Asn Cys Leu Leu Leu Leu Gly Phe Met Gly Gly Ser Gly Val Tyr Gly Cys Phe Tyr Leu Phe Gly Phe Leu Ser Ala Gly Tyr Leu Cys Cys Val Leu Trp Gly Trp Phe Ser Ala Cys Gly Leu Asp Ile Val Leu Trp Ser Phe Leu Leu Ala Val Val Cys Leu Leu Gln Leu Ala His Leu Val Tyr Arg Leu Arg Glu Asp Thr Leu Pro Glu Glu Phe Asp Leu Leu Tyr .. ._~_ --..100 105 110 Lys Thr Leu Cys Leu Pro Leu Gln Val Pro Leu Gln Thr Tyr Lys Glu Ile Val His Cys Cys Glu Glu Gln Val Leu Thr Leu Ala Thr Glu Gln Thr Tyr Ala Val Glu Gly Glu Thr Pro Ile Asn Arg Leu Ser Leu Leu Leu Ser Gly Arg Val Arg Val Ser Gln Asp Gly Gln Phe Leu His Tyr Ile Phe Pro Tyr Gln Phe Met Asp Ser Pro Glu Trp Glu Ser Leu Gln Pro Ser Glu Glu Gly Val Phe Gln Val Thr Leu Thr Ala Glu Thr Ser Cys Ser Tyr Ile Ser Trp Pro Arg Lys Ser Leu His Leu Leu Leu Thr Lys Glu Arg Tyr Ile Ser Cys Leu Phe Ser Ala Leu Leu Gly Tyr Asp Ile Ser Glu Lys Leu Tyr Thr Leu Asn Asp Lys Leu Phe Ala Lys Phe Gly Leu Arg Phe Asp Ile Arg Leu Pro Ser Leu Tyr His Val Leu Gly Pro Thr Ala Ala Asp Ala Gly Pro Glu Ser Glu Lys Gly Asp Glu Glu Val Cys Glu Pro Ala Val Ser Pro Pro Gln Ala Thr Pro Thr Ser Leu Gln Gln Thr Pro Pro Cys Ser Thr Pro Pro Ala Thr Thr Asn Phe Pro Ala Pro Pro Thr Arg Ala Arg Leu Ser Arg Pro Asp Ser Gly Ile Leu Gly Glu Asp Ser Thr Ser Leu Val Leu Glu Asp Phe Glu Glu Val Ser Gly Ser Glu Ser Phe Met Asp Tyr Arg Ser Asp Gly Glu Tyr Met Arg <210> 7 <211> 782 <212> DNA
<213> Homo Sapiens <400> 7 aggagctcta gcatcgcgac ccgccccgtc ccgtccagtc tggcctgggc gccgcgggaa 60 cgctgtccta gctgccgcca cccgaacagc ctgtcctggt gccccggctc cctgccccgc 120 gcccagtcat gaccctgcgc ccctcactcc tcccgctcca tctgctgctg ctgctgctgc 180 tcagtgcggc ggtgtgccgg gctgaggctg ggctcgaaac cgaaagtccc gtccggaccc 240 tccaagtgga gaccctggtg gagcccccag aaccatgtgc cgagcccgct gcttttggag 300 acacgcttca catacactac acgggaagct tggtagatgg acgtattatt gacacctccc 360 tgaccagaga ccctctggtt atagaacttg gccaaaagca ggtgattcca ggtctggagc 420 agagtcttct cgacatgtgt gtgggagaga agcgaagggc aatcattcct tctcacttgg 480 cctatggaaa acggggattt ccaccatctg tcccagcgga tgcagtggtg cagtatgacg 540 tggagctgat tgcactaatc cgagccaact actggctaaa gctggtgaag ggcattttgc 600 ctctggtagg gatggccatg gtgccagccc tcctgggcct cattgggtat cacctataca 660 gaaaggccaa tagacccaaa gtctccaaaa agaagctcaa ggaagagaaa cgaaacaaga 720 gcaaaaagaa ataataaata ataaatttta aaaaacttaa aaaaaaaaaa aaaaaaaaaa 780 as 782 <210> 8 <211> 201 <212> PRT
<213> Homo sapiens <400> 8 Met Thr Leu Arg Pro Ser Leu Leu Pro Leu His Leu Leu Leu Leu Leu Leu Leu Ser Ala Ala Val Cys Arg Ala Glu Ala Gly Leu Glu Thr Glu Ser Pro Val Arg Thr Leu Gln Val Glu Thr Leu Val Glu Pro Pro Glu Pro Cys Ala Glu Pro Ala Ala Phe Gly Asp Thr Leu His Ile His Tyr Thr Gly Ser Leu Val Asp Gly Arg Ile Ile Asp Thr Ser Leu Thr Arg Asp Pro Leu Val Ile Glu Leu Gly Gln Lys Gln Val Ile Pro Gly Leu Glu Gln Ser Leu Leu Asp Met Cys Val Gly Glu Lys Arg Arg Ala Ile Ile Pro Ser His Leu Ala Tyr Gly Lys Arg Gly Phe Pro Pro Ser Val Pro Ala Asp Ala Val Val Gln Tyr Asp Val Glu Leu Ile Ala Leu Ile Arg Ala Asn Tyr Trp Leu Lys Leu Val Lys Gly Ile Leu Pro Leu Val Gly Met Ala Met Val Pro Ala Leu Leu Gly Leu Ile Gly Tyr His Leu Tyr Arg Lys Ala Asn Arg Pro Lys Val Ser Lys Lys Lys Leu Lys Glu Glu Lys Arg Asn Lys Ser Lys Lys Lys <210> 9
12 <211> 1700 <212> DNA
<213> Homo Sapiens <400> 9 gctggtcagc caagggctag aggccctacg cagtgaacac caggccgtgc tgcaaagcct 60 gtcccagacc attgagtgtc tgcagcaggg aggccatgag gaagggctgg tgcatgagaa 120 ggcccggcag cttcgccgtt ctatggaaaa cattgagctc gggctgagtg aggcccaggt 180 gatgctggct ctagccagcc acctgagcac agtggagtcg gagaaacaga agctgcgggc 240 tcaggtgcgg cggctatgcc aggagaacca gtggctgcgg gatgagctgg ctggcaccca 300 gcagcggcta cagcgcagtg aacaggctgt ggctcagctg gaggaggaaa agaagcacct 360 ggagttcctg gggcagctgc ggcagtatga tgaggatgga catacctcgg aggagaaaga 420 aggcgatgcc accaaggatt ccctggatga cctctttcct aatgaggagg aagaggaccc 480 agcaatggct tgtcccgtgg tcaaggtgct acagcagctc agcagggtgg atatgagatc 540 ccagcaaggt tgcggacgtt gcacaacctg gtgatccagt acgcagccca aggtcgctat 600 gaggtggccg tgccactctg taagcaggca ctagaggacc tggagcgcac atcaggccgt 660 ggccaccctg atgtcgccac catgctcaac atccttgctt tggtgtatcg tgaccagaat 720 aagtataagg aagctgccca cctgctgaat gatgccctta gcatccggga gagcaccttg 780 ggacctgacc atcctgctgt ggctgccaca ctcaacaatt tggctgtgct ctatggcaaa 840 aggggcaagt acaaggaggc agagcctctg tgccagcggg cactggagat tcgagaaagg 900 tcctgggcac gaatcatcca gatgtggcaa aacagctgaa caacctggcc ctcttgtgcc 960 aaaaccaggg caagtatgag gccgtggaac gctactacca gcgagcactg gccatctacg 1020 aggggcagct ggggccggac aaccctaatg tagcccggac caagaacaac ctggcttcct 1080 gttacctgaa acagggcaaa tatgctgagg ctgagacact atacaaagag atcctgaccc 1140 gtgcccatgt acaggagttt gggtctgtgg atgatgacca caagcccatc tggatgcatg 1200 cagaggagcg ggaggaaatg agcaaaagcc ggcaccatga gggtgggaca ccctatgctg 1260 agtatggagg ctgggtcccc ccacccccac agccctcaca gcattcccca ttgctcctgg 1320 ctcttcccca cccctaggtg ggacagtgaa ggggagcagt ttaaccagaa gattgctgct 1380 gcccttaggg tctcagctcc ctcctcagga atcctcttag gaaggtgtct taggacaccc 1440 tctctgcacc ctgtggtcct ctagagtagc tagctctgag gccccaaggt gggtacaaag 1500 caggtatggc cctcagagat gcagcctgct gctggctttt cagtcagagg gttgggggct 1560 ggccagccaa gctgccttgc cctggccgct cttactccct ccctctgctg tctcacttca 1620 ggtccatgta tttcactttt cttaaataaa agaatcaggt aaaaaaaaaa aaaaaaaaaa 1680 aaaaaaaaaa aaaaaaaaaa 1700 <210> 10 <211> 143 <212> PRT
<213> Homo Sapiens <400> 10 Met Glu Asn Ile Glu Leu Gly Leu Ser Glu Ala Gln Val Met Leu Ala Leu Ala Ser His Leu Ser Thr Val Glu Ser Glu Lys Gln Lys Leu Arg Ala Gln Val Arg Arg Leu Cys Gln Glu Asn Gln Trp Leu Arg Asp Glu Leu Ala Gly Thr Gln Gln Arg Leu Gln Arg Ser Glu Gln Ala Val Ala Gln Leu Glu Glu Glu Lys Lys His Leu Glu Phe Leu Gly Gln Leu Arg Gln Tyr Asp Glu Asp Gly His Thr Ser Glu Glu Lys Glu Gly Asp Ala Thr Lys Asp Ser Leu Asp Asp Leu Phe Pro Asn Glu Glu Glu Glu Asp
13 Pro Ala Met Ala Cys Pro Val Val Lys Val Leu Gln Gln Leu Ser Arg Val Asp Met Arg Ser Gln Gln Gly Cys Gly Arg Cys Thr Thr Trp <210> 11 <211> 781 <212> DNA
<213> Homo Sapiens <400> 11 tcatcactgc cgtggcccac ccaggagcca agtctgtgcc ccccaagcca gcaaacacag 60 ctgcagcccg ggccatcttc ccaccagctt ctcaccgctc ccccatcagc catgaaggct 120 ccctgtcctc agctgccatg tcccccagct tctcaccctc tctgtctcct ctggctgctc 180 gctcacccgt tgtctcacca tttggggtgg cccagggtcc ctcagcctca gcactcagcg 240 cagagtctgg cctggagcca cctgatgaca cggagctgca catctagctg tggcccaggc 300 tgggccccga cctgggatgc gcacagtgtc cccaacgcag gccccactct gagcctgccc 360 tgggcagcct cggactatga ctggctacgg ggaggccacc accaggcccc agctctccac 420 cctgaactcc ccagccccct cagagtacta ggaccacaga agccctgttg ctcactgacc 480 tgtgaccagg tccaatgtgg ggagaaatat gaaggaggta gcagccctgg gttctcctca 540 gtgagggatc cctgccctgc accagcaccc tgagatggag ctgagacttt atttattggg 600 ggtaggggga tggaggaggt ccctccaaca tgtttggacc cagctccttt gggttccact 660 gacacccctg cccctgcccc tgcccagaac caagtgccat ttctcactct ggagccttaa 720 taaactgcaa tttgtatcca gtcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780 a 781 <210> 12 <211> 153 <212> PRT
<213> Homo Sapiens <400> 12 Met Lys Ala Pro Cys Pro Gln Leu Pro Cys Pro Pro Ala Ser His Pro Leu Cys Leu Leu Trp Leu Leu Ala His Pro Leu Ser His His Leu Gly Trp Pro Arg Val Pro Gln Pro Gln His Ser Ala Gln Ser Leu Ala Trp Ser His Leu Met Thr Arg Ser Cys Thr Ser Ser Cys Gly Pro Gly Trp Ala Pro Thr Trp Asp Ala His Ser Val Pro Asn Ala Gly Pro Thr Leu Ser Leu Pro Trp Ala Ala Ser Asp Tyr Asp Trp Leu Arg Gly Gly His His Gln Ala Pro Ala Leu His Pro Glu Leu Pro Ser Pro Leu Arg Val Leu Gly Pro Gln Lys Pro Cys Cys Ser Leu Thr Cys Asp Gln Val Gln
14 Cys Gly Glu Lys Tyr Glu Gly Gly Ser Ser Pro Gly Phe Ser Ser Val Arg Asp Pro Cys Pro Ala Pro Ala Pro <210> 13 <211> 1605 <212> DNA
<213> Homo Sapiens <400> 13 ttcatgagag tcacaattcc cttctacaag acttgtctcc aactgaagag gaagagccag 60 agcatccttt tggggtgggc ggtgtggaca gcgtgtctga gagcactggc agcatcctca 120 gcaagctgga ctggaatgcc atcgaagaca tggtggccag cgtggaggac cagggcctgt 180 ctgtccactg ggccctggac ctgtaagacc tggatatcat tgggtttcca tgcacaggcc 240 agcacctcag taatgtggtt ctgaaagatt aacaggttta agggacagaa gcaatgaaag 300 aagcaatgtg aattttccat ttgctttcat attattacct ggattagcca ttaccagagg 360 aaaaataaac atttctcagt aactttgcct ttatggggaa agggttgact attgatgtat 420 tatatgtttt tgtatttgat gcatcattag gcataatttt taaaatgata agtacctttc 480 aagccaagtt tgcataacct actttcaata aaaaccctct atcttgcctc ctcctttatt 540 accctctgag ttttgagaaa caaccatata cagatgaatc taataggaaa aaaaaaatct 600 tttcattgag aagaaaatca gtctcacctg agaactcaat tatgaaccct attttaaaac 660 acctatgcag ggtttagcct aggagtgaaa agaaaaacca actacctttt accaaccctg 720 aatctctaaa taagcaaagt ttcatggagg ccaggagatc ttctgtcttc tgccctgtag 780 cctgaagcct tggaggaaga aacaggaatg gatgctttgg gcaggaaagt aagggaatat 840 gactccggcc tctagaaggc tcatcttaaa tttgtaagaa ccatggtaca gagacctgat 900 tagtttttgg tattgtgctc caataatgtc atagttttaa gagataattt ttatgagaat 960 tgactaagaa ccagtatcct tcaactactt catcaatgtt tggtataata taaaagcaca 1020 ctatcatctg aaaaagctat taaatacccc tctttttcca aatatctacc tgtgtgaagc 1080 caggttttac aacatgtatt gcagcaagtt gaatgcagaa gcaggtatgg taattcagct 1140 gccttctatc aagctaaaca ttaaagagat ttgtagaact ataaaacaat gctactctcc 1200 ttaccaaatt gttttagaaa atagctttat aggctaacat tattgttaat tgtcatttaa 1260 ttgttttgtc atttaaaata ttttaaattg ttttctgtta gtttcttttt tgtatattct 1320 atgggtattt tattgataca tgatagttgt acatttttat ggggtgcatg tgatattttg 1380 atatgtgcat acaatgtgta gcaatcaaat cagggtaatt gggatattca tcacctcaaa 1440 catttatcat ttatttgtgt tggaaacatt caaacctttt cttctagcta tttatccatt 1500 gttggatact tatatcaatt ctatatctta gctgttgtga atagagctgc aataaatgta 1560 ggagtgcaga taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 1605 <210> 14 <211> 86 <212> PRT
<213> Homo Sapiens <400> 14 Met Arg Val Thr Ile Pro Phe Tyr Lys Thr Cys Leu Gln Leu Lys Arg Lys Ser Gln Ser Ile Leu Leu Gly Trp Ala Val Trp Thr Ala Cys Leu Arg Ala Leu Ala Ala Ser Ser Ala Ser Trp Thr Gly Met Pro Ser Lys Thr Trp Trp Pro Ala Trp Arg Thr Arg Ala Cys Leu Ser Thr Gly Pro Trp Thr Cys Lys Thr Trp Ile Ser Leu Gly Phe His Ala Gln Ala Ser IS

Thr Ser Val Met Trp Phe <210> 15 <211> 2607 <212> DNA
<213> Homo sapiens <400> 15 attgtgcggc gctggtcccc tcagagggtt cctgctgctg ccggtgcctt ggaccctccc 60 cctcgcttct cgttctactg ccccaggagc ccggcgggtc cgggactccc gtccgtgccg 120 gtgcgggcgc cggcatgtgg ctgtgggagg accagggcgg cctcctgggc cctttctcct 180 tcctgctgct agtgctgctg ctggtgacgc ggagcccggt caatgcctgc ctcctcaccg 240 gcagcctctt cgttctactg cgcgtcttca gctttgagcc ggtgccctct tgcagggccc 300 tgcaggtgct caagccccgg gaccgcattt ctgccatcgc ccaccgtggc ggcagccacg 360 acgcgcccga gaacacgctg gcggccattc ggcaggcagc taagaatgga gcaacaggcg 420 tggagttgga cattgagttt acttctgacg ggattcctgt cttaatgcac gataacacag 480 tagataggac gactgatggg actgggcgat tgtgtgattt gacatttgaa caaattagga 540 agctgaatcc tgcagcaaac cacagactca ggaatgattt ccctgatgaa aagatcccta 600 ccctaaggga agctgttgca gagtgcctaa accataacct cacaatcttc tttgatgtca 660 aaggccatgc acacaaggct actgaggctc taaagaaaat gtatatggaa tttcctcaac 720 tgtataataa tagtgtggtc tgttctttct tgccagaagt tatctacaag atgagacaaa 780 cagatcggga tgtaataaca gcattaactc acagaccttg gagcctaagc catacaggag 840 atgggaaacc acgctatgat actttctgga aacattttat atttgttatg atggacattt 900 tgctcgattg gagcatgcat aatatcttgt ggtacctgtg tggaatttca gctttcctca 960 tgcaaaagga ttttgtatcc ccggcctact tgaagaagtg gtcagctaaa ggaatccagg 1020 ttgttggttg gactgttaat acctttgatg aaaagagtta ctacgaatcc catcttggtt 1080 ccagctatat cactgacagc atggtagaag actgcgaacc tcacttctag actttcacgg 1140 tgggacgaaa cgggttcaga aactgccagg ggcctcatac agggatatca aaataccctt 1200 tgtgctagcc caggccctgg ggaatcaggt gactcacaca aatgcaatag ttggtcactg 1260 catttttacc tgaaccaaag ctaaacccgg tgttgccacc atgcaccatg gcatgccaga 1320 gttcaacact gttgctcttg aaaatctggg tctgaaaaaa cgcacaagag cccctgccct 1380 gccctagctg aggcacacag ggagacccag tgaggataag cacagattga attgtacagt 1440 ttgcagatgc agatgtaaat gcatgggaca tgcatgataa ctcagagttg acattttaaa 1500 acttgccaca cttatttcaa atatttgtac tcagctatgt taacatgtac tgtagacatc 1560 aaacttgtgg ccatactaat aaaattatta aaaggagcac taaaggaaaa ctgtgtgcca 1620 agcatcatat cctaaggcat acggaatttg gggaagccac catgcaatcc agtgaggctt 1680 cagtgtacag caaccaaaat ggtagggagg tcttgaagcc aatgagggat ttatagcatc 1740 ttgaatagag agctgcaaac caccaggggg cagagttgca tttttccagg ctttttagga 1800 agctctgcaa cagatgtgat ctgatcatag gcaattagaa ctggaagaaa cttccaaaaa 1860 tatctaggtt tgtcctcatt ttacaaatga ggaaactaaa ctctgtggaa gggaaggggt 1920 tgcctcaaaa gtcacagctt agctgggcac agtggctcat gccgataatc ccagcaattc 1980 agaaagctga ggcaggagga ttacttgagg ccagactggg caatatagca agaccccatc 2040 tctaaaaaat taggcatggt ggtgcatgcc tgtattccca gctactcagg aggttgaggt 2100 gggaggatca cttgagccca gaagttcaag gctgcaatga gccatgatta caccacggca 2160 ctacaacctt ggtggcacag tgagaacctg actcttaaaa aaaaaaaaaa aaaaaaaaaa 2220 aaaaaggata actagaactt ctagaacatc ttgtttacag ttagccagaa actatacaag 2280 tggtttaaca tgcattatct tactcaatcc atacaaaagt cttatggagg tgttagcact 2340 ctttctactg atgaagaact gaggtacttc ataaaaccac ttacccaagg tgtcttgagt 2400 ctggtacaac tggcattcaa atctaggtca gtctgccccc agagccacta cccttacccc 2460 tcactgaatc tgcctttata ttgttgagcc cttgacccca aactgctctt tccaatttga 2520 acttccaggg attttattgt gaacttacat agcaacatta aaatgaagtt gaattgttta 2580 aaaaaaaaaa aaaaaaaaaa aaaaaaa 2607 <210> 16 <211> 331 <212> PRT

<213> Homo Sapiens <400> 16 Met Trp Leu Trp Glu Asp Gln Gly Gly Leu Leu Gly Pro Phe Ser Phe Leu Leu Leu Val Leu Leu Leu Val Thr Arg Ser Pro Val Asn Ala Cys Leu Leu Thr Gly Ser Leu Phe Val Leu Leu Arg Val Phe Ser Phe Glu Pro Val Pro Ser Cys Arg Ala Leu Gln Val Leu Lys Pro Arg Asp Arg Ile Ser Ala Ile Ala His Arg Gly Gly Ser His Asp Ala Pro Glu Asn Thr Leu Ala Ala Ile Arg Gln Ala Ala Lys Asn Gly Ala Thr Gly Val Glu Leu Asp Ile Glu Phe Thr Ser Asp Gly Ile Pro Val Leu Met His Asp Asn Thr Val Asp Arg Thr Thr Asp Gly Thr Gly Arg Leu Cys Asp Leu Thr Phe Glu Gln Ile Arg Lys Leu Asn Pro Ala Ala Asn His Arg Leu Arg Asn Asp Phe Pro Asp Glu Lys Ile Pro Thr Leu Arg Glu Ala Val Ala Glu Cys Leu Asn His Asn Leu Thr Ile Phe Phe Asp Val Lys Gly His Ala His Lys Ala Thr Glu Ala Leu Lys Lys Met Tyr Met Glu Phe Pro Gln Leu Tyr Asn Asn Ser Val Val Cys Ser Phe Leu Pro Glu Val Ile Tyr Lys Met Arg Gln Thr Asp Arg Asp Val Ile Thr Ala Leu Thr His Arg Pro Trp Ser Leu Ser His Thr Gly Asp Gly Lys Pro Arg Tyr Asp Thr Phe Trp Lys His Phe Ile Phe Val Met Met Asp Ile Leu Leu Asp Trp Ser Met His Asn Ile Leu Trp Tyr Leu Cys Gly Ile Ser Ala Phe Leu Met Gln Lys Asp Phe Val Ser Pro Ala Tyr Leu Lys Lys Trp Ser Ala Lys Gly Ile Gln Val Val Gly Trp Thr Val Asn Thr Phe Asp Glu Lys Ser Tyr Tyr Glu Ser His Leu Gly Ser Ser Tyr Ile Thr Asp Ser Met Val Glu Asp Cys Glu Pro His Phe <210> 17 <211> 4859 <212> DNA
<213> Homo Sapiens <400> 17 gaaaactaca accggcggcc agcgggacca gagggcggct ctgcaggcag gcggcagcgg 60 tgccctcagt tccccagcat ggccccctcg gcctgggcca tttgctggct gctagggggc 120 ctcctgctcc atgggggtag ctctggcccc agccccggcc ccagtgtgcc ccgcctgcgg 180 ctctcctacc gagacctcct gtctgccaac cgctctgcca tctttctggg cccccagggc 240 tccctgaacc tccaggccat gtacctagat gagtaccgag accgcctctt tctgggtggc 300 ctggacgccc tctactctct gcggctggac caggcatggc cagatccccg ggaggtcctg 360 tggccaccgc agccaggaca gagggaggag tgtgttcgaa agggaagaga tcctttgaca 420 gagtgcgcca acttcgtgcg ggtgctacag cctcacaacc ggacccacct gctagcctgt 480 ggcactgggg ccttccagcc cacctgtgcc ctcatcacag ttggccaccg tggggagcat 540 gtgctccacc tggagcctgg cagtgtggaa agtggccggg ggcggtgccc tcacgagccc 600 agccgtccct ttgccagcac cttcatagac ggggagctgt acacgggtct cactgctgac 660 ttcctggggc gagaggccat gatcttccga agtggaggtc ctcggccagc tctgcgttcc 720 gactctgacc agagtctctt gcacgacccc cggtttgtga tggccgcccg gatccctgag 780 aactctgacc aggacaatga caaggtgtac ttcttcttct cggagacggt cccctcgccc 840 gatggtggct cgaaccatgt cactgtcagc cgcgtgggcc gcgtctgcgt gaatgatgct 900 gggggccagc gggtgctggt gaacaaatgg agcactttcc tcaaggccag gctggtctgc 960 tcggtgcccg gccctggtgg tgccgagacc cactttgacc agctagagga tgtgttcctg 1020 ctgtggccca aggccgggaa gagcctcgag gtgtacgcgc tgttcagcac cgtcagtgcc 1080 gtgttccagg gcttcgccgt ctgtgtgtac cacatggcag acatctggga ggttttcaac 1140 gggccctttg cccaccgaga tgggcctcag caccagtggg ggccctatgg gggcaaggtg 1200 cccttccctc gccctggcgt gtgccccagc aagatgaccg cacagccagg acggcctttt 1260 ggcagcacca aggactaccc agatgaggtg ctgcagtttg cccgagccca ccccctcatg 1320 ttctggcctg tgcggcctcg acatggccgc cctgtccttg tcaagaccca cctggcccag 1380 cagctacacc agatcgtggt ggaccgcgtg gaggcagagg atgggaccta cgatgtcatt 1440 ttcctgggga ctgactcagg gtctgtgctc aaagtcatcg ctctccaggc agggggctca 1500 gctgaacctg aggaagtggt tctggaggag ctccaggtgt ttaaggtgcc aacacctatc 1560 accgaaatgg agatctctgt caaaaggcaa atgctatacg tgggctctcg gctgggtgtg 1620 gcccagctgc ggctgcacca atgtgagact tacggcactg cctgtgcaga gtgctgcctg 1680 gcccgggacc catactgtgc ctgggatggt gcctcctgta cccactaccg ccccagcctt 1740 ggcaagcgcc ggttccgccg gcaggacatc cggcacggca accctgccct gcagtgcctg 1800 ggccagagcc aggaagaaga ggcagtggga cttgtggcag ccaccatggt ctacggcacg 1860 gagcacaata gcaccttcct ggagtgcctg cccaagtctc cccaggctgc tgtgcgctgg 1920 ctcttgcaga ggccagggga tgaggggcct gaccaggtga agacggacga gcgagtcttg 1980 cacacggagc gggggctgct gttccgcagg cttagccgtt tcgatgcggg cacctacacc 2040 tgcaccactc tggagcatgg cttctcccag actgtggtcc gcctggctct ggtggtgatt 2100 gtggcctcac agctggacaa cctgttccct ccggagccaa agccagagga gcccccagcc 2160 cggggaggcc tggcttccac cccacccaag gcctggtaca aggacatcct gcagctcatt 2220 ggcttcgcca acctgccccg ggtggatgag tactgtgagc gcgtgtggtg caggggcacc 2280 acggaatgct caggctgctt ccggagccgg agccggggca agcaggccag gggcaagagc 2340 tgggcagggc tggagctagg caagaagatg aagagccggg tgcatgccga gcacaatcgg 2400 acgccccggg aggtggaggc cacgtagaag ggggcagagg aggggtggtc aggatgggct 2460 ggggggccca ctagcagccc ccagcatctc ccacccaccc agctagggca gaggggtcag 2520 gatgtctgtt tgcctcttag agacaggtgt ctctgccccc acaccgctac tggggtctaa 2580 tggaggggct gggttcttga agcctgttcc ctgcccttct ctgtgctctt agacccagct 2640 ggagccagca ccctctggct gctggcagcc ccaagggatc tgccatttgt tctcagagat 2700 ggcctggctt ccgcaacaca tttccgggtg tgcccagagg caagagggtt gggtggttct 2760 ttcccagcct acagaacaat ggccattctg agtgaccctc agagtgggtg tgtgggtgcg 2820 Ig tctagggggt atcccggtag ggggcctgca gggagccaga gggtggaaat ggcctctaag 2880 ctagcacccc gtaagaagag cctacctgac cgacttgggg agggaacaca gaggtgttgg 2940 gaaggtggag caacaatgca cctcccctcc tgtcgcgccg tgatatcttg gtggctccct 3000 gccactgccc accg~ctctt ctccatctga gaatcacgga gaggtgtaga taatctagag 3060 gcatagactg ctagagcccc cagggatctg gggtggtcag ggctcgggct tcactttgta 3120 aaccaggtgg gggcatctca cagcctgact tcccttcccc aggccagggt tgctgggatg 3180 cctgcccctc ctgagaggac cccctcccca ttgtcaggct ctccatgtcc acgagcgggg 3240 aggggtgggt tctggggcat tgttgtccct tgtgtctgtg gactagagat agggtggggg 3300 agctggggaa gggtgcaggc gggaagagtg ggctgtcttt cccagggtga tgcaagcatg 3360 ccgcagccct ggaggctggg aatgtggagg ctctgtgagc cctgcagccc tcagaatcag 3420 ggccagggat gcagaagatt gagaggatat ggagatggat agagggcagg agacccttag 3480 gatagattgt gggacccagg caggaacagg tgtccacaag aactcaggat ggcatcagtt 3540 agctcagaag ccacctggaa gacccagtgt ttccatctct ggaatctctg ttttatgcta 3600 aatggattta ggaagactgt ttttctttta agggggaaac aaggtagaga aaaggacgaa 3660 gaagtgtaag tcccgctgat tctcgggggt aaggctcgga tggcaaggac gcgttctgcc 3720 tgggcatgta ggggaggtgt ttttgccatc accagtttct caggctgggg agcacagagg 3780 ggaggaggag gactaaatga aaagttgttc ccagcctgca catgaacaca ttcatgacac 3840 acaaaactgg ctggaaggag ataagagcac tgggtttgag attccctcca ttaaaacaac 3900 caagacaaag aaaggagggg aaaaaaagat aaaaagcaag ccagggttcc ctgccctatt 3960 gaaactcaaa cccagactgc cttgggtttt atctttccct tacccctggc acctccagag 4020 aactgggacc tgaaatagtc cctccgttct cccctttgac catgtaataa atgaaccaga 4080 agcactgaga ttaacctatc aacgccctga gaagccttcc agcctgcggt gctgtctgct 4140 gggaggtcag ctggtcaagg cagaggagga gaggaggaaa ggatgggggc tgaagagcag 4200 aagggagggg agacagaggg gattaaagag gggaggagag agtgcagagc tccaggaaag 4260 ggtatcagag ctgcagccag ctctgccctc taccctaggg aggccagaaa gacacaaaca 4320 gccctccggg cctttacgct ggactctggc ttggcaggct ccaggcaggg tcctctggga 4380 agttactcta gaaaacgaag ggaggaggag cacaagatcc tcagcaacga acacctgcac 4440 ttagaaaaag tggacagctt ctgccaacca caccctaccc atggtactgt atgctattaa 4500 ctcctggaaa cgccccgtaa atgcgagttg tttttgtatt tgtgtgttga gatgggcctt 4560 gtggtttctc tgtactcaga gcacatttct tgtaattact attgttattt ttattgtcat 4620 gactgcccct gagctctggt gagaaaagct gaatttacaa ggaaagggat gaagttaata 4680 tttgcatcac ataattatat cattactgtg tatctgtgta ttgtactaaa tggactgatg 4740 ctgcgcacat gagctgaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4800 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 4859 <210> 18 <211> 782 <212> PRT
<213> Homo Sapiens <400> 18 Met Ala Pro Ser Ala Trp Ala Ile Cys Trp Leu Leu Gly Gly Leu Leu Leu His Gly Gly Ser Ser Gly Pro Ser Pro Gly Pro Ser Val Pro Arg Leu Arg Leu Ser Tyr Arg Asp Leu Leu Ser Ala Asn Arg Ser Ala Ile Phe Leu Gly Pro Gln Gly Ser Leu Asn Leu Gln Ala Met Tyr Leu Asp Glu Tyr Arg Asp Arg Leu Phe Leu Gly Gly Leu Asp Ala Leu Tyr Ser Leu Arg Leu Asp Gln Ala Trp Pro Asp Pro Arg Glu Val Leu Trp Pro Pro Gln Pro Gly Gln Arg Glu Glu Cys Val Arg Lys Gly Arg Asp Pro Leu Thr Glu Cys Ala Asn Phe Val Arg Val Leu Gln Pro His Asn Arg Thr His Leu Leu Ala Cys Gly Thr Gly Ala Phe Gln Pro Thr Cys Ala Leu Ile Thr Val Gly His Arg Gly Glu His Val Leu His Leu Glu Pro Gly Ser Val Glu Ser Gly Arg Gly Arg Cys Pro His Glu Pro Ser Arg Pro Phe Ala Ser Thr Phe Ile Asp Gly Glu Leu Tyr Thr Gly Leu Thr Ala Asp Phe Leu Gly Arg Glu Ala Met Ile Phe Arg Ser Gly Gly Pro Arg Pro Ala Leu Arg Ser Asp Ser Asp Gln Ser Leu Leu His Asp Pro Arg Phe Val Met Ala Ala Arg Ile Pro Glu Asn Ser Asp Gln Asp Asn Asp Lys Val Tyr Phe Phe Phe Ser Glu Thr Val Pro Ser Pro Asp Gly Gly Ser Asn His Val Thr Val Ser Arg Val Gly Arg Val Cys Val Asn Asp Ala Gly Gly Gln Arg Val Leu Val Asn Lys Trp Ser Thr Phe Leu Lys Ala Arg Leu Val Cys Ser Val Pro Gly Pro Gly Gly Ala Glu Thr His Phe Asp Gln Leu Glu Asp Val Phe Leu Leu Trp Pro Lys Ala Gly Lys Ser Leu Glu Val Tyr Ala Leu Phe Ser Thr Val Ser Ala Val Phe Gln Gly Phe Ala Val Cys Val Tyr His Met Ala Asp Ile Trp Glu Val Phe Asn Gly Pro Phe Ala His Arg Asp Gly Pro Gln His Gln Trp Gly Pro Tyr Gly Gly Lys Val Pro Phe Pro Arg Pro Gly Val Cys Pro Ser Lys Met Thr Ala Gln Pro Gly Arg Pro Phe Gly Ser Thr Lys Asp Tyr Pro Asp Glu Val Leu Gln Phe Ala Arg Ala His Pro Leu Met Phe Trp Pro Val Arg Pro Arg His Gly Arg Pro Val Leu Val Lys Thr His Leu Ala Gln Gln Leu His Gln Ile Val Val Asp Arg Val Glu Ala Glu Asp Gly Thr Tyr Asp Val Ile Phe Leu Gly Thr Asp Ser Gly Ser Val Leu Lys Val Ile Ala Leu Gln Ala Gly Gly Ser Ala Glu Pro Glu Glu Val Val Leu Glu Glu Leu Gln Val Phe Lys Val Pro Thr Pro Ile Thr Glu Met Glu Ile Ser Val Lys Arg Gln Met Leu Tyr Val Gly Ser Arg Leu Gly Val Ala Gln Leu Arg Leu His Gln Cys Glu Thr Tyr Gly Thr Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp Pro Tyr Cys Ala Trp Asp Gly Ala Ser Cys Thr His Tyr Arg Pro Ser Leu Gly Lys Arg Arg Phe Arg Arg Gln Asp Ile Arg His Gly Asn Pro Ala Leu Gln Cys Leu Gly Gln Ser Gln Glu Glu Glu Ala Val Gly Leu Val Ala Ala Thr Met Val Tyr Gly Thr Glu His Asn Ser Thr Phe Leu Glu Cys Leu Pro Lys Ser Pro Gln Ala Ala Val Arg Trp Leu Leu Gln Arg Pro Gly Asp Glu Gly Pro Asp Gln Val Lys Thr Asp Glu Arg Val Leu His Thr Glu Arg Gly Leu Leu Phe Arg Arg Leu Ser Arg Phe Asp Ala Gly Thr Tyr Thr Cys Thr Thr Leu Glu His Gly Phe Ser Gln Thr Val Val Arg Leu Ala Leu Val Val Ile Val Ala Ser Gln Leu Asp Asn Leu Phe Pro Pro Glu Pro Lys Pro Glu Glu Pro Pro Ala Arg Gly Gly Leu Ala Ser Thr Pro Pro Lys Ala Trp Tyr Lys Asp Ile Leu Gln Leu Ile Gly Phe Ala Asn Leu Pro Arg Val Asp Glu Tyr Cys Glu Arg Val Trp Cys Arg Gly Thr Thr Glu Cys Ser Gly Cys Phe Arg Ser Arg Ser Arg Gly Lys Gln Ala Arg Gly Lys Ser Trp Ala Gly Leu Glu Leu Gly Lys Lys Met Lys Ser Arg Val His Ala Glu His Asn Arg Thr Pro Arg Glu Val Glu Ala Thr <210> 19 <211> 2342 <212> DNA
<213> Homo sapiens <400> 19 tatgaaggcc ctgattcgaa accgcagcta cgtcttctcc tccctggcca cgtcggctgt 60 ctccttcgcc acgggggccc tgggcatgtg gatcccgctc tacctgcacc gcgcccaagt 120 tgtgcagaag acagcagaga cgtgcaacag cccgccctgt ggggccaagg acagcctcat 180 ctttggggcc atcacctgct ttacgggatt tctgggcgtg gtcacggggg caggagccac 240 gcgctggtgc cgcctgaaga cccagcgggc cgacccactg gtgtgtgccg tgggcatgct 300 gggctctgcc atcttcatct gcctgatctt cgtggctgcc aagagcagca tcgtaggagc 360 ctatatctgt atcttcgtcg gggagacgct gctgttttct aactgggcca tcactgcaga 420 catcctcatg tacgtggtca tccccacgcg gcgcgccact gccgtggcct tgcagagctt 480 cacctcccac ctgctggggg acgccgggag cccctacctc attggcttta tctcagacct 540 gatccgccag agcactaagg actccccgct ctgggagttc ctgagcctgg gctacgcgct 600 catgctctgc cctttcgtcg tggtcctggg cggcatgttc ttcctcgcca ctgtgctctt 660 cttcgtcagc gaccgcgcca gggctgagca gcaggtgaac cagctggcga tgccgcccgc 720 atctgtgaaa gtctgaggtg gtgccattgg gacaatgaag aacccacact cccacctcgt 780 ctgggaggtg tcctacagcg tccgggaccg gctgggctgc cccaaagctt tctgtgtgat 840 ccacggctag gcacccaccc tctctggccc aggcctgctg agtggccctg gcatcaagag 900 gaggctgtgt cctcagttac cctggaagga tgtgtgtgtt ggagccacac ggttggacag 960 gttcccagcc ctaggtttgg gccgcagggc ccctggggcc aaggaagaag acagccccaa 1020 gtgggtgtcc ggggagagcc tggcctgcca ccagcttatg tgatcttggg caagtccctg 1080 ccctccctgg aacgaagggc cagggggctg gactttccca cacaacttgc tgggcaaagc 1140 acgatctgca gctttgaaga ctcaacagac cctggaccat acggagagca ggtggcccag 1200 gcctcagggc ggcagtcccg gctttgaggc tcacgcgagg gcctggtatg cagggaccac 1260 tgctcagctg ggcctcggac cttggggata ttggacgcaa catggcaaat gaagctgggc 1320 gcccaagtct ctgggtactc cctggaggac actgtctcac tgtctcgggt tggctcccag 1380 cctggaggtc ccagatgggg actgttctga caagctggca tcaccagggg tgaaggccct 1440 ggctgcagct gtacaccacc tgtgccccca ggctcaaggt ctctggcagg tgcacaccag 1500 cccaactctg cagggcttct ctccctgcca ccacccccca agccaggacc ccactccttc 1560 cccgaggctg agctgagcct tttccagggg cagggcccag gagaccattc ccagaatcca 1620 tggggcagta gccagggctc cggctgctgg aggaagcagc tatccacaaa gcttcctgcc 1680 ccagagctga ggctgaggcc ccgggagagg cggcccctac ccaaacactg gctgctggca 1740 ttccaccaag tgaccccagg ggccaggcct tcgatcaccc acctcccatc catgcacaca 1800 ccaggatgca gctgccaact tcacaccagc cccaacccgc tttgggggag cttagccccc 1860 tgcgtcaccc actccctgca cttctgctgc aatcaaggtg gttctggtgc gggggtgggg 1920 tggggggtga ggccttgtgg ccaatggggg accccccaag agccagcttg gacaatgctc 1980 ttcttgcccc ttagttactg gctggctgtg gcttcagtgg tgtgtaagca ggtggaatac 2040 tcacccacca agctctgggg taccccgagg gcctgacaag aggatggggt gggggtggca 2100 tcctccaaag accagcctcc acccccactc cagcctcagc ggggccccag cgatgttttc 2160 ttgttgtaca agaaccaggt ccgagtgttg cctcctcttc cttccggaag ccaaactgct 2220 cctttatttt ttagagctgc tgattgtgaa tctcagagtc ttaagagaga agccaaatat 2280 attcctcttg taaatgaaga aataaaccta tttaaatcaa aaaaaaaaaa aaaaaaaaaa 2340 as <210> 20 <211> 244 <212> PRT
<213> Homo Sapiens <400> 20 Met Lys Ala Leu Ile Arg Asn Arg Ser Tyr Val Phe Ser Ser Leu Ala Thr Ser Ala Val Ser Phe Ala Thr Gly Ala Leu Gly Met Trp Ile Pro Leu Tyr Leu His Arg Ala Gln Val Val Gln Lys Thr Ala Glu Thr Cys Asn Ser Pro Pro Cys Gly Ala Lys Asp Ser Leu Ile Phe Gly Ala Ile Thr Cys Phe Thr Gly Phe Leu Gly Val Val Thr Gly Ala Gly Ala Thr Arg Trp Cys Arg Leu Lys Thr Gln Arg Ala Asp Pro Leu Val Cys Ala Val Gly Met Leu Gly Ser Ala Ile Phe Ile Cys Leu Ile Phe Val Ala Ala Lys Ser Ser Ile Val Gly Ala Tyr Ile Cys Ile Phe Val Gly Glu Thr Leu Leu Phe Ser Asn Trp Ala Ile Thr Ala Asp Ile Leu Met Tyr Val Val Ile Pro Thr Arg Arg Ala Thr Ala Val Ala Leu G1n Ser Phe Thr Ser His Leu Leu Gly Asp Ala Gly Ser Pro Tyr Leu Ile Gly Phe Ile Ser Asp Leu Ile Arg Gln Ser Thr Lys Asp Ser Pro Leu Trp Glu Phe Leu Ser Leu Gly Tyr Ala Leu Met Leu Cys Pro Phe Val Val Val Leu Gly Gly Met Phe Phe Leu Ala Thr Val Leu Phe Phe Val Ser Asp Arg Ala Arg Ala Glu Gln Gln Val Asn Gln Leu Ala Met Pro Pro Ala Ser Val Lys Val <210> 21 <211> 3202 <212> DNA
<213> Homo sapiens <400> 21 gagagcgctc ctggctgtga gctgctcctg ccgcttcgct ccgcgctctc ctgccgctcc 60 gctccgggtc tcccgcgctc ctctccccgg ctcggccgag cgcgctgccc cgacgccgcc 120 acccagagcc gggccgcgcc gggcgccgag atgaaggtgc tgggacaccg gctggagctg 180 ctcacaggcc tcctgctcca cgacgtgacc atggccgggc tgcaggagct gcgattccct 240 gaggagaagc cgctgctccg gggccaggac gccaccgagc tggagagctc cgatgccttc 300 ctcttggctg cagacacaga ctggaaggaa catgacatcg agacacccta cggccttctg 360 catgtagtga tccggggctc ccccaagggg aaccgcccag ccatcctcac ctaccatgat 420 gtgggcctca accacaaact atgcttcaac accttcttca acttcgagga catgcaggag 480 atcaccaagc actttgtggt gtgtcacgtg gatgcccctg gacaacaggt gggggcgtcg 540 cagtttcctc aggggtacca gttcccctcc atggagcagc tggctgccat gctccccagc 600 gtggtgcagc atttcgggtt caagtatgtg attggcatcg gagtgggcgc cggagcctat 660 gtgctggcca agtttgcact catcttcccc gacctggtgg aggggctggt gctggtgaac 720 atcgacccca atggcaaagg ctggatagac tgggctgcca ccaagctctc cggcctaact 780 agcactttac ccgacacggt gctctcccac ctcttcagcc aggaggagct ggtgaacaac 840 acagagttgg tgcagagcta ccggcagcag attgggaacg tggtgaacca ggccaacctg 900 cagctcttct ggaacatgta caacagccgc agagacctgg acattaaccg gcctggaacg 960 gtgcccaatg ccaagacgct ccgctgcccc gtgatgctgg tggttgggga taatgcaccc 1020 gctgaggacg gggtggtgga gtgcaactcc aaactggacc cgaccactac gaccttcctg 1080 aagatggcag actctggagg gctgccccag gtcacacagc cagggaagct gactgaagcc 1140 ttcaaatact tcctgcaagg catgggctac atgccctcag ccagcatgac ccgcctggca 1200 cgctcccgca ctgcatccct caccagtgcc agctcggtgg atggcagccg cccacaggcc 1260 tgcacccact cagagagcag cgaggggctg ggccaggtca accacaccat ggaggtgtcc 1320 tgttgaagcc cttgatcccg ctgacgacgc ccacgtcgag gccccaccgc catccttgcg 1380 ccggctcatg ttccctttag tttatttttg tgagggcaaa ggggaggaaa tggggttctg 1440 tttgaaaaaa atgaggggat cttagatgct gcagcagaac agtctccagg tgttttaagg 1500 ggctcagtcc tcctcatccc atctcactct ccgtggtaac ttagccaact tgacccctct 1560 catcccactc ccggcggccc aggcacagaa gggcagggcc atagggaggg agattcgcta 1620 cggatccagg ccattcctgg gtgagccctt gggcaggcat gtttggagat gagagaggct 1680 tcgagagggt gggtgctggg ccacaggggt gcggggccag ctcaggcact ggcgtgggag 1740 ccctgggaga ccccttcccc caccctccac caagcacacc tgtttctgtc tcatagcaca 1800 tgtgacaatc atctggacaa cagccacaag ggggcgctcg gaccaggcag ccactttcct 1860 ggtgctctct gggcccagct ggtgctgtag ggccacgcag gcaggggcgt caaggggttt 1920 ctctgcccaa ggaagacaga acatggagaa ccgtcagggc aggaacccca cagactgtcc 1980 cttccagccc acactctgcc acctcctggc cctgtcccaa ttctgagcca aggcctcccc 2040 gaggcagaag ttgcctggtc ctctgtcccc acagtgacct gactgggggt gagggagaag 2100 gaggagagag cccatgtgtg gtgtgtgtgc ccctgagaac ttcgtggtga ctgcctttgg 2160 gagcccgcag gtggccagag gcaggggtag ctgagttcct ggagacccct tttttgcccc 2220 caggttcccc agagggcaac gccatcagta gcagtgtggt gtttcaggca gagctctggc 2280 caggctgtgc cagtgtgtcc cggacgcatc actaaggaag agagagttta tttagtcaac 2340 tggcccaagg cagcgaggct tctacagtcc cacaccccat agccgcctgg gctggggctt 2400 actgggggct gaaggttctg gacatgaaca agggtcaggt agaagagaaa ggcttcccct 2460 acaccccagc ctcctgctgt cccctgaagc ccaggactgc gttgtatgct ttccatccac 2520 tcaccttacc ccatagcatc ttgcggccca gaaaccagag ccatttgtct cagaccctaa 2580 atcaataatc acaaacccca aaacgggaga gagcagtgaa aacatgcagg gctgtggacg 2640 ggggaagggt tgtggcgggt gttctgaggc tgagaggaca cctatatgcg tatttcctct 2700 acacacatca ccccccttct ataatcttaa gccatgacta gcctggtggc gtgttagttt 2760 ctgcccagtt ctaccccctc atgtgcttct tctgaatact gaatgtgact gtttgaaagc 2820 tggtagaatt catccctctt actgtagata acactgcaaa tcttggaatt ttgttttttg 2880 ctgtttccag atgtatctat aaatatctat acattatatg tgtgtgtgtg tgtgtgtgtg 2940 tgtgtgtgtg tacatcgggt cctcccatgt gtggtgttct tctggaggtt gtctctttgg 3000 tcaaggtgaa cttttaatgt ttattatttt cttctccgca caaagtaaag agcctaattt 3060 tgtgtattct ggtggctgct gtcatgagat gataaaatgt aaaacaaaac tctagtcaac 3120 gtagaaagag ttaactgtgc tgaaaaacta ataaagaacc taagaagaaa aaaaaaaaaa 3180 aaaaaaaaaa aaaaaaaaaa as 3202 <210> 22 <211> 391 <212> PRT
<213> Homo sapiens <400> 22 Met Lys Val Leu Gly His Arg Leu Glu Leu Leu Thr Gly Leu Leu Leu His Asp Val Thr Met Ala Gly Leu Gln Glu Leu Arg Phe Pro Glu Glu Lys Pro Leu Leu Arg Gly Gln Asp Ala Thr Glu Leu Glu Ser Ser Asp Ala Phe Leu Leu Ala Ala Asp Thr Asp Trp Lys Glu His Asp Ile Glu Thr Pro Tyr Gly Leu Leu His Val Val Ile Arg Gly Ser Pro Lys Gly Asn Arg Pro Ala Ile Leu Thr Tyr His Asp Val Gly Leu Asn His Lys Leu Cys Phe Asn Thr Phe Phe Asn Phe Glu Asp Met Gln Glu Ile Thr Lys His Phe Val Val Cys His Val Asp Ala Pro Gly Gln Gln Val Gly Ala Ser Gln Phe Pro Gln Gly Tyr Gln Phe Pro Ser Met Glu Gln Leu Ala Ala Met Leu Pro Ser Val Val Gln His Phe Gly Phe Lys Tyr Val Ile Gly Ile Gly Val Gly Ala Gly Ala Tyr Val Leu Ala Lys Phe Ala Leu Ile Phe Pro Asp Leu Val Glu Gly Leu Val Leu Val Asn Ile Asp Pro Asn Gly Lys Gly Trp Ile Asp Trp Ala Ala Thr Lys Leu Ser Gly Leu Thr Ser Thr Leu Pro Asp Thr Val Leu Ser His Leu Phe Ser Gln Glu Glu Leu Val Asn Asn Thr Glu Leu Val Gln Ser Tyr Arg Gln Gln Ile Gly Asn Val Val Asn Gln Ala Asn Leu Gln Leu Phe Trp Asn Met Tyr Asn Ser Arg Arg Asp Leu Asp Ile Asn Arg Pro Gly Thr Val Pro Asn Ala Lys Thr Leu Arg Cys Pro Val Met Leu Val Val Gly Asp Asn Ala Pro Ala Glu Asp Gly Val Val Glu Cys Asn Ser Lys Leu Asp Pro Thr Thr Thr Thr Phe Leu Lys Met Ala Asp Ser Gly Gly Leu Pro Gln Val Thr Gln Pro Gly Lys Leu Thr Glu Ala Phe Lys Tyr Phe Leu Gln Gly Met Gly Tyr Met Pro Ser Ala Ser Met Thr Arg Leu Ala Arg Ser Arg Thr Ala Ser Leu Thr Ser Ala Ser Ser Val Asp Gly Ser Arg Pro Gln Ala Cys Thr His Ser Glu Ser Ser Glu Gly Leu Gly Gln Val Asn His Thr Met Glu Val Ser Cys <210> 23 <211> 1007 <212> DNA
<213> Homo sapiens <400> 23 ggccttttct ctgctctcct gaacctttag gcttgtctcg gcccatttga agaccaggaa 60 gttgatcaat cccgaggctg ctgagagacg gtggcgcgat tgggacagtc gccagggatg 120 gctgagcgtg aagatgcagc gggtgtccgg gctgctctcc tggacgctga gcagagtcct 180 gtggctctcc ggcctctctg agccgggagc tgcccggcag ccccggatca tggaagagaa 240 agcgctagag gtttatgatt tgattagaac tatccgggac ccagaaaagc ccaatacttt 300 agaagaactg gaagtggtct cggaaagttg tgtggaagtt caggagataa atgaagaaga 360 atatctggtt attatcaggt tcacgccaac agtacctcat tgctctttgg cgactcttat 420 tgggctgtgc ttaagagtaa aacttcagcg atgtttacca tttaaacata agttggaaat 480 ctacatttct gaaggaaccc actcaacaga agaagacatc aataagcaga taaatgacaa 540 agagcgagtg gcagctgcaa tggaaaaccc caacttacgg gaaattgtgg aacagtgtgt 600 ccttgaacct gactgatagc tgttttaaga gccactggcc tgtaattgtt tgatatattt 660 gtttaaactc tttgtataat gtcagagact catgtttaat acataggtga tttgtacctc 720 agagcatttt ttaaaggatt ctttccaagc gagatttaat tataaggtag tacctaattt 780 gttcaatgta taacattctc aggatttgta acacttaaat gatcagacag aataatattt 840 tctagttatt atgtgtaaga tgagttgcta tttttctgat gctcattctg atacaactat 900 ttttcgtgtc aaatatctac tgtgcccaaa tgtactcaat ttaaatcatt actctgtaaa 960 ataaataagc agatgattct taaaaaaaaa aaaaaaaaaa aaaaaaa 1007 <210> 24 <211> 160 <212> PRT
<213> Homo sapiens <400> 24 Met Gln Arg Val Ser Gly Leu Leu Ser Trp Thr Leu Ser Arg Val Leu Trp Leu Ser Gly Leu Ser Glu Pro Gly Ala Ala Arg Gln Pro Arg Ile Met Glu Glu Lys Ala Leu Glu Val Tyr Asp Leu Ile Arg Thr Ile Arg Asp Pro Glu Lys Pro Asn Thr Leu Glu Glu Leu Glu Val Val Ser Glu Ser Cys Val Glu Val Gln Glu Ile Asn Glu Glu Glu Tyr Leu Val Ile Ile Arg Phe Thr Pro Thr Val Pro His Cys Ser Leu Ala Thr Leu Ile Gly Leu Cys Leu Arg Val Lys Leu Gln Arg Cys Leu Pro Phe Lys His Lys Leu Glu Ile Tyr Ile Ser Glu Gly Thr His Ser Thr Glu Glu Asp Ile Asn Lys Gln Ile Asn Asp Lys Glu Arg Val Ala Ala Ala Met Glu Asn Pro Asn Leu Arg Glu Ile Val Glu Gln Cys Val Leu Glu Pro Asp <210> 25 <211> 2026 <212> DNA
<213> Homo sapiens <400> 25 ggacagtgac acagtgacca ctataaaagt caggcgggct gaggaggaga caaaggccag 60 gacgctccgc agctgttggg gaagaggagc tgcctcctgg gatggagaaa tttaaggctg 120 cgatgttgct ggggagcgtc ggcgatgctc ttggctacag aaatgtctgc aaggagaaca 180 gcactgtagg catgaagatc caggaggagc tgcaacgttc cgggggcctg gaccacctcg 240 tactctcgcc aggagaatgg cccgtgagtg acaacaccat catgcacatc gcaaccgccg 300 aggccctcac cacagactac tggtgcctgg atgatctgta ccgggagatg gtgagatgct 360 atgtggaaat cgttgagaag cttccagaac gccggccaga cccagctacc attgaaggct 420 gtgctcagct aaagcccaat aactaccttc tcgcctggca cacaccgttc aatgaaaaag 480 gctcagggtt tggagcggcc accaaggcca tgtgcatcgg cctgcggtac tggaagcctg 540 agcggctgga gaccctcatc gaggtcagcg tggagtgcgg ccggatgacc cacaaccatc 600 ccacaggctt cctgggctcc ctgtgcacgg ccctgtttgt gtcgttcgcc gcacaaggaa 660 agcccctggt ccagtggggg agagacatgc tgcgggcggt gcctctggca gaagagtact 720 gcaggaagac catccggcac acggcagaat accaggagca ctggttttac tttgaagcta 780 aatggcaatt ttatttggag gagaggaaaa tcagtaaaga ctcagaaaat aaagccatct 840 tccccgacaa ttatgatgca gaagagaggg aaaagaccta caggaagtgg agctcggaag 900 gtcgaggggg aagacgaggc cacgatgccc ccatgatagc ctatgacgcc ctccttgcag 960 caggaaacag ctggactgag ctgtgtcacc gggccatgtt tcatggaggg gagagcgcgg 1020 ccacgggcac cattgcaggc tgcctgttcg ggttgctgta cggcctggac ctcgttccca 1080 aaggcttgta ccaggacctg gaggacaagg agaagctgga ggacctgggc gcggctctct 1140 accgcctgtc cacagaggag aagtaaagcc atttctgcca ctttccccct agagagccga 1200 ttccaccccg gggcccgtag ggccctctcg cagcccctgg gtgagggtgt ctctgtgagg 1260 ctccactgcg gtctgtgcct gactggccac atctaactct ctgtttccaa tttcagaatc 1320 ctaactgttg cataaaatac attgtttgtc ctgcgagaat attttccgtc ctccaccatc 1380 aacattgaca ctgcgtagat ttgccgcact tggacctcca tgcgtggcac tcacccgcag 1440 tctcctggac aggcgctgta ttttattctg tcgcagagct aatgctgttt actcactcac 1500 ttcaacaaca ctaactgcgg tggtggcctc cagcaggccc ccccgctgca gaccctctgt 1560 cctgcctctg cctccaggca tgcgtttccc cgtgagggcc aatgcacctc cccccacccc 1620 ccaccctccc atgtccacag tgggtcgtgt gttcctggac agagaaacag tccacactgg 1680 ggcctgcggg acacatatag cagcatattt tgctcttaac cccacccacc tttttaatca 1740 cactagattt taagatcaat ccctttttga aacaactcac ggagaaaacc agaacataaa 1800 tggcctcctg ccagctccgg cgtctctctg tggtctgcct tagtgggcca agtccaaatg 1860 cagagaaggc ctttcccttc cgcgcctgcc ccatcgggct cgctgacgag gaagcgctgt 1920 ccctgtgatg aggttctctc tcagagagtc ttggaaaaga gaccacttgc tcttgtttaa 1980 aataaatttg gacgtgattt taaaaaaaaa aaaaaaaaaa aaaaaa 2026 <210> 26 <211> 354 <212> PRT
<213> Homo sapiens <400> 26 Met Glu Lys Phe Lys Ala Ala Met Leu Leu Gly Ser Val Gly Asp Ala Leu Gly Tyr Arg Asn Val Cys Lys Glu Asn Ser Thr Val Gly Met Lys Ile Gln Glu Glu Leu Gln Arg Ser Gly Gly Leu Asp His Leu Val Leu Ser Pro Gly Glu Trp Pro Val Ser Asp Asn Thr Ile Met His Ile Ala Thr Ala Glu Ala Leu Thr Thr Asp Tyr Trp Cys Leu Asp Asp Leu Tyr Arg Glu Met Val Arg Cys Tyr Val Glu Ile Val Glu Lys Leu Pro Glu Arg Arg Pro Asp Pro Ala Thr Ile Glu Gly Cys Ala Gln Leu Lys Pro Asn Asn Tyr Leu Leu Ala Trp His Thr Pro Phe Asn Glu Lys Gly Ser Gly Phe Gly Ala Ala Thr Lys Ala Met Cys Ile Gly Leu Arg Tyr Trp Lys Pro Glu Arg Leu Glu Thr Leu Ile Glu Val Ser Val Glu Cys Gly Arg Met Thr His Asn His Pro Thr Gly Phe Leu Gly Ser Leu Cys Thr Ala Leu Phe Val Ser Phe Ala Ala Gln Gly Lys Pro Leu Val Gln Trp Gly Arg Asp Met Leu Arg Ala Val Pro Leu Ala Glu Glu Tyr Cys Arg Lys Thr Ile Arg His Thr Ala Glu Tyr Gln Glu His Trp Phe Tyr Phe Glu Ala Lys Trp Gln Phe Tyr Leu Glu Glu Arg Lys Ile Ser Lys Asp Ser Glu Asn Lys Ala Ile Phe Pro Asp Asn Tyr Asp Ala Glu Glu Arg Glu Lys Thr Tyr Arg Lys Trp Ser Ser Glu Gly Arg Gly Gly Arg Arg Gly His Asp Ala Pro Met Ile Ala Tyr Asp Ala Leu Leu Ala Ala Gly Asn Ser Trp Thr Glu Leu Cys His Arg Ala Met Phe His Gly Gly Glu Ser Ala Ala Thr Gly Thr Ile Ala Gly Cys Leu Phe Gly Leu Leu Tyr Gly Leu Asp Leu Val Pro Lys Gly Leu Tyr Gln Asp Leu Glu Asp Lys Glu Lys Leu Glu Asp Leu Gly Ala Ala Leu Tyr Arg Leu Ser Thr Glu Glu Lys <210> 27 <211> 2512 <212> DNA
<213> Homo Sapiens <400> 27 tgcactgtgt ggttggcacc taacccatct gaatgtaact ccttaaagtg cttgcaaata 60 aaaccgatgc tttgccttct ctgccacatc gcaaaaagag gtacttttgt taattggata 120 atttatctct tattattttt tcctcatact cagcttggaa atcagaactt acctgccagt 180 gtgttggagg taaatgcttc acagacacac agacaaacca caccagaagc ttctcctccg 240 tgccctcctt ccgtggtacc tttgaaccga gccactttct caccaggcag tggcaccagc 300 tcagcatcac tcagccttcc gccccccgat ggtgtggggt cttcacgcct gcataatccc 360 cagagccttt cccattgctt atacaaacac ctgctcccag ctccagaaag cctcatccac 420 agccacgaca caggctctct gacaacagac tcctccctgg ccgagcactc ctcccgctcg 480 gagagtgagt cctccacagc catgctggag gagctgcaga ttggtgactc tgacaccact 540 ggccgttctg agacaccctc ccccacctgg ggtcagaggt ctgctgtgac agatggcacc 600 accttaacca cccctgcggc cactcatgta attattctgc ctttctttgc ctccaccgtt 660 tccttaaaag gactgatttg ttgtgccatc tcatttttcg gctgacattt ttatttacat 720 aggtgttgat tcccaaacca attctatgcc atctgtcagg gaaatcatta gtcatcctat 780 aagcttgctt aaggctgaaa aagtcacttc attctcttca ttcattttag aattacttat 840 agttactcta aaatagttac ttacggtttc ccgtgttact gtagctggta agttctacag 900 tgatttgcct tattagctaa gtatacatca caatatgttg tgatcataaa gtctaaaatt 960 tttcaaaaaa ttttaaccca gtattaatac atgttagcag tttttctcac agactcacat 1020 taatgtgtcc tgtgtgactc ttttctatat cctttttctc acataaatga ttactgactg 1080 catgaggcta atttttcttg ttcctccttc tctaacagct acaacttttg aactcatcta 1140 ttgtccagga gtgaatgatg tcgataatcc tatctacctt tcagaaattt agctgttcga 1200 tttttaaaaa ttattcttcc tgagccattt caggacagaa atttatgaat acatttttta 1260 ttttgtttat caataatttg tctttcattt atagcaatat atacatcttt tccatacata 1320 tattatttaa atatatctat gtgataagca atccctaata aatgatctgt gaatggctaa 1380 aatgtttcaa aattttatgg cacagattct atattgcata taatgtctaa gtaatggctt 1440 ccatttaaga gacacatagc ttcaggcaaa aaaatcagat ttttttttta aattgatatt 1500 ataatgaagt tccgaataag cactgtcata gacaaaattt tatttgtgct acattgtttt 1560 atgttctatc aagctgataa gtctgcaaat tttatgcgca gagaaatgtt ataataagcc 1620 atatgttttt taagacacta caatttacat aaagtaaaag atgctttttt tggtaatggg 1680 atttggtatt cccccaatgg ctgtgtctaa cactttgcat tcaaatgctc cattcagaga 1740 ctggctacag aaggagcctc attttccagg cctaacccca tagcgagtcc ctccctgcca 1800 cagaggacca gcccaactac gggcaccagg agcacagcag gtgtgggttc ctcccatgcc 1860 ctactgtgct tcaatggttc ttagctttta aaactttacc aggaccttta accaaaaaaa 1920 gaaggcagtg agagggtatc aatctaccaa ctaacctgtt caattttctg tttttaagac 1980 tttacaggag actaactgtc ttatatacag tcttgtgggc acgagcagag ctacttgtaa 2040 gggaaattaa ttgcaattat cagtttaaaa ttgcaaatag attattcatg acatgttttt 2100 cctaataatg aattcactat aacaatacag tattttctaa aatgctaatg atagtatttt 2160 agtcataaaa tcctgattgg ttgaacacaa taaaagaata aatctaggcc gggcgcggtg 2220 gctcacgcct gtaatcccag cactttggga ggccgaggtg ggtggatcac gaggtcagga 2280 gatcgagacc atcctggcta acatggtgaa accccgtctc tactaaaaat acaaaaaatt 2340 agccgggcgt ggtggtgggc gcctgtagtc ccaactactc gggaggctga ggcaggagaa 2400 tgacatgaac ccgggaggcg gagcttgcag tgagccgaga ctgcgccact gcactccagc 2460 ctgggcgaca gagcgagact ccatctcaaa aaaaaaaaaa aaaaaaaaaa as 2512 <210> 28 <211> 212 <212> PRT
<213> Homo Sapiens <400> 28 Met Leu Cys Leu Leu Cys His Ile Ala Lys Arg Gly Thr Phe Val Asn Trp Ile Ile Tyr Leu Leu Leu Phe Phe Pro His Thr Gln Leu Gly Asn Gln Asn Leu Pro Ala Ser Val Leu Glu Val Asn Ala Ser Gln Thr His Arg Gln Thr Thr Pro Glu Ala Ser Pro Pro Cys Pro Pro Ser Val Val Pro Leu Asn Arg Ala Thr Phe Ser Pro Gly S-er Gly Thr Ser Ser Ala Ser Leu Ser Leu Pro Pro Pro Asp Gly Val Gly Ser Ser Arg Leu His Asn Pro Gln Ser Leu Ser His Cys Leu Tyr Lys His Leu Leu Pro Ala Pro Glu Ser Leu Ile His Ser His Asp Thr Gly Ser Leu Thr Thr Asp Ser Ser Leu Ala Glu His Ser Ser Arg Ser Glu Ser Glu Ser Ser Thr Ala Met Leu Glu Glu Leu Gln Ile Gly Asp Ser Asp Thr Thr Gly Arg Ser Glu Thr Pro Ser Pro Thr Trp Gly Gln Arg Ser Ala Val Thr Asp Gly Thr Thr Leu Thr Thr Pro Ala Ala Thr His Val Ile Ile Leu Pro Phe Phe Ala Ser Thr Val Ser Leu Lys Gly Leu Ile Cys Cys Ala Ile Ser Phe Phe Gly <210> 29 <211> 1495 <212> DNA
<213> Homo Sapiens <400> 29 tcagaggcag ggcttgcgac ggaagtggcc tctctgcttc tgcagggctg gggaagatgc 60 tgcgtccagc gttaccgtgg ctgtgccttg gcctctgcag cctcctggtg ggggaggcag 120 aggccccgag ccccgtggat ccgctggagc ggagccggcc gtacgcggtg ctgcgagggc 180 agaacctggt gttgatggga accattttca gcatcctgct ggtgactgtc atccttatgg 240 cattttgtgt ctacaagccc attcggcgtc ggtgacagcc agacaagttc ttcaatgagt 300 atttgggaat aggataagtt gtgttgcaca caggccagtg gagaagttgg aaccaaaact 360 ttcctacttg gaaatgacct ttggtctgga cagttggtaa atgctaaatg aattagaaga 420 aaacatgtac tagacattat tttttcctaa cactgtagcg caaataattg gcccctgagt 480 ccgcttctca gtgtttctga ctgtacttgt taaaagtaag acctgaaagc tccaaaggtc 540 agtgtaaaga tggagtgttc atgagaaaga aaacatggta accttgtgag tgcctgtaag 600 aaccacactg taaagaactc atcattaatg cttgaaaatg ttattaagaa ggagacttac 660 catgcagaca ttccctattt aagaaccatt tggttacagt gggttaagaa tcacagattt 720 ttttttttaa tctcacctga gttagcctag aatgcgctgg ttgcaaagtg gtgtcagctg 780 tggggatctt gggccctcgt tcctcacctg catcctgccc tgcactcagg tgctccccct 840 gaagtcaggg tcacatcagg tagacctgtt actatatgca cctttggcct ggaatgctct 900 gaagttggac tggaaatgtt actaggttgg cctgttacaa aaaggacccc atcctgctta 960 aacacattga tctcccttgc cctgcatttg agtctttcta gcccacggtc tgaaacttga 1020 ggcagctttc cagatttgga atgtaaaagg ctcagtgggc actctgttca tccctgggtg 1080 gggagggccc agccaacaga agtgcatgtc cactgtgcgg gccagtgtgt gtttacacaa 1140 atttcatctc agctttgaaa atgctgctat tagtttccac tgttggtgaa ctggattttt 1200 tcctcctatt gaaatgatac tttcatactt ataaagctgt cgtcaatatt tatttcaagg 1260 tgctagattt aattttgtta ttaaattgaa atgcttatct tgtgttcaag cacagcactg 1320 attttaacaa cctgcattta atgtgaagta accgaagtag gatactgtaa ctgtgtaagg 1380 attttgtttg taatcttgta acattgaacc attgaaatgt tcagttcttt gcttttgagc 1440 aaaacgtcaa ttaaaactaa agtaaaatcc taaaaaaaaa aaaaaaaaaa aaaaa 1495 <210> 30 <211> 72 <212> PRT
<213> Homo sapiens <400> 30 Met Leu Arg Pro Ala Leu Pro Trp Leu Cys Leu Gly Leu Cys Ser Leu Leu Val Gly Glu Ala Glu Ala Pro Ser Pro Val Asp Pro Leu Glu Arg Ser Arg Pro Tyr Ala Val Leu Arg Gly Gln Asn Leu Val Leu Met Gly Thr Ile Phe Ser Ile Leu Leu Val Thr Val Ile Leu Met Ala Phe Cys Val Tyr Lys Pro Ile Arg Arg Arg <210> 31 <211> 2714 <212> DNA
<213> Homo Sapiens <400> 31 tatccgccag ttgcaggagc aacactatca gcagtacatg cagcagttgt atcaagtcca 60 gcttgcacag caacaggcag cattacagaa acaacaggaa gtagtagtgg ctgggttttc 120 cttgcctaca tcatcaaaag tgaatgcaac tgtaccaagt aatatgatgt cagttaatgg 180 acaggccaaa acacacactg acagctccga aaaagaactg gaaccagaag ctgcagaaga 240 agccctggag aatggaccaa aagaatctct tccagtaata gcagctccat ccatgtggac 300 acgacctcag atcaaagact tcaaagagaa gattcagcag gatgcagatt ccgtgattac 360 agtgggccga ggagaagtgg tcactgttcg agtacccacc catgaagaag gatcatatct 420 cttttgggaa tttgccacag acaattatga cattgggttt ggggtgtatt ttgaatggac 480 agactctcca aacactgctg tcagcgtgca tgtcagtgag tccagcgatg acgacgagga 540 ggaagaagaa aacatcggtt gtgaagagaa agccaaaaag aatgccaaca agcctttgct 600 ggatgagatt gtgcctgtgt accgacggga ctgtcatgag gaggtgtatg ctggcagcca 660 tcaatatcca gggagaggag tctatctcct caagtttgac aactcctact ctttgtggcg 720 gtcaaaatca gtctactaca gagtctatta tactagataa aaatgttgtt acaaagtctg 780 gagtctaggg ttgggcagaa gatgacattt aatttggaaa tttcttttta cttttgtgga 840 gcattagagt cacagtttac cttattgata ttggtctgat ggtttgtgaa ctcttgctgg 900 gaatcaaaat ttccttgaga ctctttagca ttcatacttt ggggttaaag gagattcctc 960 agactcatcc agcccttggg tgctgaccag cagagtcact agtggatgct gaagttacat 1020 gagctacatg ttaaatattt aaagtctcca aaataaaaca ccccaacgtt gaccttaccc 1080 ggctgatggt tagccccttg ctgcctgctc catgtgtctt atgagagccc gtagttacag 1140 tgtcctctaa tttgaaatcc ataagttaac aagtctatat caggtgcagc tggctttgat 1200 taaaggccat ttttaaaact taaaaactca acacctcaca gattataata gaaaaagaaa 1260 tggcctcagt ttgatctcgt tcagaatgac ccagattgtt tctgctttgg gtgcagctgt 1320 ttagttcaga gttatattac agagaattat tttctgagat aatcttaaac tagaatgttc 1380 aaaactaatt gataattgaa gtatcaagat acgtagaaca cctcagagat ttttcttcag 1440 gaacttccac aaactttgaa tccttgtatc tttatttggt attcatacta ctagtagcaa 1500 aatacaggtt ttttgttttg ttttgttttg ttttggcttc atagagtatc tcaaattgaa 1560 acttttctgc acaaagaata aaattaagga ttttataaac tcaaattggc acctactgaa 1620 ttaaaataca taaaatcatt taaatataat tcagcatatg ggaagtaaca ttgcactaat 1680 atggaaatca ctgccagaga cagtctattt tcttttaatt tgttactact tagtcacaaa 1740 ccccacatta ttccagtttg gaattactta ttaaggagaa ttggaaatac atatgcccat 1800 gcttaaattt tatagcttta atttgtgtta tttctttatt gacgggaaga ggtacatctt 1860 tttttcctta ctgaaaacaa atatggatta attgcctcaa atttgtataa gtgattggct 1920 agtgattctt gttttcagaa gggagagtgg tatagataga aaatgacaaa gatggcaata 1980 tacacttaat gttgttattg tatgttgtta ctgaagtact tagattttta aaatttcaaa 2040 tcctaaatca cttcttgtag gagggttttc attaactgca gtatatacag ttcactacat 2100 atgggttgtt tgagtttttt gtgtgctgta tttctttctg ttttttaata cctggttttg 2160 tacatatcta actctgttct cttttggttg ttcagaaact ggattttttt ttttcttaag 2220 cagtgcttaa tttgtgtttt ttaattttga ttcagaagta gtcccagctc ataggtgttc 2280 atactgttac atccagaaca tttgtcaggc tctctgtcag ctttcatgta catatggtat 2340 agaaaccatg gagttaggca cttcctggat ttttttttta tgagaaaaat actgtattta 2400 aaatgtaaaa taaactttta aaaagcaggc actaatatat atttcttcca gcctttgatc 2460 acaaatttgt ccttgcacat gttaagatga attatctcct aaaaatatca ttgttcttgg 2520 gagcagtgta tgttacttta catagcagcg gttcctgtca tgtgttcatg tcagaatatt 2580 tttggtttta aactttctta ttgcctttgg ctgttgatta gtacagtaca agtgcgattt 2640 caaaaagatc ttgaaagtaa tatatttaat caattaaaat gtttatctgt aaaaaaaaaa 2700 aaaaaaaaaa aaaa 2714 <210> 32 <211> 240 <212> PRT
<213> Homo Sapiens <400> 32 Met Gln Gln Leu Tyr Gln Val Gln Leu Ala Gln Gln Gln Ala Ala Leu Gln Lys Gln Gln Glu Val Val Val Ala Gly Phe Ser Leu Pro Thr Ser Ser Lys Val Asn Ala Thr Val Pro Ser Asn Met Met Ser Val Asn Gly Gln Ala Lys Thr His Thr Asp Ser Ser Glu Lys Glu Leu Glu Pro Glu Ala Ala Glu Glu Ala Leu Glu Asn Gly Pro Lys Glu Ser Leu Pro Val Ile Ala Ala Pro Ser Met Trp Thr Arg Pro Gln Ile Lys Asp Phe Lys .Glu Lys Ile Gln Gln Asp Ala Asp Ser Val Ile Thr Val Gly Arg Gly Glu Val Val Thr Val Arg Val Pro Thr His Glu Glu Gly Ser Tyr Leu Phe Trp Glu Phe Ala Thr Asp Asn Tyr Asp Ile Gly Phe Gly Val Tyr Phe Glu Trp Thr Asp Ser Pro Asn Thr Ala Val Ser Val His Val Ser Glu Ser Ser Asp Asp Asp Glu Glu Glu Glu Glu Asn Ile Gly Cys Glu Glu Lys Ala Lys Lys Asn Ala Asn Lys Pro Leu Leu Asp Glu Ile Val Pro Val Tyr Arg Arg Asp Cys His Glu Glu Val Tyr Ala Gly Ser His Gln Tyr Pro Gly Arg Gly Val Tyr Leu Leu Lys Phe Asp Asn Ser Tyr Ser Leu Trp Arg Ser Lys Ser Val Tyr Tyr Arg Val Tyr Tyr Thr Arg <210> 33 <211> 1136 <212> DNA
<213> Homo Sapiens <400> 33 tagttctctt ccatttataa gactcactcc tccatcccaa cccctgcacc acaggacaag 60 gaagtgttct tggtcttcaa ctttcatccc tgatggtgaa agcagttgct cctgacctat 120 ttgcccacca gcttctcctc tggagcctga ggcttctgat gcctgcctgg ctggttctca 180 gtaagaaggt caagttcaac cagaggggag atgctgatgc ctttcagtac ttaaatatga 240 gttcagaccc tggggcctgg acataagatt tggggtcccc tggatataag atttctgaaa 300 acactcagac tgtggagacc cctgctgagg gagaagctcc aaactgtggc ttcaggggaa 360 tgcaccaagg ctctcattga ggccaccttc tccaacaagc tcccctcctg cttccccatg 420 gctggcatgg ctgaggaaaa aggacactga gcacagcccg tgcatgagcg gcttgccatg 480 caacaggata aaacccataa tgccactcag caagccttgg ttgtaaatct agtttgatta 540 catttgtaat caaatgatgg ccatttgttc tgtttctggt ttgtgaacca actgaagaca 600 taagcagggc ctcagctaac ccacaaatag cacatgtgtg caaactggaa aaatgaaccc 660 ttcttctggg aggacgccag cccaggccag gtcacccggc ttggccagca gaacacagag 720 tggattttgg tcccgtttgt tccccagtgg ggtatctatc cttgtgcagg gcacaagcct 780 acatggtggc tctggtcata tcattagaaa atagacagaa atgggctgca caccagaatg 840 aatgaattga attgaaaggg aggagtgatg gtggaaaaaa aaacaagtca attcatttag 900 actggtagaa ccagaaccac tgtgtagtac atccaaacgg ttaaaattcc ctggaagatg 960 ttacataatc ctatcatggt gtttatttat ggaaatctat tttaaaaatt ttatgtaata 1020 ctgcacagtc tgtttgcatg atgccttgta cgtagtagca actcagtaaa tactttttga 1080 atgaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1136 <210> 34 <211> 57 <212> PRT
<213> Homo Sapiens <400> 34 Met Val Lys Ala Val Ala Pro Asp Leu Phe Ala His Gln Leu Leu Leu Trp Ser Leu Arg Leu Leu Met Pro Ala Trp Leu Val Leu Ser Lys Lys Val Lys Phe Asn Gln Arg Gly Asp Ala Asp Ala Phe Gln Tyr Leu Asn Met Ser Ser Asp Pro Gly Ala Trp Thr <210> 35 <211> 1394 <212> DNA
<213> Homo Sapiens <400> 35 gagggtgctg agcgtgtgac cagcagtgag cagaggccgg ccatggccag cctggggctg 60 ctgctcctgc tcttactgac agcactgcca ccgctgtggt cctcctcact gcctgggctg 120 gacactgctg aaagtaaagc caccattgca gacctgatcc tgtctgcgct ggagagagcc 180 accgtcttcc tagaacagag gctgcctgaa atcaacctgg atggcatggt gggggtccga 240 gtgctggaag agcagctaaa aagtgtccgg gagaagtggg cccaggagcc cctgctgcag 300 ccgctgagcc tgcgcgtggg gatgctgggg gagaagctgg aggctgccat ccagagatcc 360 ctccactacc tcaagctgag tgatcccaag tacataagag agttccagct gaccctccag 420 cccgggtttt ggaagctccc acatgcctgg atccacactg atgcctcctt ggtgtacccc 480 acgttcgggc ctcaggactc attctcagag gagagaagtg acgtgtgcct ggtgcagctg 540 ctgggaaccg ggacggacag cagcgagccc tgcggcctct cagacctctg caggagcctc 600 atgaccaagc ccggctgctc aggctactgc ctgtcccacc aactgctctt cttcctctgg 660 gccagaatga gggggtgcac acagggacca ctccaacaga gccaggacta tatcaacctc 720 ttctgcgcca acatgatgga cttgaaccgc agagctgagg ccatcggata cgcctaccct 780 acccgggaca tcttcatgga aaacatcatg ttctgtggaa tgggcggctt ctccgacttc 840 tacaagctcc ggtggctgga ggccattctc agctggcaga aacagcagga aggatgcttc 900 ggggagcctg atgctgaaga tgaagaatta tctaaagcta ttcaatatca gcagcatttt 960 tcgaggagag tgaagaggcg agaaaaacaa tttccagatg gctgctcctc ccacaacaca 1020 gccacagcag tggcagccct gggtggcttc ctatacatcc tggcagaata ccccccagca 1080 aacagagagc cacacccatc cacaccgcca ccaccaagca gccgctgaga cggacggttc 1140 catgccagct gcctggagga ggaacagacc cctttagtcc tcatccctta gatcctggag 1200 ggcacggatc acatcctggg aagaaggcat ctggaggata agcaaagcca ccccgacacc 1260 caatcttgga agccctgagt aggcagggcc agggtaggtg ggggccggga gggacccagg 1320 tgtgaacgga tgaataaagt tcaactgcaa ctgaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380 aaaaaaaaaa aaaa 1394 <210> 36 <211> 361 <212> PRT
<213> Homo Sapiens <400> 36 Met Ala Ser Leu Gly Leu Leu Leu Leu Leu Leu Leu Thr Ala Leu Pro Pro Leu Trp Ser Ser Ser Leu Pro Gly Leu Asp Thr Ala Glu Ser Lys Ala Thr Ile Ala Asp Leu Ile Leu Ser Ala Leu Glu Arg Ala Thr Val Phe Leu Glu Gln Arg Leu Pro Glu Ile Asn Leu Asp Gly Met Val Gly Val Arg Val Leu Glu Glu Gln Leu Lys Ser Val Arg Glu Lys Trp Ala Gln Glu Pro Leu Leu Gln Pro Leu Ser Leu Arg Val Gly Met Leu Gly Glu Lys Leu Glu Ala Ala Ile Gln Arg Ser Leu His Tyr Leu Lys Leu Ser Asp Pro Lys Tyr Ile Arg Glu Phe Gln Leu Thr Leu Gln Pro Gly Phe Trp Lys Leu Pro His Ala Trp Ile His Thr Asp Ala Ser Leu Val Tyr Pro Thr Phe Gly Pro Gln Asp Ser Phe Ser Glu Glu Arg Ser Asp Val Cys Leu Val Gln Leu Leu Gly Thr Gly Thr Asp Ser Ser Glu Pro Cys Gly Leu Ser Asp Leu Cys Arg Ser Leu Met Thr Lys Pro Gly Cys Ser Gly Tyr Cys Leu Ser His Gln Leu Leu Phe Phe Leu Trp Ala Arg Met Arg Gly Cys Thr Gln Gly Pro Leu Gln Gln Ser Gln Asp Tyr Ile Asn Leu Phe Cys Ala Asn Met Met Asp Leu Asn Arg Arg Ala Glu Ala Ile Gly Tyr Ala Tyr Pro Thr Arg Asp Ile Phe Met Glu Asn Ile Met Phe Cys Gly Met Gly Gly Phe Ser Asp Phe Tyr Lys Leu Arg Trp Leu Glu Ala Ile Leu Ser Trp Gln Lys Gln Gln Glu Gly Cys Phe Gly Glu Pro Asp Ala Glu Asp Glu Glu Leu Ser Lys Ala Ile Gln Tyr Gln Gln His Phe Ser Arg Arg Val Lys Arg Arg Glu Lys Gln Phe Pro Asp Gly Cys Ser Ser His Asn Thr Ala Thr Ala Val Ala Ala Leu Gly Gly Phe Leu Tyr Ile Leu Ala Glu Tyr Pro Pro Ala Asn Arg Glu Pro His Pro Ser Thr Pro Pro Pro Pro Ser Ser Arg <210> 37 <211> 1138 <212> DNA
<213> Homo Sapiens <400> 37 tctcttcttt gtccccttgt cttacctgct gatggtgact gtcatcctcc tcccctatgt 60 cagcaaggtc accggctggt gcagagacag gctcctgggc cacagggagc cctcggctca 120 cccagtggaa gtcttctcgt ttgacctcca cgagccactc agcaaggagc gcgtggaagc 180 cttcagcgac ggagtctacg ccatcgtggc cacgcttctc atcctggaca tctgcgaaga 240 caacgtcccg gaccccaagg atgtgaagga gaggttcagc ggcagcctcg tggccgccct 300 gagtgcgacc gggccgcgct tcctggcgta cttcggctcc ttcgccacag tgggactgct 360 gtggttcgcc caccactcac tcttcctgca tgtgcgcaag gccacgcggg ccatggggct 420 gctgaacacg ctctcgctgg ccttcgtggg tggcctccca ctagcctacc agcagacctc 480 ggccttcgcc cggcagcccc gcgatgagct ggagcgcgtg cgtgtcagct gcaccatcat 540 cttcctggcc agcatcttcc agctggccac gtggaccacg gcgctgctgc accaggcgga 600 gacgctgcag ccctcggtgt ggtttggcgg ccgggagcat gtgctcatgt tcgccaagct 660 ggcgctgtac ccctgtgcca gcctgctggc cttcgcctcc acctgcctgc tgagcaggtt 720 cagtgtgggc atcttccacc tcatggagat cgccgtgccc tgcgccttcc tgttgctgcg 780 cctgctcgtg ggcctggccc tggccaccct gcgggtcctg cggggcctcg cccggcccga 840 acaccccccg ccagccccca cgggccagga cgacccacag tcccagctcc tccctgcccc 900 ctgctagcag ccacagagcc cactcccagc cgtcctcacc agagatggac cagggaggac 960 aggatgctgg gcaggggaag ccaagtcacg ggcaggccgc agtggttctt gcgtggcctg 1020 gttttatttt cgttgtgaaa tatcatgctc ttatttcagt cctcaaaaaa aaaaaaaaaa 1080 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1138 <210> 38 <211> 291 <212> PRT
<213> Homo Sapiens <400> 38 Met Val Thr Val Ile Leu Leu Pro Tyr Val Ser Lys Val Thr Gly Trp Cys Arg Asp Arg Leu Leu Gly His Arg Glu Pro Ser Ala His Pro Val Glu Val Phe Ser Phe Asp Leu His Glu Pro Leu Ser Lys Glu Arg Val Glu Ala Phe Ser Asp Gly Val Tyr Ala Ile Val Ala Thr Leu Leu Ile Leu Asp Ile Cys Glu Asp Asn Val Pro Asp Pro Lys Asp Val Lys Glu Arg Phe Ser Gly Ser Leu Val Ala Ala Leu Ser Ala Thr Gly Pro Arg Phe Leu Ala Tyr Phe Gly Ser Phe Ala Thr Val Gly Leu Leu Trp Phe Ala His His Ser Leu Phe Leu His Val Arg Lys Ala Thr Arg Ala Met Gly Leu Leu Asn Thr Leu Ser Leu Ala Phe Val Gly Gly Leu Pro Leu Ala Tyr Gln Gln Thr Ser Ala Phe Ala Arg Gln Pro Arg Asp Glu Leu Glu Arg Val Arg Val Ser Cys Thr Ile Ile Phe Leu Ala Ser Ile Phe Gln Leu Ala Thr Trp Thr Thr Ala Leu Leu His Gln Ala Glu Thr Leu Gln Pro Ser Val Trp Phe Gly Gly Arg Glu His Val Leu Met Phe Ala Lys Leu Ala Leu Tyr Pro Cys Ala Ser Leu Leu Ala Phe Ala Ser Thr Cys Leu Leu Ser Arg Phe Ser Val Gly Ile Phe His Leu Met Glu Ile Ala Val Pro Cys Ala Phe Leu Leu Leu Arg Leu Leu Val Gly Leu Ala Leu Ala Thr Leu Arg Val Leu Arg Gly Leu Ala Arg Pro Glu His Pro Pro Pro Ala Pro Thr Gly Gln Asp Asp Pro Gln Ser Gln Leu Leu Pro Ala Pro Cys <210> 39 <211> 1478 <212> DNA
<213> Homo sapiens <400> 39 agagggggct gctgaccatg ctggaactgc ggcgactact gagcctgcgg gaacctcccc 60 tttcgcccaa gatctgctct gtccccctca tcctcctccc agggccctgg cgtctgggtc 120 aagcagcgcc ccacacctcg acccctcacc ccctcctccc gggctcttcc tgcggcctcc 180 cctccacagt ccgcaggctc tgggacagga ccgagtcctt ggctgcctgt ggagctcctg 240 tgccagcagc tgcgccccgg ctgcgctccg gataccccca tccccgccac cgccgacctc 300 ccgctccacc gactgctgct cacgcccgac gggttcacgc cgcccctgcc ccgtgaagga 360 ccgcgctgcg gtgcggaggc aggatgacgc aaaacacggt gattgtgaat ggagttgcta 420 tggcctctag gccatcccag cccacccacg tcaacgtcca catccaccag gagtcagctt 480 tgacacaact gctgaaagct ggaggttctc tgaagaagtt tctttttcac cctggggaca 540 ctgtgccttc cacagccagg attggttatg agcagctggc tctaggggtg actcagatat 600 tgctgggggt tgtgagttgt gttcttggag tgtgtctcag cttggggccc tggactgtgc 660 tgagtgcctc aggctgtgcc ttctgggcgg ggtctgtggt gatcgcagca ggagctgggg 720 ccattgtcca tgagaagcac ccgggcaaac ttgctggcta tatatccagc ctgctcaccc 780 tggcaggctt tgctacagct atggctgctg ttgtcctctg cgtgaatagc ttcatctggc 840 aaactgaacc ctttttatac atcgacactg tgtgtgatcg ctcagaccct gtcttcccta 900 ccactgggta cagatggatg cggcgaagtc aagagaacca atggcagaag gaggagtgta 960 gagcttacat gcagatgctg aggaagttgt tcacagcaat ccgtgccctg ttcctggctg 1020 tctgtgtctt gaaggtcatt gtgtccttgg tttccttggg agtaggtctt cgaaacttgt 1080 ttggccagag ctcccagccc ctgaatgagg aaggatcaga gaagaggcta ctgggggaga 1140 attcagtgcc cccttcgccc tctagggagc agacctccac tgccattgtc ctgtgagctg 1200 ccaaagaccc cacggggtgc ccgcatgtcc ctgtctaggg cagcccaggg cccccactcc 1260 tggctcctca cacttgcctc ccctatggcc gctctccaga ccctcctcct ttcttctccc 1320 cacatccgca cctgctgttc ccactctggg gttctcaagt ccatgaacag atattgttgc 1380 attttccaca atgctgatta aacataataa acaatccaga aaagcagttt tgcccagaaa 1440 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1478 <210> 40 <211> 270 <212> PRT
<213> Homo sapiens <400> 40 Met Thr Gln Asn Thr Val Ile Val Asn Gly Val Ala Met Ala Ser Arg Pro Ser Gln Pro Thr His Val Asn Val His Ile His Gln Glu Ser Ala Leu Thr Gln Leu Leu Lys Ala Gly Gly Ser Leu Lys Lys Phe Leu Phe His Pro Gly Asp Thr Val Pro Ser Thr Ala Arg Ile Gly Tyr Glu Gln Leu Ala Leu Gly Val Thr Gln Ile Leu Leu Gly Val Val Ser Cys Val Leu Gly Val Cys Leu Ser Leu Gly Pro Trp Thr Val Leu Ser Ala Ser Gly Cys Ala Phe Trp Ala Gly Ser Val Val Ile Ala Ala Gly Ala Gly Ala Ile Val His Glu Lys His Pro Gly Lys Leu Ala Gly Tyr Ile Ser Ser Leu Leu Thr Leu Ala Gly Phe Ala Thr Ala Met Ala Ala Val Val Leu Cys Val Asn Ser Phe Ile Trp Gln Thr Glu Pro Phe Leu Tyr Ile Asp Thr Val Cys Asp Arg Ser Asp Pro Val Phe Pro Thr Thr Gly Tyr Arg Trp Met Arg Arg Ser Gln Glu Asn Gln Trp Gln Lys Glu Glu Cys Arg Ala Tyr Met Gln Met Leu Arg Lys Leu Phe Thr Ala Ile Arg Ala Leu Phe Leu Ala Val Cys Val Leu Lys Val Ile Val Ser Leu Val Ser Leu Gly Val Gly Leu Arg Asn Leu Phe Gly Gln Ser Ser Gln Pro Leu Asn Glu Glu Gly Ser Glu Lys Arg Leu Leu Gly Glu Asn Ser Val Pro Pro Ser Pro Ser Arg Glu Gln Thr Ser Thr Ala Ile Val Leu <210> 41 <211> 2828 <212> DNA
<213> Homo Sapiens <400> 41 atcccagagt gctccctcca ggcctgcttc ttggttttgt ttgatcactg cgttcttcaa 60 gggatgaatc cagagccctc catgaggcca agcttgtcct tcaatcatgt ttcctctcag 120 atgcgtccgt gatgcctcct aatgtggaac tggttgtcca ttgtttgggc ctatggccaa 180 gtcacccagc tgtggaagca gaggtagaag acgaggccag ccaggagggc gacttcagtc 240 acagctccca tgcctcagct ttgtacctgt tttcaaaagc acaactgagg tgtgcgggct 300 ggagctgtct tgcagtgatt ctggccttct ggctcatggt tcagtccagc agcctggctg 360 acccactatt tctcctctgc ttcagaggaa acccaggaaa tgcccttact gccaggctga 420 gtctccaccc atgctggttg gtgctggcta ggctgagggg gccaccactt ttcctggcta 480 gaagctactt gacctttgat gtttgagttc tgtaagtctt cgtgttctga cttactgctt 540 cagagggatt ggcctgtccc ctttcccttt ctcggctatg ggaaggaagg attgctcatt 600 ggttgccttc atcagttaca gcatgagacg gaattcatca ttccttccga aacccctgat 660 atttaatatt taatatttaa aaacccaaat tatcaaacca ttaagaactc attactggtt 720 ctcagcctcc tccagtacta gcctcagtgt ggctgctgca taagtatctg tagcctgtct 780 acctcctgca gtggggccgc tcgcctcttc cctgtctact gctcaggctc tcccacttcg 840 tggcatccat gtaaagtagg tggcagggca gagatgtcac tctcattcaa cagggaggat 900 gtctgttgct cagagaggtt gtcctgaggg gctgggtgat tcctgggcct acattcttcc 960 cgaggctcca ggccgctgtc tctggaagta aaagagcctt gtctgacctt aatgcaagca 1020 gtctgtttga acccctgtag gctgcattca ggagacagaa ggtgtctggg ccatcctggg 1080 cggccggtca gcgttgctag gcaggctcgg ctgtctggcc gggacttggg cctgggtggc 1140 ttttgagacc agtgaagaag ggagagccgg cctcatgccg atggggcttg tggcacggct 1200 gggatgtgag ggaggactca gatctacaca cagaaacccc tcttctcccc gccctccccc 1260 agctcctacc tgcctcccac gcctcaggtg tggctgcctg tgggaccatc ccccaacccc 1320 tttcctcgca cctccttgtc ctcacccagt tcctgcagtg tctctgaccc acgcctcccg 1380 cctcctggcc gacttgccca ggaggtgtct ctggctcacc tccgtctgtt catcaccttc 1440 ctccccagtg tttccactta tcttggatgt tttagattga aacagcctga ttcccggaag 1500 aatcctcttc attcattgct agtgcttccc ctcacctccc actctccact tcccagtttg 1560 caaatgtggc tttcgcccac caagtgaaag cggactgaga gcagcccttg gggacggccc 1620 ggtgcctggc tgcaaggccg cgctggggct ctgtcttggt gcacatggct tgaccggact 1680 ttccctgctt cccaccactt ccctcactcc cagacctccc tcattctttt tgtctcttct 1740 ttttgcctaa agccagtcct taacacccta ttcttcctct gcaggtggct tgcagacttt 1800 tccccacctt tggggctcgt ggtggtggag agggcagctg gtgttaagaa tgtaggttac 1860 cgggcatgac ccggcagatg cttgcccagt agttctggag gaaggcccgg gaatctgcaa 1920 atgagcgcat tccccaggca gttcccatgc aggtgatcca cggaccacat gttgagaaac 1980 tgcagtcacc cttagggcca caccgtccct ctcctcgctg tcccctctct gtagtgactg 2040 gccctgacct tcaggagtgc actttccact ctaccaggaa gccctatgac atcctcaggc 2100 tccccagacc tgcagcttgc atggggcccc tcccttcttc cacacccacc ctccgtatgg 2160 tcccctgctc tgccctcgtg ctttgctggc ccctgcccgc tactcccact ctcagacacc 2220 caggggtggt gggccctaac tggctggccc ctcccagcgc tgccctctgc cgtccagatg 2280 ctgcagtgtg gccagattta ccttccagta acatacttct agtcacccct cctcctgcga 2340 agtgatctgc agtggctgtt tgaccagacc acaaagttca catctcctga gcttagtgtc 2400 cgtggctgtc cacctcccag ccatacttga ctgtccccaa actctccctg cagccacatg 2460 tttcccatga cctgtgggct ctgcagatgg acctctctcc gctagagatg cccttctccc 2520 aaatggcttc cctcctggaa ggcccagcct gagtcctcgt ctcctttcca gtgcttctgc 2580 cagaagcatc cccatgatgt tgtgaccgca cagcactttg tgtctcgctt tgagcacttg 2640 ccactctggc tggtgctgct gccactgatt gtgtactgtc ttgctgccct ttctagactg 2700 tgagctcctc gtgggcaggg accgcctgtg ttctctgtat ttcccacggc gcctagcaca 2760 gtgccttgca cttgataggt gcttaataaa tgtctgctca actgaaaaaa aaaaaaaaaa 2820 aaaaaaaa 2828 <210> 42 <211> 124 <212> PRT
<213> Homo Sapiens <400> 42 Met Pro Pro Asn Val Glu Leu Val Val His Cys Leu Gly Leu Trp Pro Ser His Pro Ala Val Glu Ala Glu Val Glu Asp Glu Ala Ser Gln Glu Gly Asp Phe Ser His Ser Ser His Ala Ser Ala Leu Tyr Leu Phe Ser Lys Ala Gln Leu Arg Cys Ala Gly Trp Ser Cys Leu Ala Val Ile Leu Ala Phe Trp Leu Met Val Gln Ser Ser Ser Leu Ala Asp Pro Leu Phe Leu Leu Cys Phe Arg Gly Asn Pro Gly Asn Ala Leu Thr Ala Arg Leu Ser Leu His Pro Cys Trp Leu Val Leu Ala Arg Leu Arg Gly Pro Pro Leu Phe Leu Ala Arg Ser Tyr Leu Thr Phe Asp Val <210> 43 <211> 646 <212> DNA
<213> Homo Sapiens <400> 43 attcgccgcc cggcccctgc tccgtggctg gttttctccg cgggcgcctc gggcggaacc 60 tggagataat gggcagcacc tgggggagcc ctggctgggt gcggctcgct ctttgcctga 120 cgggcttagt gctctcgctc tacgcgctgc acgtgaaggc ggcgcgcgcc cgggaccggg 180 attaccgcgc gctctgcgac gtgggcaccg ccatcagctg ttcgcgcgtc ttctcctcca 240 ggtggggcag gggtttcggg ctggtggagc atgtgctggg acaggacagc atcctcaatc 300 aatccaacag catattcggt tgcatcttct acacactaca gctattgtta ggttgcctgc 360 ggacacgctg ggcctctgtc ctgatgctgc tgagccttgc ctaagggggc atatctgggt 420 ccctagaagg ccctagatgt ggggcttcta gattaccccc tcctcctgcc atacccgcac 480 atgacaatgg accaaatgtg ccacacgctc gctctttttt acacccagtg cctctgactc 540 tgtccccatg ggctggtctc caaagctctt tccattgccc agggagggaa ggttctgagc 600 aataaagttt cttagatcaa tcaaaaaaaa aaaaaaaaaa aaaaaa 646 <210> 44 <211> 111 <212> PRT
<213> Homo Sapiens <400> 44 Met Gly Ser Thr Trp Gly Ser Pro Gly Trp Val Arg Leu Ala Leu Cys Leu Thr Gly Leu Val Leu Ser Leu Tyr Ala Leu His Val Lys Ala Ala Arg Ala Arg Asp Arg Asp Tyr Arg Ala Leu Cys Asp Val Gly Thr Ala Ile Ser Cys Ser Arg Val Phe Ser Ser Arg Trp Gly Arg Gly Phe Gly Leu Val Glu His Val Leu Gly Gln Asp Ser Ile Leu Asn Gln Ser Asn Ser Ile Phe Gly Cys Ile Phe Tyr Thr Leu Gln Leu Leu Leu Gly Cys Leu Arg Thr Arg Trp Ala Ser Val Leu Met Leu Leu Ser Leu Ala <210> 45 <211> 1612 <212> DNA
<213> Homo Sapiens <400> 45 atcttatcgc gactaaacgg agtggcggcg gcatttcctg gtgtctgagc ctggcgcgga 60 ggctatgggc agccaggagg tgctgggcca cgcggcccgg ctggcctcct ccggtctcct 120 cctgcaggtg ttgtttcggt tgatcacctt tgtcttgaat gcatttattc ttcgcttcct 180 gtcaaaggaa atcgttggcg tagtaaatgt aagactaacg ctgctttact caaccaccct 240 cttcctggcc agagaggcct tccgcagagc atgtctcagt gggggcaccc agcgagactg 300 gagccagacc ctcaacctgc tgtggctaac agtccccctg ggtgtgtttt ggtccttatt 360 cctgggctgg atctggttgc agctgcttga agtgcctgat cctaatgttg tccctcacta 420 tgcaactgga gtggtgctgt ttggtctctc ggcagtggtg gagcttctag gagagccctt 480 ttgggtcttg gcacaagcac atatgtttgt gaagctcaag gtgattgcag agagcctgtc 540 ggtaattctt aagagcgttc tgacagcttt tctcgtgctg tggttgcctc actggggatt 600 gtacattttc tctttggccc agcttttcta taccacagtt ctggtgctct gctatgttat 660 ttatttcaca aagttactgg gttccccaga atcaaccaag cttcaaactc ttcctgtctc 720 cagaataaca gatctgttac ccaatattac aagaaatgga gcgtttataa actggaaaga 780 ggctaaactg acttggagtt ttttcaaaca gtctttcttg aaacagattt tgacagaagg 840 cgagcgatat gtgatgacat ttttgaatgt attgaacttt ggtgatcagg gtgtgtatga 900 tatagtgaat aatcttggct cccttgtggc cagattaatt ttccagccaa tagaggaaag 960 tttttatata ttttttgcta aggtgctgga gaggggaaag gatgccacac ttcagaagca 1020 ggaggacgtt gctgtggctg ctgcagtctt ggagtccctg ctcaagctgg ccctgctggc 1080 cggcctgacc atcactgttt ttggctttgc ctattctcag ctggctctgg atatctacgg 1140 agggaccatg cttagctcag gatccggtat tcctctgctg tgagcagggc tggccagcca 1200 gactggcaca cattgctgtg ggggccttct gtctgggagc aactctcggg acagcattcc 1260 tcacagagac caagctgatc catttcctca ggactcagtt aggtgtgccc agacgcactg 1320 acaaaatgac gtgacttcag ggaagcctgg acacccgagg cacctggacc agctatgggt 1380 agttctgtgg gtggaacaca ttctgtgtaa gagccccact gagggctctg cagcggagtg 1440 acagcaaccc cagagatgag gcaccagaga gtgccactgc atgagacacc tgtgaccatt 1500 cgaagtctga aatgcggggg gggagtttca tttttaagtg aagaccaaaa gcccttttga 1560 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa as 1612 <210> 46 <211> 372 <212> PRT
<213> Homo Sapiens <400> 46 Met Gly Ser Gln Glu Val Leu Gly His Ala Ala Arg Leu Ala Ser Ser Gly Leu Leu Leu Gln Val Leu Phe Arg Leu Ile Thr Phe Val Leu Asn Ala Phe Ile Leu Arg Phe Leu Ser Lys Glu Ile Val Gly Val Val Asn Val Arg Leu Thr Leu Leu Tyr Ser Thr Thr Leu Phe Leu Ala Arg Glu Ala Phe Arg Arg Ala Cys Leu Ser Gly Gly Thr Gln Arg Asp Trp Ser Gln Thr Leu Asn Leu Leu Trp Leu Thr Val Pro Leu Gly Val Phe Trp Ser Leu Phe Leu Gly Trp Ile Trp Leu Gln Leu Leu Glu Val Pro Asp Pro Asn Val Val Pro His Tyr Ala Thr Gly Val Val Leu Phe Gly Leu Ser Ala Val Val Glu Leu Leu Gly Glu Pro Phe Trp Val Leu Ala Gln Ala His Met Phe Val Lys Leu Lys Val Ile Ala Glu Ser Leu Ser Val Ile Leu Lys Ser Val Leu Thr Ala Phe Leu Val Leu Trp Leu Pro His Trp Gly Leu Tyr Ile Phe Ser Leu Ala Gln Leu Phe Tyr Thr Thr Val Leu Val Leu Cys Tyr Val Ile Tyr Phe Thr Lys Leu Leu Gly Ser Pro Glu Ser Thr Lys Leu Gln Thr Leu Pro Val Ser Arg Ile Thr Asp Leu Leu Pro Asn Ile Thr Arg Asn Gly Ala Phe Ile Asn Trp Lys Glu Ala Lys Leu Thr Trp Ser Phe Phe Lys Gln Ser Phe Leu Lys Gln Ile Leu Thr Glu Gly Glu Arg Tyr Val Met Thr Phe Leu Asn Val Leu Asn Phe Gly Asp Gln Gly Val Tyr Asp Ile Val Asn Asn Leu Gly Ser Leu Val Ala Arg Leu Ile Phe Gln Pro Ile Glu Glu Ser Phe Tyr Ile Phe Phe Ala Lys Val Leu Glu Arg Gly Lys Asp Ala Thr Leu Gln Lys Gln Glu Asp Val Ala Val Ala Ala Ala Val Leu Glu Ser Leu Leu Lys Leu Ala Leu Leu Ala Gly Leu Thr Ile Thr Val Phe Gly Phe Ala Tyr Ser Gln 340 , 345 350 Leu Ala Leu Asp Ile Tyr Gly Gly Thr Met Leu Ser Ser Gly Ser Gly Ile Pro Leu Leu <210> 47 <211> 3094 <212> DNA
<213,> Homo Sapiens <400> 47 gaggctgtcc aggcgcaatg tggtggctgc ttctctgggg agtcctccag gcttgcccaa 60 cccggggctc cgtcctcttg gcccaagagc taccccagca gctgacatcc cccgggtacc 120 cagagccgta tggcaaaggc caagagagca gcacggacat caaggctcca gagggctttg 180 ctgtgaggct cgtcttccag gacttcgacc tggagccgtc ccaggactgt gcaggggact 240 ctgtcacaat ctcattcgtc ggttcggatc caagccagtt ctgtggtcag caaggctccc 300 ctctgggcag gccccctggt cagagggagt ttgtatcctc agggaggagt ttgcggctga 360 ccttccgcac acagccttcc tcggagaaca agactgccca cctccacaag ggcttcctgg 420 ccctctacca aaccgtggct gtgaactata gtcagcccat cagcgaggcc agcaggggct 480 ctgaggccat caacgcacct ggagacaacc ctgccaaggt ccagaaccac tgccaggagc 540 cctattatca ggccgcggca gcaggggcac tcacctgtgc aaccccaggg acctggaaag 600 acagacagga tggggaggag gttcttcagt gtatgcctgt ctgcggacgg ccagtcaccc 660 ccattgccca gaatcagacg accctcggtt cttccagagc caagctgggc aacttcccct 720 ggcaagcctt caccagtatc cacggccgtg ggggcggggc cctgctgggg gacagatgga 780 tcctcactgc tgcccacacc gtctacccca aggacagtgt ttctctcagg aagaaccaga 840 gtgtgaatgt gttcttgggc cacacagcca tagatgagat gctgaaactg gggaaccacc 900 ctgtccaccg tgtcgttgtg caccccgact accgtcagaa tgagtcccat aactttagcg 960 gggacatcgc cctcctggag ctgcagcaca gcatccccct gggccccaac gtcctcccgg 1020 tctgtctgcc cgataatgag accctctacc gcagcggctt gttgggctac gtcagtgggt 1080 ttggcatgga gatgggctgg ctaactactg agctgaagta ctcgaggctg cctgtagctc 1140 ccagggaggc ctgcaacgcc tggctccaaa agagacagag acccgaggtg ttttctgaca 1200 atatgttctg tgttggggat gagacgcaaa ggcacagtgt ctgccagggg gacagtggca 1260 gcgtctatgt ggtatgggac aatcatgccc atcactgggt ggccacgggc attgtgtcct 1320 ggggcatagg gtgtggcgaa gggtatgact tctacaccaa ggtgctcagc tatgtggact 1380 ggatcaaggg agtgatgaat ggcaagaatt gaccctgggg gcttgaacag ggactgacca 1440 gcacagtgga ggccccaggc aacagagggc ctggagtgag gactgaacac tggggtaggg 1500 gttgggggtg gggggttggg ggaggcaggg aaatcctatt cacatcactg ttgcaccaag 1560 ccactgcaag agaaaccccc acccggcaag cccgccccat cccagacagg aagcagagtc 1620 ccacagaccg ctcctcctca ccctctacct ccctgtgctc atgcactagg ccccgggaag 1680 cctgtacatc tcaacaactt tcgccttgaa tgtccttaga accaccttcc cctacttcat 1740 ctgttgacac agcttttata ctcacctgtg gaagagtcag ctactcaccc gctattagag 1800 tatggaggaa ggggttttca ttgcattgca tttctgaaac attcctaaga ccctttagtt 1860 gaccttcaaa tattcaagct attctgcagc tccaagatgc aattatagaa acagctcctt 1920 ttttatttta tgtcctctat atgccaggtg cttcacctgt tatttcactt aatcctcata 1980 ccatatttgc aaaggatgtg ttattatcta tgtgtgacaa atgaggaaac tgaggctcag 2040 gggataaagg gacttgccca agtcccacag ctggtgtgtg actgcagaga ctgtgctctt 2100 cccagtgtgc tgcaatactt ctcaaccctc ctctaacctg ctgtgtcacc cgctttccct 2160 cccagccccc acatccttac cattttccct ccctgggaat tcctgcttct gcgaaaatgg 2220 tatcctctag ctcacacttt cctaatggcc ccatctcctg cagaagccag gtgagcccag 2280 cactggactg aagttcttgc agacacccca cctgtgcccc tatcatcagg ggaactgctc 2340 cacctgagag gaccaactct ttaattttta gtaaaacctg gaggtgatgg gccgggcgca 2400 gtggctcacg cctgtaatcc caacacctta ggagtccgag gtgggtggat cacgaggtca 2460 ggagatccag cccatcctgg ccaacatggt gaaaccccat ctctactaaa aatacaaaaa 2520 ttagccgggc gtggtgacac gtgcctgtag tcccagctac tcgggaggct gaggcaggag 2580 aatcacttga acctgggagg cggaggttgc agtgagctaa gatcacgcca ctgcactcca 2640 gcctgcggac agaccaagac ttcatccccc ccaaaaaaaa aagattggag gtgatttaca 2700 gtgaaagaca caaataaaat acaactgttc aatggaaata gaaaataaac accataaaag 2760 agagaagaga ggtaatttgt tagcatcaag agtcaagttg ctatatggtc aaaggttaaa 2820 tttatctcta aaaaatggca ggattcaaag ttgtacatac atgtgattac ttctgttttt 2880 tacacccacatacagtac aa agattatta aatattcccaaaaggcaggtgcaatgat 2940 a aa gcacacttatacccccagcc ctcaggagg gatgcaagaggatcgcttgagcccagga 3000 a ct gttgaagtccagcctaagca catagtgaa cccatctccaaaaatataataataattc 3060 a ac tctcaaaaaaaaaaaaaaaa aaaaaaaaa aa 3094 a aa <210>

<211>

<212>
PRT

<213> sapiens Homo <400>

Met Trp LeuLeuLeuTrpGly ValLeuGlnAlaCysProThrArg Trp Gly Ser LeuLeuAlaGlnGlu LeuProGlnGlnLeuThrSerPro Val Gly Tyr GluProTyrGlyLys GlyGlnGluSerSerThrAspIle Pro Lys Ala GluGlyPheAlaVal ArgLeuValPheGlnAspPheAsp Pro Leu Glu SerGlnAspCysAla GlyAspSerValThrIleSerPhe Pro Val Gly AspProSerGlnPhe CysGlyGlnGlnGlySerProLeu Ser Gly Arg ProGlyGlnArgGlu PheValSerSerGlyArgSerLeu Pro Arg Leu PheArgThrGlnPro SerSerGluAsnLysThrAlaHis Thr Leu His GlyPheLeuAlaLeu TyrGlnThrValAlaValAsnTyr Lys Ser Gln IleSerGluAlaSer ArgGlySerGluAlaIleAsnAla Pro Pro Gly AsnProAlaLysVal GlnAsnHisCysGlnGluProTyr Asp Tyr Gln AlaAlaAlaGlyAla LeuThrCysAlaThrProGlyThr Ala Trp Lys ArgGlnAspGlyGlu GluValLeuGlnCysMetProVal Asp Cys Gly ProValThrProIle AlaGlnAsnGlnThrThrLeuGly Arg Ser Ser AlaLysLeuGlyAsn PheProTrpGlnAlaPheThrSer Arg Ile His ArgGlyGlyGlyAla LeuLeuGlyAspArgTrpIleLeu Gly Thr Ala HisThrValTyrPro LysAspSerValSerLeuArgLys Ala Asn Gln Ser Val Asn Val Phe Leu Gly His Thr Ala Ile Asp Glu Met Leu Lys Leu Gly Asn His Pro Val His Arg Val Val Val His Pro Asp Tyr Arg Gln Asn Glu Ser His Asn Phe Ser Gly Asp Ile Ala Leu Leu Glu Leu Gln His Ser Ile Pro Leu Gly Pro Asn Val Leu Pro Val Cys Leu Pro Asp Asn Glu Thr Leu Tyr Arg Ser Gly Leu Leu Gly Tyr Val Ser Gly Phe Gly Met Glu Met Gly Trp Leu Thr Thr Glu Leu Lys Tyr Ser Arg Leu Pro Val Ala Pro Arg Glu Ala Cys Asn Ala Trp Leu Gln Lys Arg Gln Arg Pro Glu Val Phe Ser Asp Asn Met Phe Cys Val Gly Asp Glu Thr Gln Arg His Ser Val Cys Gln Gly Asp Ser Gly Ser Val Tyr Val Val Trp Asp Asn His Ala His His Trp Val Ala Thr Gly Ile Val Ser Trp Gly Ile Gly Cys Gly Glu Gly Tyr Asp Phe Tyr Thr Lys Val Leu Ser Tyr Val Asp Trp Ile Lys Gly Val Met Asn Gly Lys Asn <210> 49 <211> 2927 <212> DNA
<213> Homo Sapiens <400> 49 tgctttgcag gcccaggctc aaggcaaatt ataagtaggg aaccaatttg agggaaagac 60 atgtgaacag agttaaggta ccacgtcctg ggagcgacca gcagccccac ctgaagtccg 120 catgcaactc tgacaagctc aggtgcttgt tttaaggaaa ggggctacta gagtcttacc 180 aacagcgagc ccaggtggga gatgaaacag gtactcccca aaataggtca tccgagggag 240 gaaaactgat ggagagcaca atgtgctctg agcgttttta atgtttttaa gcttttaaat 300 gatttcttca aggccgagca gcagcagcaa aggtgtggct taaaggatta agggggtttc 360 tgctggcacc tagaatgaag ttactctatt actaatcaag ccgagaggag gcccactatg 420 cccccgttta tcatcctttc ccagttcctt tttgctggtc acaaaacgat gctcatcaat 480 cccacctaaa gcaggaggcc aggagcccag cctcttgtag aaacagcgag ggtataactg 540 ccctcccgtt ctgcccccaa gacgaaggag gactctcgga agccaagaaa ggtttaagaa 600 gtctttctgg atagagagca gtgcccaggc aggaagcctt tcgccggcag agcggggtcc 660 gaggacgagc tggagaggac agaggcgcga tgggcctgct gcagggcttg ctccgagtcc 720 ggaagctgct gctggtcgtc tgcgtcccgc tcctgctgct gcctctgccc gtcctccacc 780 ccagcagcga ggcctcgtgt gcttacgtgc tgatcgtgac tgctgtgtac tgggtgtcgg 840 aggcagtgcc tctgggagct gcagccctgg tgccggcctt cctctacccg ttcttcggag 900 tcctccggtc caatgaggtg gcggcggagt acttcaagaa caccacgctg ctgctggtgg 960 gggtcatctg cgtggcggct gccgtggaga agtggaacct gcataagcgc attgctctgc 1020 gcatggtctt gatggccggg gccaagccgg gcatgctgct gctctgcttc atgtgctgta 1080 ccacgttgct gtccatgtgg ctgtccaaca cctccaccac cgccatggtg atgcccatcg 1140 tggaggccgt gctgcaggag ctggtcagtg ctgaggacga gcagctcgtg gcgggcaact 1200 ccaacaccga agaggccgaa cccatcagtc tggatgtaaa gaacagccaa ccttctctgg 1260 aactcatctt tgtcaatgaa gacaggtcca acgcagacct caccactctg atgcacaacg 1320 agaacctgaa tggtgtgccc tcgatcacca accccatcaa aactgcaaac caacaccagg 1380 gcaagaagca acacccatcc caggaaaagc cacaagtcct gacccccagc cccaggaagc 1440 agaagctgaa cagaaagtac aggtcccacc atgaccagat gatctgcaag tgcctctccc 1500 tgagcatatc ctactccgct accattggcg gcctgaccac catcatcggc acctccacca 1560 gcctcatctt cctggaacac ttcaacaacc agtatccagc cgcagaggtg gtgaactttg 1620 gcacctggtt cctcttcagc ttccccatat ccctcatcat gctggtggtc agctggttct 1680 ggatgcactg gctgttcctg ggctgcaatt ttaaagagac ctgctctctg agcaagaaga 1740 agaagaccaa aagggaacag ttgtcagaga agaggatcca agaagaatat gaaaaactgg 1800 gagacattag ctacccagaa atggtgactg gatttttctt catcctgatg accgtactgt 1860 ggtttacccg ggagcctggc tttgtccctg gctgggattc tttctttgaa aagaaaggct 1920 accgtactga tgccacagtc tctgtcttcc ttggcttcct cctcttcctc attccagcga 1980 agaagccctg ctttgggaaa aagaatgatg gagagaacca ggagcactca ctggggaccg 2040 agcccatcat cacgtggaag gacttccaga agaccatgcc ctgggagatt gtcattctgg 2100 ttgggggagg ctatgctctg gcttctggta gcaagagctc tggcctctct acatggattg 2160 ggaaccagat gttgtccctg agcagcctcc caccgtgggc tgtcaccctg ctggcatgca 2220 tcctcgtgtc cattgtcact gagtttgtga gcaacccagc aaccatcacc atcttcctgc 2280 ccatcctgtg cagcctgtct gaaacgctgc acattaaccc cctctacacc ctgatcccag 2340 tcaccatgtg catctccttt gcagtgatgc tgcctgtggg caatccccct aatgccatcg 2400 tcttcagcta tgggcactgc cagatcaaag atatggtgaa agctggcctg ggagtcaacg 2460 ttattggact ggtgatagta atggtggcca tcaacacctg gggagttagc ctcttccacc 2520 tggacactta cccagcatgg gcgagggtca gcaacatcac tgatcaagcc taacgccaag 2580 tgtacaaact ggcccaacca caggagctgc cagtatccag cagtatctgg accacaggca 2640 aagaaaacca ctaggaccac caggagcaca caaccccaga cccacgccgg agggcatccc 2700 tccaccagaa gattccgcca cctcaagtga actgcaggaa tcctccaaca accacaaaca 2760 catgcttcgc tgttagtgtc ttcttcctgc cctcagcacc acagctcaag aaaacctaaa 2820 gtttcaatac aagccatagg ctcacagaaa aagaaaaaga aaataaaaat taaattaaaa 2880 aaaaagaaga caaagaaaac ctaaaaaaaa aaaaaaaaaa aaaaaaa 2927 <210> 50 <211> 627 <212> PRT
<213> Homo Sapiens <400> 50 Met Gly Leu Leu Gln Gly Leu Leu Arg Val Arg Lys Leu Leu Leu Val Val Cys Val Pro Leu Leu Leu Leu Pro Leu Pro Val Leu His Pro Ser Ser Glu Ala Ser Cys Ala Tyr Val Leu Ile Val Thr Ala Val Tyr Trp Val Ser Glu Ala Val Pro Leu Gly Ala Ala Ala Leu Val Pro Ala Phe Leu Tyr Pro Phe Phe Gly Val Leu Arg Ser Asn Glu Val Ala Ala Glu Tyr Phe Lys Asn Thr Thr Leu Leu Leu Val Gly Val Ile Cys Val Ala Ala Ala Val Glu Lys Trp Asn Leu His Lys Arg Ile Ala Leu Arg Met Val Leu Met Ala Gly Ala Lys Pro Gly Met Leu Leu Leu Cys Phe Met Cys Cys Thr Thr Leu Leu Ser Met Trp Leu Ser Asn Thr Ser Thr Thr Ala Met Val Met Pro Ile Val Glu Ala Val Leu Gln Glu Leu Val Ser Ala Glu Asp Glu Gln Leu Val Ala Gly Asn Ser Asn Thr Glu Glu Ala Glu Pro Ile Ser Leu Asp Val Lys Asn Ser Gln Pro Ser Leu Glu Leu Ile Phe Val Asn Glu Asp Arg Ser Asn Ala Asp Leu Thr Thr Leu Met His Asn Glu Asn Leu Asn Gly Val Pro Ser Ile Thr Asn Pro Ile Lys Thr Ala Asn Gln His Gln Gly Lys Lys Gln His Pro Ser Gln Glu Lys Pro Gln Val Leu Thr Pro Ser Pro Arg Lys Gln Lys Leu Asn Arg Lys Tyr Arg Ser His His Asp Gln Met Ile Cys Lys Cys Leu Ser Leu Ser Ile Ser Tyr Ser Ala Thr Ile Gly Gly Leu Thr Thr Ile Ile Gly Thr Ser Thr Ser Leu Ile Phe Leu Glu His Phe Asn Asn Gln Tyr Pro Ala Ala Glu Val Val Asn Phe Gly Thr Trp Phe Leu Phe Ser Phe Pro Ile Ser Leu Ile Met Leu Val Val Ser Trp Phe Trp Met His Trp Leu Phe Leu Gly Cys Asn Phe Lys Glu Thr Cys Ser Leu Ser Lys Lys Lys Lys Thr Lys Arg Glu Gln Leu Ser Glu Lys Arg Ile Gln Glu Glu Tyr Glu Lys Leu Gly Asp Ile Ser Tyr Pro Glu Met Val Thr Gly Phe Phe Phe Ile Leu Met Thr Val Leu Trp Phe Thr Arg Glu Pro Gly Phe Val Pro Gly Trp Asp Ser Phe Phe Glu Lys Lys Gly Tyr Arg Thr Asp Ala Thr Val Ser Val Phe Leu Gly Phe Leu Leu Phe Leu Ile Pro Ala Lys Lys Pro Cys Phe Gly Lys Lys Asn Asp Gly Glu Asn Gln Glu His Ser Leu Gly Thr Glu Pro Ile Ile Thr Trp Lys Asp Phe Gln Lys Thr Met Pro Trp Glu Ile Val Ile Leu Val Gly Gly Gly Tyr Ala Leu Ala Ser Gly Ser Lys Ser Ser Gly Leu Ser Thr Trp Ile Gly Asn Gln Met Leu Ser Leu Ser Ser Leu Pro Pro Trp Ala Val Thr Leu Leu Ala Cys Ile Leu Val Ser Ile Val Thr Glu Phe Val Ser Asn Pro Ala Thr Ile Thr Ile Phe Leu Pro Ile Leu Cys Ser Leu Ser Glu Thr Leu His Ile Asn Pro Leu Tyr Thr Leu Ile Pro Val Thr Met Cys Ile Ser Phe Ala Val Met Leu Pro Val Gly Asn Pro Pro Asn Ala Ile Val Phe Ser Tyr Gly His Cys Gln Ile Lys Asp Met Val Lys Ala Gly Leu Gly Val Asn Val Ile Gly Leu Val Ile Val Met Val Ala Ile Asn Thr Trp Gly Val Ser Leu Phe His Leu Asp Thr Tyr Pro Ala Trp Ala Arg Val Ser Asn Ile Thr Asp Gln Ala <210> 51 <211>. 2134 <212> DNA
<213> Homo Sapiens <400> 51 gaacctttag ggtgcgcggg tgcagtatat ctcgcgctct ctcccctttc cccctcccct 60 ttccccaccc cgggcgctca ggttggtctg gaccggaagc gaagatggcg acttctggcg 120 cggcctcggc ggagctggtg atcggctggt gcatattcgg cctcttacta ctggctattt 180 tggcattctg ctggatatat gttcgtaaat accaaagtcg gcgggaaagt gaagttgtct 240 ccaccataac agcaattttt tctctagcaa ttgcacttat cacatcagca cttctaccag 300 tggatatatt tttggtttct tacatgaaaa atcaaaatgg tacatttaag gactgggcta 360 atgctaatgt cagcagacag attgaggaca ctgtattata cggttactat actttatatt 420 ctgttatatt gttctgtgtg ttcttctgga tcccttttgt ctacttctat tatgaagaaa 480 aggatgatga tgatactagt aaatgtactc aaattaaaac ggcactcaag tatactttgg 540 gatttgttgt gatttgtgca ctgcttcttt tagttggtgc ctttgttcca ttgaatgttc 600 ccaataacaa aaattctaca gagtgggaaa aagtgaagtc cctatttgaa gaacttggaa 660 gtagtcatgg tttagctgca ttgtcatttt ctatcagttc tctgaccttg attggaatgt 720 tggcagctat aacttacaca gcctatggca tgtctgcgtt acctttaaat ctgataaaag 780 gcactagaag cgctgcttat gaacgtttgg aaaacactga agacattgaa gaagtagaac 840 aacacattca aacgattaaa tcaaaaagca aagatggtcg acctttgcca gcaagggata 900 aacgcgcctt aaaacaattt gaagaaaggt tacgaacact taagaagaga gagaggcatt 960 tagaattcat tgaaaacagc tggtggacaa aattttgtgg cgctctgcgt cccctgaaga 1020 tcgtctgggg aatatttttc atcttagttg cattgctgtt tgtaatttct ctcttcttgt 1080 caaatttaga taaagctctt cattcagctg gaatagattc tggtttcata atttttggag 1140 ctaacctgag taatccactg aatatgcttt tgcctttact acaaacagtt ttccctcttg 1200 attatattct tataacaatt attattatgt actttatttt tacttcaatg gcaggaattc 1260 gaaatattgg catatggttc ttttggatta gattatataa aatcagaaga ggtagaacca 1320 ggccccaagc actccttttt ctctgcatga tacttctgct tattgtcctt cacactagct 1380 acatgattta tagtcttgct ccccaatatg ttatgtatgg aagccaaaat tacttaatag 1440 agactaatat aacttctgat aatcataaag gcaattcaac cctttctgtg ccaaagagat 1500 gtgatgcaga agctcctgaa gatcagtgta ctgttacccg gacataccta ttccttcaca 1560 agttctggtt cttcagtgct gcttactatt ttggtaactg ggcctttctt ggggtatttt 1620 tgattggatt aattgtatcc tgttgtaaag ggaagaaatc ggttattgaa ggagtagatg 1680 aagattcaga cataagtgat gatgagccct ctgtctattc tgcttgacag ccttctgtct 1740 taaaggtttt ataatgctga ctgaatatct gttatgcatt tttaaagtat taaactaaca 1800 ttaggatttg ctaactagct ttcatcaaaa atgggagcat ggctataaga caactatatt 1860 ttattatatg ttttctgaag taacattgta tcatagatta acattttaaa ttaccataat 1920 catgctatgt aaatataaga ctactggctt tgtgagggaa tgtttgtgca aaattttttc 1980 ctctaatgta taatagtgtt aaattgatta aaaatcttcc agaattaata ttcccttttg 2040 tcactttttg aaaacataat aaatcatttg tatctgtgaa aaaaaaaaaa aaaaaaaaaa 2100 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2134 <210> 52 <211> 540 <212> PRT
<213> Homo Sapiens <400> 52 Met Ala Thr Ser Gly Ala Ala Ser Ala Glu Leu Val Ile Gly Trp Cys Ile Phe Gly Leu Leu Leu Leu Ala Ile Leu Ala Phe Cys Trp Ile Tyr Val Arg Lys Tyr Gln Ser Arg Arg Glu Ser Glu Val Val Ser Thr Ile Thr Ala Ile Phe Ser Leu Ala Ile Ala Leu Ile Thr Ser Ala Leu Leu Pro Val Asp Ile Phe Leu Val Ser Tyr Met Lys Asn Gln Asn Gly Thr Phe Lys Asp Trp Ala Asn Ala Asn Val Ser Arg Gln Ile Glu Asp Thr Val Leu Tyr Gly Tyr Tyr Thr Leu Tyr Ser Val Ile Leu Phe Cys Val Phe Phe Trp Ile Pro Phe Val Tyr Phe Tyr Tyr Glu Glu Lys Asp Asp Asp Asp Thr Ser Lys Cys Thr Gln Ile Lys Thr Ala Leu Lys Tyr Thr Leu Gly Phe Val Val Ile Cys Ala Leu Leu Leu Leu Val Gly Ala Phe Val Pro Leu Asn Val Pro Asn Asn Lys Asn Ser Thr Glu Trp Glu Lys Val Lys Ser Leu Phe Glu Glu Leu Gly Ser Ser His Gly Leu Ala Ala Leu Ser Phe Ser Ile Ser Ser Leu Thr Leu Ile Gly Met Leu Ala Ala Ile Thr Tyr Thr Ala Tyr Gly Met Ser Ala Leu Pro Leu Asn Leu Ile Lys Gly Thr Arg Ser Ala Ala Tyr Glu Arg Leu Glu Asn Thr Glu Asp Ile Glu Glu Val Glu Gln His Ile Gln Thr Ile Lys Ser Lys Ser Lys Asp Gly Arg Pro Leu Pro Ala Arg Asp Lys Arg Ala Leu Lys Gln Phe Glu Glu Arg Leu Arg Thr Leu Lys Lys Arg Glu Arg His Leu Glu Phe Ile Glu Asn Ser Trp Trp Thr Lys Phe Cys Gly Ala Leu Arg Pro Leu Lys Ile Val Trp Gly Ile Phe Phe Ile Leu Val Ala Leu Leu Phe Val Ile Ser Leu Phe Leu Ser Asn Leu Asp Lys Ala Leu His Ser Ala Gly Ile Asp Ser Gly Phe Ile Ile Phe Gly Ala Asn Leu Ser Asn Pro Leu Asn Met Leu Leu Pro Leu Leu Gln Thr Val Phe Pro Leu Asp Tyr Ile Leu Ile Thr Ile Ile Ile Met Tyr Phe Ile Phe Thr Ser Met Ala Gly Ile Arg Asn Ile Gly Ile Trp Phe Phe Trp Ile Arg Leu Tyr Lys Ile Arg Arg Gly Arg Thr Arg Pro Gln Ala Leu Leu Phe Leu Cys Met Ile Leu Leu Leu Ile Val Leu His Thr Ser Tyr Met Ile Tyr Ser Leu Ala Pro Gln Tyr Val Met Tyr Gly Ser Gln Asn Tyr Leu Ile Glu Thr Asn Ile Thr Ser Asp Asn His Lys Gly Asn Ser Thr Leu Ser Val Pro Lys Arg Cys Asp Ala Glu Ala Pro Glu Asp Gln Cys Thr Val Thr Arg Thr Tyr Leu Phe Leu His Lys Phe Trp Phe Phe Ser Ala Ala Tyr Tyr Phe Gly Asn Trp Ala Phe Leu Gly Val Phe Leu Ile Gly Leu Ile Val Ser Cys Cys Lys Gly Lys Lys Ser Val Ile Glu Gly Val Asp Glu Asp Ser Asp Ile Ser Asp Asp Glu Pro Ser Val Tyr Ser Ala <210> 53 <211> 1987 <212> DNA
<213> Homo sapiens <400> 53 tgatggacgg agggctggaa cttgtggaaa aggctgggtg gacgcagcag ctacctgggg 60 accacccctc acacctccca ccccttcatc tgggttctgc tctccaaacc ccactgttgt 120 ctttacagac tgcggaggaa aaggaagccc cttcccaggc ccctgagggg gacgtgatct 180 cgatgcctcc cctccacaca tctgaggagg agctgggctt ctcgaagttt gtctcagcgt 240 agggcaggag gccctcctgg ccaggccagc agtgaagcag tatggctggc tggatcagca 300 ccgattcccg aaagctttcc acctcagcct cagagtccag ctgcccggac tccagggctc 360 tccccaccct ccccaggctc tcctcttgca tgttccagcc tgacctagaa gcgtttgtca 420 gccctggagc ccagagcggt ggccttgctc ttccggctgg agactgggac atccctgata 480 ggttcacatc cctgggcaga gtaccaggct gctgaccctc agcagggcca gacaaggctc 540 agtggatctg gtctgagttt caatctgcca ggaactcctg ggcctcatgc ccagtgtcgg 600 accctgcctt cctcccactc cagaccccac cttgtcttcc ctccctggcg tcctcagact 660 tagtcccacg gtctcctgca tcagctggtg atgaagagga gcatgctggg gtgagactgg 720 gattctggct tctctttgaa ccacctgcat cccagccctt caggaagcct gtgaaaaacg 780 tgattcctgg gccccaccaa gacccaccaa aaccatctct ggggcttggt gcaggactct 840 gaatttctaa caatgcccag tgactgtcgc acttgagttt gagggccagt gggcctgatg 900 aacgctcaga cccctccagc ttagagtctg catttgggct gtgacgtctc ccacctgccc 960 caataagatc tgctctgtct gcgacaccaa gatccagctg gggactcccc tgaggcctgc 1020 ctaagtccag gccttggtca ggtcaggtgc acattgcagg gataagccca ggaccggcag 1080 agagtggttg cctttccatt tgccctccct ggccatgcct tcttgccttt ggaaaaatga 1140 tgaagaaaac cttggctcct tccttgtctg gaaagggtta cttgcctatg ggttctggtg 1200 gctagagaga aaagtagaaa accagagtgc acgtaggtgt ctaacacaga ggagagtagg 1260 aacagggcgg atacctgaag gtgactccga gtccagcccc ctggagaagg ggtcgggggt 1320 ggtggtaaag tagcacaact actatttttt ttctttttcc attattattg ttttttaaga 1380 cagaatctcg tgctgctgcc caggctggag tgcagtggca cgatctgcaa actccgcctc 1440 ctgggttcaa gtgattcttc tgcctcagcc tcccgagtag ctgggattac aggcacgcac 1500 caccacacct ggctaatttt tgtactttta gtagagatgg ggtttcacca tgttggccag 1560 gctggtcttg aactcctgac ctcaaatgag cctcctgctt cagtctccca aattgccggg 1620 attacaggca tgagccactg tgtctggccc tatttccttt aaaaagtgaa attaagagtt 1680 gttcagtatg caaaacttgg aaagatggag gagaaaaaga aaaggaagaa aaaaatgtca 1740 cccatagtct caccagagac tatcattatt tcgttttgtt gtacttcctt ccactctttt 1800 cttcttcaca taatttgccg gtgttctttt tacagagcaa ttatcttgta tatacaactt 1860 tgtatcctgc cttttccacc ttatcgttcc atcactttat tccagcactt ctctgtgttt 1920 tacagacctt tttataaata aaatgttcat cagctgcata ttccaaaaaa aaaaaaaaaa 1980 aaaaaaa 1987 <210> 54 <211> 79 <212> PRT
<213> Homo sapiens <400> 54 Met Asp Gly Gly Leu Glu Leu Val Glu Lys Ala Gly Trp Thr Gln Gln Leu Pro Gly Asp His Pro Ser His Leu Pro Pro Leu His Leu Gly Ser Ala Leu Gln Thr Pro Leu Leu Ser Leu Gln Thr Ala Glu Glu Lys Glu Ala Pro Ser Gln Ala Pro Glu Gly Asp Val Ile Ser Met Pro Pro Leu His Thr Ser Glu Glu Glu Leu Gly Phe Ser Lys Phe Val Ser Ala <210> 55 <211> 1747 <212> DNA
<213> Homo sapiens <400> 55 gtgcggactg gcctcccaag cgtggggcga caagctgccg gagctgcaat gggccgcggc 60 tggggattct tgtttggcct cctgggcgcc gtgtggctgc tcagctcggg ccacggagag 120 gagcagcccc cggagacagc ggcacagagg tgcttctgcc aggttagtgg ttacttggat 180 gattgtacct gtgatgttga aaccattgat agatttaata actacaggct tttcccaaga 240 ctacaaaaac ttcttgaaag tgactacttt aggtattaca aggtaaacct gaagaggccg 300 tgtcctttct ggaatgacat cagccagtgt ggaagaaggg actgtgctgt caaaccatgt 360 caatctgatg aagttcctga tggaattaaa tctgcgagct acaagtattc tgaagaagcc 420 aataatctca ttgaagaatg tgaacaagct gaacgacttg gagcagtgga tgaatctctg 480 agtgaggaaa cacagaaggc tgttcttcag tggaccaagc atgatgattc ttcagataac 540 ttctgtgaag ctgatgacat tcagtcccct gaagctgaat atgtagattt gcttcttaat 600 cczgagcgct acactggtta caagggacca gatgcttgga aaatatggaa tgtcatctac 660 gaagaaaact gttttaagcc acagacaatt aaaagacctt taaatccttt ggcttctggt 720 caagggacaa gtgaagagaa cactttttac agttggctag aaggtctctg tgtagaaaaa 780 agagcattct acagacttat atctggccta catgcaagca ttaatgtgca tttgagtgca 840 agatatcttt tacaagagac ctggttagaa aagaaatggg gacacaacat tacagaattt 900 caacagcgat ttgatggaat tttgactgaa ggagaaggtc caagaaggct taagaacttg 960 tattttctct acttaataga actaagggct ttatccaaag tgttaccatt cttcgagcgc 1020 ccagattttc aactctttac tggaaataaa attcaggatg aggaaaacaa aatgttactt 1080 ctggaaatac ttcatgaaat caagtcattt cctttgcatt ttgatgagaa ttcatttttt 1140 gctggggata aaaaagaagc acacaaacta aaggaggact ttcgactgca ttttagaaat 1200 atttcaagaa ttatggattg tgttggttgt tttaaatgtc gtctgtgggg aaagcttcag 1260 actcagggtt tgggcactgc tctgaagatc ttattttctg agaaattgat agcaaatatg 1320 ccagaaagtg gacctagtta tgaattccat ctaaccagac aagaaatagt atcattattc 1380 aacgcatttg gaagaatttc tacaagtgtg aaagaattag aaaacttcag gaacttgtta 1440 cagaatattc attaaagaaa acaagctgat atgtgcctgt ttctggacaa tggaggcgaa 1500 agagtggaat ttcattcaaa ggcataatag caatgacagt cttaagccaa acattttata 1560 taaagttgct tttgtaaagg agaattatat tgttttaagt aaacacattt ttaaaaattg 1620 tgttaagtct atgtataata ctactgtgag taaaagtaat actttaataa tgtggtacaa 1680 attttaaagt ttaatattga ataaaaggag gattatcaaa ttcaaaaaaa aaaaaaaaaa 1740 aaaaaaa 1747 <210> 56 <211> 468 <212> PRT
<213> Homo sapiens <400> 56 Met Gly Arg Gly Trp Gly Phe Leu Phe Gly Leu Leu Gly Ala Val Trp Leu Leu Ser Ser Gly His Gly Glu Glu Gln Pro Pro Glu Thr Ala Ala Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys Asp Val Glu Thr Ile Asp Arg Phe Asn Asn Tyr Arg Leu Phe Pro Arg Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn Leu Lys Arg Pro Cys Pro Phe Trp Asn Asp Ile Ser Gln Cys Gly Arg Arg Asp Cys Ala Val Lys Pro Cys Gln Ser Asp Glu Val Pro Asp Gly Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Asn Leu Ile Glu Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu Ser Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser Ser Asp Asn Phe Cys Glu Ala Asp Asp Ile Gln Ser Pro Glu Ala Glu Tyr Val Asp Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly Pro Asp Ala Trp Lys Ile Trp Asn Val Ile Tyr Glu Glu Asn Cys Phe Lys Pro Gln Thr Ile Lys Arg Pro Leu Asn Pro Leu Ala Ser Gly Gln Gly Thr Ser Glu Glu Asn Thr Phe Tyr Ser Trp Leu Glu Gly Leu Cys Val Glu Lys Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn Val His Leu Ser Ala Arg Tyr Leu Leu Gln Glu Thr Trp Leu Glu Lys Lys Trp Gly His Asn Ile Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu Thr Glu Gly Glu Gly Pro Arg Arg Leu Lys Asn Leu Tyr Phe Leu Tyr Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu Arg Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Ile Gln Asp Glu Glu Asn Lys Met Leu Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Lys Glu Ala His Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe His Leu Thr Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr Ser Val Lys Glu Leu Glu Asn Phe Arg Asn Leu Leu Gln Asn Ile His <210> 57 <211> 1293 <212> DNA
<213> Homo sapiens <400> 57 ttcgaggctg tgccccgcga ccccgccttc ggcgctcggc tcgcaggatg gatcccgtac 60 ccgggacaga ctcggcgccg ctggctggcc tggcctggtc gtcggcctct gcacccccgc 120 cgcgggggtt cagcgcgatc tcctgcaccg tcgagggggc acccgccagc tttggcaaga 180 gcttcgcgca gaaatctggc tacttcctgt gccttagttc tctgggcagc ctagagaacc 240 cgcaggagaa cgtggtggcc gatatccaga tcgtggtgga caagagcccc ctgccgctgg 300 gcttctcccc cgtctgcgac cccatggatt ccaaggcctc tgtgtccaag aagaaacgca 360 tgtgtgtgaa gctgttgccc ctgggagcca cggacacggc tgtgtttgat gtccggctga 420 gtgggaagac caagacagtg cctggatacc ttcgaatagg ggacatgggc ggctttgcca 480 tctggtgcaa gaaggccaag gccccgaggc cagtgcccaa gccccgaggt ctcagccggg 540 acatgcaggg cctctctctg gatgcagcca gccagccaag taagggcggc ctcctggagc 600 ggacagcgtc aaggctgggc tctcgggcat ccactctgcg gaggaatgac tccatctacg 660 aggcctccag cctctatggc atctcagcca tggatggggt tcccttcaca ctccacccac 720 gatttgaggg caagagctgc agccccctgg ccttctctgc ttttggggac ctgaccatca 780 agtctctggc ggacattgag gaggagtata actacggctt cgtggtggag aagaccgcgg 840 ctgcccgcct gccccccagc gtctcatagt ccctcaccct tccgcggaaa gagccccctt 900 actccacctc cccgccagcc tggggccacc ccccctcact gcatcctggg gccaccccca 960 ctcactgcat cctgggaacc ttcgccctgc aaggcgtttg ctatcttcag ccactgggcg 1020 gagctgcagc cctggaggag ggggcgggtc gaggctgcgt ggtgatgggg tctccgcccc 1080 cacgccctgc cgggcagggc tggagctgga cagaagccag tgcctttaag tcatttgtgt 1140 caaaaccctc tggggtccgg aggctgtgcg ggtgtcctcc tggcaataaa cactacccgg 1200 ttctcgccca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1293 <210> 58 <211> 273 <212> PRT
<213> Homo Sapiens <400> 58 Met Asp Pro Val Pro Gly Thr Asp Ser Ala Pro Leu Ala Gly Leu Ala Trp Ser Ser Ala Ser Ala Pro Pro Pro Arg Gly Phe Ser Ala Ile Ser Cys Thr Val Glu Gly Ala Pro Ala Ser Phe Gly Lys Ser Phe Ala Gln Lys Ser Gly Tyr Phe Leu Cys Leu Ser Ser Leu Gly Ser Leu Glu Asn Pro Gln Glu Asn Val Val Ala Asp Ile Gln Ile Val Val Asp Lys Ser Pro Leu Pro Leu Gly Phe Ser Pro Val Cys Asp Pro Met Asp Ser Lys Ala Ser Val Ser Lys Lys Lys Arg Met Cys Val Lys Leu Leu Pro Leu Gly Ala Thr Asp Thr Ala Val Phe Asp Val Arg Leu Ser Gly Lys Thr Lys Thr Val Pro Gly Tyr Leu Arg Ile Gly Asp Met Gly Gly Phe Ala Ile Trp Cys Lys Lys Ala Lys Ala Pro Arg Pro Val Pro Lys Pro Arg Gly Leu Ser Arg Asp Met Gln Gly Leu Ser Leu Asp Ala Ala Ser Gln Pro Ser Lys Gly Gly Leu Leu Glu Arg Thr Ala Ser Arg Leu Gly Ser Arg Ala Ser Thr Leu Arg Arg Asn Asp Ser Ile Tyr Glu Ala Ser Ser Leu Tyr Gly Ile Ser Ala Met Asp Gly Val Pro Phe Thr Leu His Pro Arg Phe Glu Gly Lys Ser Cys Ser Pro Leu Ala Phe Ser Ala Phe Gly Asp Leu Thr Ile Lys Ser Leu Ala Asp Ile Glu Glu Glu Tyr Asn Tyr Gly Phe Val Val Glu Lys Thr Ala Ala Ala Arg Leu Pro Pro Ser Val Ser <210> 59 <211> 2941 <212> DNA
<213> Homo sapiens <400> 59 ggactcca'gt ttagccgccg ccggagagga cgggcgccga gccggggctg cggacttcgg 60 cctgcccctc acctcactcc cgctgcttgc acctcccgga tggtgctgac tgctccctaa 120 gcggcggcgg cggcgagtcg tgaggacgcg ccgcggaggc tgttcggggt cgaggcttcc 180 cgtcgccggc acttcctctt gcggcgcccg tgcgcggccg gcccggcagg cgggatggcg 240 gccgcggctc cggggaacgg ccgcgcatcg gcgccccggc tgcttctgct ctttctggtt 300 ccgctgctgt gggccccggc tgcggtccgg gccggcccag atgaagacct tagccaccgg 360 aacaaagaac cgccggcgcc ggcccagcag ctgcagccgc agcctgtggc tgtgcagggc 420 cccgagccgg cccgggtcga ggtgagcggg ccgggatggg gcgagcgagg ctgcagggcc 480 ggctgcgccg agtaccaggc tccaggcctt tgaaagcgcc gcactccgcc ggcctcggct 540 gggggagggg agcccggccc ctgctcccgg ggtggagggc ggtcggctgc gctgttttcc 600 ggtgaggcct ggtcttgcgc gctcctttag ggaaagggag agggagagtc caagaggagc 660 ccgctataaa cgttgatctc cggagggcca agatgctgct ccgggatggg cgttttattg 720 atcagatgtg tcttagagta gctagaaaga ctcatcccta ccaaaaagtt tttaacagaa 780 ggctgctagg aggctttttg tattccctga ggatcatcac atcggccatt tcattgttga 840 aatagcttat gccaaactgc ttacccaaat tcaacttggc actgcctgtg ctttttgcca 900 aatatggatt atgaaccatg actctcactt tttaaaaatg tgctttggct agcaggaagt 960 agcctttagg aacgcagagg aattagtctc cggcagtaca gcgtgctgca gcgatgtggg 1020 atgccaaaac tacatttata agtaaaacag aatcctgtat tttgtccttc cctgaataga 1080 tactagaaat caacttttta atctgttaat agaattagtc cttagtcact tggcagcgtt 1140 ttaacatttc tcccttctcc cagtcgtggg ctttgtcgtc atttccagta tctgctccct 1200 gaatcccggc cagtgtggca ctcaaacccc cactcccacc caggccacat ccagcccatc 1260 tccacgtaac taatcttccc gaacattgaa ttctgccatc ttgtcagaag tcgtcggtga 1320 gttgcctcca ctaatttcag tccagccttt ttaggagagt gatgttcagg tttcttctga 1380 tctggctcca gctcacctcc aggcttttta gccaccgctt tcttgctcat atgctaaagg 1440 gttatgctca tctgcaaaaa agaatgtgct tcaagagccc tttgggacag gctttgtgct 1500 ctcttgccag ttcctcccta acacaagacc ttttcaaaga aaaaaaaaaa aagacctgga 1560 gtttgaagcc acggatcaac tcttcccacc ttggagaacc agcagatacc tactctctgt 1620 gaagacttcc ctaaaatttc ttggttaagg gtgatttatc tgaccctttc ctttcctttc 1680 ctttcctctc ctttctcctt tttcctttcc tctcctttct cctttttcct ttccattcct 1740 ttcatttctc ctttcctttc ctttttcctt tcctttctcc cttcctttcc tttttccttt 1800 ttctttgttg agacagggtc tcgctctgtc gcccaggctg gagtgcagtg gccccgtctt 1860 ggctcactgc aacctctaat tgatcctccc acctcagcct cctgagtggc tgggactgca 1920 tgcgtgtgct gacacgcccg gctaattttt gtttattttt tttttttgag agaggaggtc 1980 tcactatgtt gccgagtcta gtctcaaact cctgggctca agcgcttctc cggccttggc 2040 ctcccaagtg ctggtgagct ctcacaccgg tgcattgttt tcgtgtttca tgttttcgtt 2100 acatgttact ttcttaggct tttccaattt tctgttgttt ttctgtgtaa gaccgtagga 2160 tagaactttc tgagagactg atcttggttt cactaagcaa gaacatttgt aagaatcagt 2220 gctgtcccag atgtagtaat cgctattgag aaataatgaa gttcccctta ctggaagtac 2280 tcaggaagaa gttgaataac taactgccta tgaggagatt ctgatatggg agggaatctg 2340 ggagataaag ttactgggaa gtgaagattc tgggagccga tttaatcctc acaacagcac 2400 gttaaacagg tagaggaggt ttgtaaggaa tagtggttta atatcacaga gctagaagct 2460 agtttcagca gaaccagaat tagaatctgg acttctgtgc cttactaagt tttattagca 2520 ttcattgtgt cttactcttt tgacttattt aattcactaa tggattttaa tggtttattg 2580 gattgtatgc tggtgcagtt ctttgatctt gagcctagct ttctctttct ccttttttgg 2640 gaactttatt gtgtatgttg tggcatgttt acacacacat cttgctgcct tgggttcttg 2700 caagttgtgt gcgtgtttta tctgccccta ctagctttta ggtgtcttga gagcatgact 2760 ctggcttact catctgtcta ttccagaaga ccttgtctgt tcttggcatt tattaagtaa 2820 ttttctaaga ctgggttgaa gtagttgcat gtcaagttta tatcagctgt taaatacctt 2880 tctggaaaaa ctggctgtaa aataaactca accaggaaaa aaaaaaaaaa aaaaaaaaaa 2940 a <210> 60 <211> 92 <212> PRT
<213> Homo Sapiens.....
<400> 60 Met Ala Ala Ala Ala Pro Gly Asn Gly Arg Ala Ser Ala Pro Arg Leu Leu Leu Leu Phe Leu Val Pro Leu Leu Trp Ala Pro Ala Ala Val Arg Ala Gly Pro Asp Glu Asp Leu Ser His Arg Asn Lys Glu Pro Pro Ala Pro Ala Gln Gln Leu Gln Pro Gln Pro Val Ala Val Gln Gly Pro Glu Pro Ala Arg Val Glu Val Ser Gly Pro Gly Trp Gly Glu Arg Gly Cys Arg Ala Gly Cys Ala Glu Tyr Gln Ala Pro Gly Leu <210> 61 <211> 1996 <212> DNA
<213> Homo Sapiens <400> 61 actagattag tccagtgtaa gaggtagaca attcatgttg aattttctgg aattactgca 60 ggggagacct tgattcctag gagggaacta aagggatcat caaagctaag ggtggagcca 120 agcaagtggg gagaccataa gtgaaaaggg gagagtttgg agcctgatcc taccctatgc 180 tgatgtctct tcttatgtct atttcaccag gagactctct gggggccagg cctgggcttc 240 cctatgggct gagcgacgat gagtctgggg gcggccgggc actaagtgcg gagagtgaag 300 ttgaggagcc agccaggggt ccaggggagg ccaggggtga gaggccaggc ccagcctgcc 360 agctgtgtgg ggggccgaca ggtgaggggc cgtgttgtgg ggcaggaggg ccgggtgggg 420 ggcccctgct gcccccacgg ctactgtact catgccgcct ctgcaccttc gtgtcccact 480 actcgagcca cctgaagcgg cacatgcaga cacacagcgg agagaagccg ttccgctgtg 540 gccgctgccc ctacgcctca gcccagctcg tcaacctgac acgacatacc cgcacccaca 600 ctggcgagaa gccctaccgc tgtccccact gcccctttgc ctgcagcagc ctgggcaacc 660 tgaggcggca tcagcgtacc cacgcagggc cccccactcc tccctgcccg acctgtggct 720 tccgctgctg tactccacga ccagcccggc ctcccagtcc cacagagcag gagggggcgg 780 tgccccggcg acctgaagat gctctgctcc ttccagattt gagcctccat gtgccaccag 840 gtggtgccag tttcctgcca gactgtgggc agctgcgggg tgaaggggag ggcctctgcg 900 ggactggatc agaaccactg ccagagctgc tattcccttg gacctgccgg ggctgtggac 960 aagagctgga ggagggtgag ggtagtcggc tgggagctgc catgtgtggg cgctgcatgc 1020 gaggagaggc tggagggggt gccagtgggg ggccccaggg ccccagtgac aaaggctttg 1080 cctgtagcct ctgccccttt gccactcact atcccaacca cctggcccgg cacatgaaga 1140 cacacagtgg tgagaagccc ttccgctgcg cccgctgtcc ttatgcctct gctcatctgg 1200 ataacctgaa acggcaccag cgcgtccata caggagagaa gccctacaag tgccccctct 1260 gcccttatgc ctgtggcaat ctggccaacc tcaagcgtca tggtcgcatc cactctggtg 1320 acaaaccttt tcggtgtagc ctttgcaact acagctgcaa ccagagcatg aacctcaaac 1380 gtcacatgct gcggcacaca ggcgagaagc ccttccgctg tgccacctgc gcctatacca 1440 cgggccactg ggacaactac aagcgccacc agaaggtgca tggccacggt ggggcaggag 1500 ggcctggtct ctctgcctct gagggctggg ccccacctca tagcccaccc tctgttttga 1560 gctctcgggg cccaccagcc ctggggactg ctggcagccg ggctgtccac acagactcat 1620 cctgaactag gtccttcttc cccatgtttt atacagacgg accagaagcc acctttttct 1680 cccccgctgg ccaggggctc cacacagact aacgtaggca ctataaggac cagcccaacc 1740 ccatgggcgg gggggcccat atggaccagg ggaccttgcc ttgactgagg cacttcacga 1800 gctcagtgag aagggccctg tattcacctc cactgccccc aggggctgtg gacaaaccgg 1860 ctgggggact gcccagcctc ccacctgttt atttaactta tttcaagtgc tttataataa 1920 aggaaacact aacaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980 aaaaaaaaaa aaaaaa 1996 <210> 62 <211> 482 <212> PRT
<213> Homo Sapiens <400> 62 Met Leu Met Ser Leu Leu Met Ser Ile Ser Pro Gly Asp Ser Leu Gly Ala Arg Pro Gly Leu Pro Tyr Gly Leu Ser Asp Asp Glu Ser Gly Gly 20 25~ 30 Gly Arg Ala Leu Ser Ala Glu Ser Glu Val Glu Glu Pro Ala Arg Gly Pro Gly Glu Ala Arg Gly Glu Arg Pro Gly Pro Ala Cys Gln Leu Cys Gly Gly Pro Thr Gly Glu Gly Pro Cys Cys Gly Ala Gly Gly Pro Gly Gly Gly Pro Leu Leu Pro Pro Arg Leu Leu Tyr Ser Cys Arg Leu Cys Thr Phe Val Ser His Tyr Ser Ser His Leu Lys Arg His Met Gln Thr His Ser Gly Glu Lys Pro Phe Arg Cys Gly Arg Cys Pro Tyr Ala Ser Ala Gln Leu Val Asn Leu Thr Arg His Thr Arg Thr His Thr Gly Glu Lys Pro Tyr Arg Cys Pro His Cys Pro Phe Ala Cys Ser Ser Leu Gly Asn Leu Arg Arg His Gln Arg Thr His Ala Gly Pro Pro Thr Pro Pro Cys Pro Thr Cys Gly Phe Arg Cys Cys Thr Pro Arg Pro Ala Arg Pro Pro Ser Pro Thr Glu Gln Glu Gly Ala Val Pro Arg Arg Pro Glu Asp Ala Leu Leu Leu Pro Asp Leu Ser Leu His Val Pro Pro Gly Gly Ala Ser Phe Leu Pro Asp Cys Gly Gln Leu Arg Gly Glu Gly Glu Gly Leu Cys Gly Thr Gly Ser Glu Pro Leu Pro Glu Leu Leu Phe Pro Trp Thr Cys Arg Gly Cys Gly Gln Glu Leu Glu Glu Gly Glu Gly Ser Arg Leu Gly Ala Ala Met Cys Gly Arg Cys Met Arg Gly Glu Ala Gly Gly Gly Ala Ser Gly Gly Pro Gln Gly Pro Ser Asp Lys Gly Phe Ala Cys Ser Leu Cys Pro Phe Ala Thr His Tyr Pro Asn His Leu Ala Arg His Met Lys Thr His Ser Gly Glu Lys Pro Phe Arg Cys Ala Arg Cys Pro Tyr Ala Ser Ala His Leu Asp Asn Leu Lys Arg His Gln Arg Val His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Leu Cys Pro Tyr Ala Cys Gly Asn Leu Ala Asn Leu Lys Arg His Gly Arg Ile His Ser Gly Asp Lys Pro Phe Arg Cys Ser Leu Cys Asn Tyr Ser Cys Asn Gln Ser Met Asn Leu Lys Arg His Met Leu Arg His Thr Gly Glu Lys Pro Phe Arg Cys Ala Thr Cys Ala Tyr Thr Thr Gly His Trp Asp Asn Tyr Lys Arg His Gln Lys Val His Gly His Gly Gly Ala Gly Gly Pro Gly Leu Ser Ala Ser Glu Gly Trp Ala Pro Pro His Ser Pro Pro Ser Val Leu Ser Ser Arg Gly Pro Pro Ala Leu Gly Thr Ala Gly Ser Arg Ala Val His Thr Asp Ser Ser <210> 63 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> oligonucleotide <400> 63 tctttttcca aggggtagag a <210> 64 <211> 21 <212> DNA
<213> Artificial Sequence <220>

<223> oligonucleotide <400> 64 cgcagcaaaa cacagtagtg a 21 <210> 65 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 65 tataccaggt gtgccagctg <210> 66 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 66 ccaagcttcc cgtgtagtgt 20 <210> 67 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 67 agagagggtg tcctgagggt <210> 68 <211> 20 <212> DNA

<213> Artificial Sequence <220>
<223> oligonucleotide <400> 68 tctcagctcc atctcagggt 20 <210> 69 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> oligonucleotide <400> 69 ttggtaagga gagtagcatt g <210> 70 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 70 tcaagtgatc ctcccacctc 20 <210> 71 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 71 agaaaccaca aggcccatct 20 <210> 72 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 72 aaaggagcag tttggcttcc <210> 73 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 73 atgctttcca tccactcacc 20 <210> 74 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 74 tctcgcttgg aaagaatcct <210> 75 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 75 tttggacttg gcccactaag <210> 76 <211> 21 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 76 aagtctgcaa attttatgcg c 21 <210> 77 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 77 gctgcctcaa gtttcagacc <210> 78 <211> 21 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 78 tgcagttaat gaaaaccctc c 21 <210> 79 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 79 tgatatgacc agagccacca 20 <210> 80 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 80 agatgccttc ttcccaggat 20 <210> 81 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 81 gatctgcatg aggtggaaga 20 <210> 82 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 82 aaaggaggag ggtctggaga <210> 83 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 83 aagcactgga aaggagacga 20 <210> 84 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 84 ggggtaatct agaagcccca 20 <210> 85 <211> 20 <212> DNA

<213> Artificial Sequence <220>

<223> oligonucleotide <400> 85 gctcgccttc tgtcaaaatc 20 <210> 86 <211> 21 <212> DNA

<213> Artificial Sequence <220>
<223> oligonucleotide <400> 86 caactttgaa tcctgccatt t 21 <210> 87 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> oligonucleotide <400> 87 gctctggcct ctctacatgg <210> 88 <211> 128 <212> PRT
<213> Homo Sapiens <400> 88 Met Thr Ser Arg Arg Ser Ser Thr Leu Ser Met Thr Ser Ser Leu Leu Ser Leu Gly Cys Ala Leu Thr Ser Ala Phe Pro Ala Ser Thr Met Ser Trp Val Pro Leu Leu Gln Met Leu Asp Gln Ser Pro Arg Arg Val Met Arg Lys Ser Val Ser Gln Leu Cys Pro Leu Leu Arg Pro His Pro Pro Leu Ser Ser Lys His Pro Leu Val Leu Pro Leu Gln Leu Pro Pro Thr Phe Leu His Leu Leu Pro Gly Pro Gly Cys Pro Gly Gln Thr Val Ala Tyr Trp Val Arg Thr Pro Pro Val Trp Cys Trp Arg Ile Leu Arg Arg Cys Gln Asp Gln Asn Arg Leu Trp Ile Ile Gly Val Met Gly Ser Thr <210> 89 <211> 77 <212> PRT
<213> Homo Sapiens <400> 89 Met Thr Leu Arg Pro Ser Leu Leu Pro Leu His Leu Leu Leu Leu Leu Leu Leu Ser Ala Ala Val Cys Arg Ala Glu Ala Gly Leu Glu Thr Glu Ser Pro Val Arg Thr Leu Gln Val Glu Thr Leu Val Glu Pro Pro Glu Pro Cys Ala Glu Pro Ala Ala Phe Gly Asp Thr Leu His Ile His Tyr Thr Gly Ser Leu Val Met Asp Val Leu Leu Thr Pro Pro <210> 90 <211> 152 <212> PRT
<213> Homo Sapiens <400> 90 Met Cys Arg Ala Arg Cys Phe Trp Arg His Ala Ser His Thr Leu His Gly Lys Leu Gly Asn Gly Arg Ile Ile Asp Thr Ser Leu Thr Arg Asp Pro Leu Val Ile Glu Leu Gly Gln Lys Gln Val Ile Pro Gly Leu Glu Gln Ser Leu Leu Asp Met Cys Val Gly Glu Lys Arg Arg Ala Ile Ile Pro Ser His Leu Ala Tyr Gly Lys Arg Gly Phe Pro Pro Ser Val Pro Ala Asp Ala Val Val Gln Tyr Asp Val Glu Leu Ile Ala Leu Ile Arg Ala Asn Tyr Trp Leu Lys Leu Val Lys Gly Ile Leu Pro Leu Val Gly Met Ala Met Val Pro Ala Leu Leu Gly Leu Ile Gly Tyr His Leu Tyr Arg Lys Ala Asn Arg Pro Lys Val Ser Lys Lys Lys Leu Lys Glu Glu Lys Arg Asn Lys Ser Lys Lys Lys <210> 91 <211> 398 <212> PRT
<213> Homo Sapiens <400> 91 Met Glu Asn Ile Glu Leu Gly Leu Ser Glu Ala Gln Val Met Leu Ala Leu Ala Ser His Leu Ser Thr Val Glu Ser Glu Lys Gln Lys Leu Arg Ala Gln Val Arg Arg Leu Cys Gln Glu Asn Gln Trp Leu Arg Asp Glu Leu Ala Gly Thr Gln Gln Arg Leu Gln Arg Ser Glu Gln Ala Val Ala Gln Leu Glu Glu Glu Lys Lys His Leu Glu Phe Leu Gly Gln Leu Arg Gln Tyr Asp Glu Asp Gly His Thr Ser Glu Glu Lys Glu Gly Asp Ala Thr Lys Asp Ser Leu Asp Asp Leu Phe Pro Asn Glu Glu Glu Glu Asp Pro Ser Asn Gly Leu Ser Arg Gly Gln Gly Ala Thr Ala Ala Gln Gln Gly Gly Tyr Glu Ile Pro Ala Arg Leu Arg Thr Leu His Asn Leu Val Ile Gln Tyr Ala Ala Gln Gly Arg Tyr Glu Val Ala Val Pro Leu Cys Lys Gln Ala Leu Glu Asp Leu Glu Arg Thr Ser Gly Arg Gly His Pro Asp Val Ala Thr Met Leu Asn Ile Leu Ala Leu Val Tyr Arg Asp Gln Asn Lys Tyr Lys Glu Ala Ala His Leu Leu Asn Asp Ala Leu Ser Ile Arg Glu Ser Thr Leu Gly Pro Asp His Pro Ala Val Ala Ala Thr Leu Asn Asn Leu Ala Val Leu Tyr Gly Lys Arg Gly Lys Tyr Lys Glu Ala Glu Pro Leu Cys Gln Arg Ala Leu Glu Ile Arg Glu Lys Val Leu Gly Thr Asn His Pro Asp Val Ala Lys Gln Leu Asn Asn Leu Ala Leu Leu Cys Gln Asn Gln Gly Lys Tyr Glu Ala Val Glu Arg Tyr Tyr Gln Arg Ala Leu Ala Ile Tyr Glu Gly Gln Leu Gly Pro Asp Asn Pro Asn Val Ala Arg Thr Lys Asn Asn Leu Ala Ser Cys Tyr Leu Lys Gln Gly Lys Tyr Ala Glu Ala Glu Thr Leu Tyr Lys Glu Ile Leu Thr Arg Ala His Val Gln Glu Phe Gly Ser Val Asp Asp Asp His Lys Pro Ile Trp Met His Ala Glu Glu Arg Glu Glu Met Ser Lys Ser Arg His His Glu Gly Gly Thr Pro Tyr Ala Glu Tyr Gly Ala Trp Val Pro Pro Pro Pro Gln Pro Ser Gln His Ser Pro Leu Leu Leu Ala Leu Pro His Pro <210> 92 <211> 785 <212> PRT
<213> Homo sapiens <400> 92 Met Ala Pro Ser Ala Trp Ala Ile Cys Trp Leu Leu Gly Gly Leu Leu Leu His Gly Gly Ser Ser Gly Pro Ser Pro Gly Pro Ser Val Pro Arg Leu Arg Leu Ser Tyr Arg Asp Leu Leu Ser Ala Asn Arg Ser Ala Ile Phe Leu Gly Pro Gln Gly Ser Leu Asn Leu Gln Ala Met Tyr Leu Asp Glu Tyr Arg Asp Arg Leu Phe Leu Gly Gly Leu Asp Ala Leu Tyr Ser Leu Arg Leu Asp Gln Ala Trp Pro Asp Pro Arg Glu Val Leu Trp Pro Pro Gln Pro Gly Gln Arg Glu Glu Cys Val Arg Lys Gly Arg Asp Pro Leu Thr Glu Cys Ala Asn Phe Val Arg Val Leu Gln Pro His Asn Arg Thr His Leu Leu Ala Cys Gly Thr Gly Ala Phe Gln Pro Thr Cys Ala Leu Ile Thr Val Gly His Arg Gly Glu His Val Leu His Leu Glu Pro Gly Ser Val Glu Ser Gly Arg Gly Arg Cys Pro His Glu Pro Ser Arg Pro Phe Ala Ser Thr Phe Ile Asp Gly Glu Leu Tyr Thr Gly Leu Thr Ala Asp Phe Leu Gly Arg Glu Ala Met Ile Phe Met Ile Phe Arg Ser Gly Gly Pro Arg Pro Ala Leu Arg Ser Asp Ser Asp Gln Ser Leu Leu His Asp Pro Arg Phe Val Met Ala Ala Arg Ile Pro Glu Asn Ser Asp Gln Asp Asn Asp Lys Val Tyr Phe Phe Phe Ser Glu Thr Val Pro Ser Pro Asp Gly Gly Ser Asn His Val Thr Val Ser Arg Val Gly Arg Val Cys Val Asn Asp Ala Gly Gly Gln Arg Val Leu Val Asn Lys Trp Ser Thr Phe Leu Lys Ala Arg Leu Val Cys Ser Val Pro Gly Pro Gly Gly Ala Glu Thr His Phe Asp Gln Leu Glu Asp Val Phe Leu Leu Trp Pro Lys Ala Gly Lys Ser Leu Glu Val Tyr Ala Leu Phe Ser Thr Val Ser Ala Val Phe Gln Gly Phe Ala Val Cys Val Tyr His Met Ala Asp Ile Trp Glu Val Phe Asn Gly Pro Phe Ala His Arg Asp Gly Pro Gln His Gln Trp Gly Pro Tyr Gly Gly Lys Val Pro Phe Pro Arg Pro Gly Val Cys Pro Ser Lys Met Thr Ala Gln Pro Gly Arg Pro Phe Gly Ser Thr Lys Asp Tyr Pro Asp Glu Val Leu Gln Phe Ala Arg Ala His Pro Leu Met Phe Trp Pro Val Arg Pro Arg His Gly Arg Pro Val Leu Val Lys Thr His Leu Ala Gln Gln Leu His Gln Ile Val Val Asp Arg Val Glu Ala Glu Asp Gly Thr Tyr Asp Val Ile Phe Leu Gly Thr Asp Ser Gly Ser Val Leu Lys Val Ile Ala Leu Gln Ala Gly Gly Ser Ala Glu Pro Glu Glu Val Val Leu Glu Glu Leu Gln Val Phe Lys Val Pro Thr Pro Ile Thr Glu Met Glu Ile Ser Val Lys Arg Gln Met Leu Tyr Val Gly Ser Arg Leu Gly Val Ala Gln Leu Arg Leu His Gln Cys Glu Thr Tyr Gly Thr Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp Pro Tyr Cys Ala Trp Asp Gly Ala Ser Cys Thr His Tyr Arg Pro Ser Leu Gly Lys Arg Arg Phe Arg Arg Gln Asp Ile Arg His Gly Asn Pro Ala Leu Gln Cys Leu Gly Gln Ser Gln Glu Glu Glu Ala Val Gly Leu Val Ala Ala Thr Met Val Tyr Gly Thr Glu His Asn Ser Thr Phe Leu Glu Cys Leu Pro Lys Ser Pro Gln Ala Ala Val Arg Trp Leu Leu Gln Arg Pro Gly Asp Glu Gly Pro Asp Gln Val Lys Thr Asp Glu Arg Val Leu His Thr Glu Arg Gly Leu Leu Phe Arg Arg Leu Ser Arg Phe Asp Ala Gly Thr Tyr Thr Cys Thr Thr Leu Glu His Gly Phe Ser Gln Thr Val Val Arg Leu Ala Leu Val Val Ile Val Ala Ser Gln Leu Asp Asn Leu Phe Pro Pro Glu Pro Lys Pro Glu Glu Pro Pro Ala Arg Gly Gly Leu Ala Ser Thr Pro Pro Lys Ala Trp Tyr Lys Asp Ile Leu Gln Leu Ile Gly Phe Ala Asn Leu Pro Arg Val Asp Glu Tyr Cys Glu Arg Val Trp Cys Arg Gly Thr Thr Glu Cys Ser Gly Cys Phe Arg Ser Arg Ser Arg Gly Lys Gln 740 745 ~ 750 Ala Arg Gly Lys Ser Trp Ala Gly Leu Glu Leu Gly Lys Lys Met Lys Ser Arg Val His Ala Glu His Asn Arg Thr Pro Arg Glu Val Glu Ala Thr <210> 93 <211> 277 <212> PRT
<213> Homo Sapiens <400> 93 Met Glu Lys Phe Lys Ala Ala Met Leu Leu Gly Ser Val Gly Asp Ala Leu Gly Tyr Arg Asn Val Cys Lys Glu Asn Ser Thr Val Gly Met Lys Ile Gln Glu Glu Leu Gln Arg Ser Gly Gly Leu Asp His Leu Val Leu Ser Pro Gly Glu Trp Pro Val Ser Asp Asn Thr Ile Met His Ile Ala Thr Ala Glu Ala Leu Thr Thr Asp Tyr Trp Cys Leu Asp Asp Leu Tyr Arg Glu Met Val Arg Cys Tyr Val Glu Ile Val Glu Lys Leu Pro Glu Arg Arg Pro Asp Pro Ala Thr Ile Glu Gly Cys Ala Gln Leu Lys Pro Asn Asn Tyr Leu Leu Ala Trp His Thr Pro Phe Asn Glu Lys Gly Ser Gly Phe Gly Ala Ala Thr Lys Ala Met Cys Ile Gly Leu Arg Tyr Trp Lys Pro Glu Arg Leu Glu Thr Leu Ile Glu Val Ser Val Glu Cys Gly Arg Met Thr His Asn His Pro Thr Gly Phe Leu Gly Ser Leu Cys Thr Ala Leu Phe Val Ser Phe Ala Ala Gln Gly Lys Pro Leu Val Gln Trp Gly Arg Asp Met Leu Arg Ala Val Pro Leu Ala Glu Glu Tyr Cys Arg Lys Thr Ile Arg His Thr Ala Glu Tyr Gln Glu His Trp Phe Tyr Leu Lys Leu Asn Gly Asn Phe Ile Trp Arg Arg Gly Lys Ser Val Lys Thr Gln Lys Ile Lys Pro Ser Ser Pro Thr Ile Met Met Gln Lys Arg Gly Lys Arg Pro Thr Gly Ser Gly Ala Arg Lys Val Glu Gly Glu Asp Glu Ala Thr Met Pro Pro <210> 94 <211> 54 <212> PRT
<213> Homo sapiens <400> 94 Met Leu Leu Tyr Ile Ala Ala Val Pro Val Met Cys Ser Cys Gln Asn Ile Phe Gly Phe Lys Leu Ser Tyr Cys Leu Trp Leu Leu Ile Ser Thr Val Gln Val Arg Phe Gln Lys Asp Leu Glu Ser Asn Ile Phe Asn Gln Leu Lys Cys Leu Ser Val <210> 95 <211> 128 <212> PRT
<213> Homo Sapiens <400> 95 Met Lys Lys Asp His Ile Ser Phe Gly Asn Leu Pro Gln Thr Ile Met Thr Leu Gly Leu Gly Cys Ile Leu Asn Gly Gln Thr Leu Gln Thr Leu Leu Ser Ala Cys Met Ser Val Ser Pro Ala Met Thr Thr Arg Arg Lys Lys Lys Thr Ser Val Val Lys Arg Lys Pro Lys Arg Met Pro Thr Ser Leu Cys Trp Met Arg Leu Cys Leu Cys Thr Asp Gly Thr Val Met Arg Arg Cys Met Leu Ala Ala Ile Asn Ile Gln Gly Glu Glu Ser Ile Ser Ser Ser Leu Thr Thr Pro Thr Leu Cys Gly Gly Gln Asn Gln Ser Thr Thr Glu Ser Ile Ile Leu Asp Lys Asn Val Val Thr Lys Ser Gly Val <210> 96 <211> 227 <212> PRT
<213> Homo Sapiens <400> 96 Met Val Thr Val Ile Leu Leu Pro Tyr Val Ser Lys Val Thr Gly Trp Cys Arg Asp Arg Leu Leu Gly His Arg Glu Pro Ser Ala His Pro Val Glu Val Phe Ser Phe Asp Leu His Glu Pro Leu Ser Lys Glu Arg Val Glu Ala Phe Ser Asp Gly Val Tyr Ala Ile Val Ala Thr Leu Leu Ile Leu Asp Ile Cys Glu Asp Asn Val Pro Asp Pro Lys Asp Val Lys Glu Arg Phe Ser Gly Ser Leu Val Ala Ala Leu Ser Ala Thr Gly Pro Arg Phe Leu Ala Tyr Phe Gly Ser Phe Ala Thr Val Gly Leu Leu Trp Phe Ala His His Ser Leu Phe Leu His Val Arg Lys Ala Thr Arg Ala Met Gly Leu Leu Asn Thr Leu Ser Leu Ala Phe Val Gly Gly Leu Pro Leu Ala Tyr Gln Gln Thr Ser Ala Phe Ala Arg Gln Pro Arg Asp Glu Leu Glu Arg Val Arg Val Ser Cys Thr Ile Ile Phe Leu Ala Ser Ile Phe Gln Leu Ala Thr Trp Thr Thr Ala Leu Leu His Gln Ala Glu Thr Leu Gln Pro Ser Val Trp Phe Gly Gly Arg Glu His Val Leu Met Phe Arg Gln Gly Trp Arg Cys Thr Pro Val Pro Ala Cys Trp Pro Ser Pro Pro Pro Ala Cys <210> 97 <211> 112 <212> PRT
<213> Homo sapiens <400> 97 Met Leu Glu Leu Arg Arg Leu Leu Ser Leu Arg Glu Pro Pro Leu Ser Pro Lys Ile Cys Ser Val Pro Leu Ile Leu Leu Pro Gly Pro Trp Arg Leu Gly Gln Ala Ala Pro His Thr Ser Thr Pro His Pro Leu Leu Pro Gly Ser Ser Cys Gly Leu Pro Ser Thr Val Arg Arg Leu Trp Asp Arg Thr Glu Ser Leu Ala Ala Cys Gly Ala Pro Val Pro Ala Ala Ala Pro Arg Leu Arg Ser Gly Tyr Pro His Pro Arg His Arg Arg Pro Pro Ala Pro Pro Thr Ala Ala His Ala Arg Arg Val His Ala Ala Pro Ala Pro <210> 98 <211> 132 <212> PRT
<213> Homo sapiens <400> 98 Met Gln Val Ile His Gly Pro His Val Glu Lys Leu Gln Ser Pro Leu Gly Pro His Arg Pro Ser Pro Arg Cys Pro Leu Ser Val Val Thr Gly Pro Asp Leu Gln Glu Cys Thr Phe His Ser Thr Arg Lys Pro Tyr Asp Ile Leu Arg Leu Pro Arg Pro Ala Ala Cys Met Gly Pro Leu Pro Ser Ser Thr Pro Thr Leu Arg Met Val Pro Cys Ser Ala Leu Val Leu Cys Trp Pro Leu Pro Ala Thr Pro Thr Leu Arg His Pro Gly Val Val Gly Pro Asn Trp Leu Ala Pro Pro Ser Ala Ala Leu Cys Arg Pro Asp Ala Ala Val Trp Pro Asp Leu Pro Ser Ser Asn Ile Leu Leu Val Thr Pro Pro Pro Ala Lys <210> 99 <211> 421 <212> PRT
<213> Homo Sapiens <400> 99 Met Gly Ser Gln Glu Val Leu Gly His Ala Ala Arg Leu Ala Ser Ser Gly Leu Leu Leu Gln Val Leu Phe Arg Leu Ile Thr Phe Val Leu Asn Ala Phe Ile Leu Arg Phe Leu Ser Lys Glu Ile Val Gly Val Val Asn Val Arg Leu Thr Leu Leu Tyr Ser Thr Thr Leu Phe Leu Ala Arg Glu Ala Phe Arg Arg Ala Cys Leu Ser Gly Gly Thr Gln Arg Asp Trp Ser Gln Thr Leu Asn Leu Leu Trp Leu Thr Val Pro Leu Gly Val Phe Trp Ser Leu Phe Leu Gly Trp Ile Trp Leu Gln Leu Leu Glu Val Pro Asp Pro Asn Val Val Pro His Tyr Ala Thr Gly Val Val Leu Phe Gly Leu Ser Ala Val Val Glu Leu Leu Gly Glu Pro Phe Trp Val Leu Ala Gln Ala His Met Phe Val Lys Leu Lys Val Ile Ala Glu Ser Leu Ser Val Ile Leu Lys Ser Val Leu Thr Ala Phe Leu Val Leu Trp Leu Pro His Trp Gly Leu Tyr Ile Phe Ser Leu Ala Gln Leu Phe Tyr Thr Thr Val Leu Val Leu Cys Tyr Val Ile Tyr Phe Thr Lys Leu Leu Gly Ser Pro Glu Ser Thr Lys Leu Gln Thr Leu Pro Val Ser Arg Ile Thr Asp Leu Leu Pro Asn Ile Thr Arg Asn Gly Ala Phe Ile Asn Trp Lys Glu Ala Lys Leu Thr Trp Ser Phe Phe Lys Gln Ser Phe Leu Lys Gln Ile Leu Thr Glu Gly Glu Arg Tyr Val Met Thr Phe Leu Asn Val Leu Asn Phe Gly Asp Gln Gly Val Tyr Asp Ile Val Asn Asn Leu Gly Ser Leu Val Ala Arg Leu Ile Phe Gln Pro Ile Glu Glu Ser Phe Tyr Ile Phe Phe 290 295 ' 300 Ala Lys Val Leu Glu Arg Gly Lys Asp Ala Thr Leu Gln Lys Gln Glu Asp Val Ala Val Ala Ala Ala Val Leu Glu Ser Leu Leu Lys Leu Ala Leu Leu Ala Gly Leu Thr Ile Thr Phe Trp Leu Cys Leu Phe Ser Ala Gly Ser Gly Tyr Leu Arg Arg Thr Met Leu Ser Ser Asp Pro Val Phe Leu Cys Cys Glu Gln Ala Gly Gln Pro Asp Trp Ala His Ile Ala Val Gly Ala Phe Cys Leu Gly Ala Thr Leu Gly Thr Ala Phe Leu Thr Glu Thr Lys Leu Ile His Phe Leu Arg Thr Gln Leu Gly Val Pro Arg Arg Thr Asp Lys Met Thr <210> 100 <211> 86 <212> PRT
<213> Homo Sapiens <400> 100 Met Phe Arg Phe Leu Leu Ile Trp Leu Gln Leu Thr Ser Arg Leu Phe Ser His Arg Phe Leu Ala His Met Leu Lys Gly Tyr Ala His Leu Gln Lys Arg Met Cys Phe Lys Ser Pro Leu Gly Gln Ala Leu Cys Ser Leu Ala Ser Ser Ser Leu Thr Gln Asp Leu Phe Lys Glu Lys Lys Lys Lys Thr Trp Ser Leu Lys Pro Arg Ile Asn Ser Ser His Leu Gly Glu Pro 65 70 75 gp Ala Asp Thr Tyr Ser Leu <210> 101 <211> 86 <212> PRT
<213> Homo Sapiens <400> 101 Met Asp Phe Asn Gly Leu Leu Asp Cys Met Leu Val Gln Phe Phe Asp Leu Glu Pro Ser Phe Leu Phe Leu Leu Phe Trp Glu Leu Tyr Cys Val Cys Cys Gly Met Phe Thr His Thr Ser Cys Cys Leu Gly Phe Leu Gln Val Val Cys Val Phe Tyr Leu Pro Leu Leu Ala Phe Arg Cys Leu Glu Ser Met Thr Leu Ala Tyr Ser Ser Val Tyr Ser Arg Arg Pro Cys Leu Phe Leu Ala Phe Ile Lys 7$

Claims (71)

What is claimed is:
1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:1;

(b) the nucleotide sequence of SEQ ID NO:1 from nucleotide 737 to nucleotide 5302;

(c) the nucleotide sequence of SEQ ID NO:1 from nucleotide 782 to nucleotide 5302;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vb24_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vb24_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:2;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:1.
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:

(a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2;
and (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. An isolated polynucleotide encoding the protein of claim 6.
8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 361.
9. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and (c) the amino acid sequence encoded by the cDNA insert of clone vb24_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:3;

(b) the nucleotide sequence of SEQ ID NO:3 from nucleotide 60 to nucleotide 1130;

(c) the nucleotide sequence of SEQ ID NO:3 from nucleotide 156 to nucleotide 1130;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc64_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc64_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to anyone of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:3.
13. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and (c) the amino acid sequence encoded by the cDNA insert of clone vc64_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
14. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:5;

(b) the nucleotide sequence of SEQ ID NO:5 from nucleotide 195 to nucleotide 1298;

(c) the nucleotide sequence of SEQ ID NO:5 from nucleotide 333 to nucleotide 1298;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vp20_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp20_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vp20_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp20_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:5.
15. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:6;

(b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and (c) the amino acid sequence encoded by the cDNA insert of clone vp20_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
16. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:7;

(b) the nucleotide sequence of SEQ ID NO:7 from nucleotide 129 to nucleotide 731;

(c) the nucleotide sequence of SEQ ID NO:7 from nucleotide 186 to nucleotide 731;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq4_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq4_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq4_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq4_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:7.
17. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:8;

(b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and (c) the amino acid sequence encoded by the cDNA insert of clone vq4_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
18. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:9;

(b) the nucleotide sequence of SEQ ID NO:9 from nucleotide 143 to nucleotide 571;

(c) the nucleotide sequence of SEQ ID NO:9 from nucleotide 221 to nucleotide 571;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo7_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo7_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo7_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the eDNA insert of clone vo7_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:9.
19. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:10;

(b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and (c) the amino acid sequence encoded by the cDNA insert of clone vo7_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
20. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:11;

(b) the nucleotide sequence of SEQ ID NO:11 from nucleotide 112 to nucleotide 570;

(c) the nucleotide sequence of SEQ ID NO:11 from nucleotide 190 to nucleotide 570;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc65_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc65_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc65_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc65_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:11.
21. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:12;

(b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and (c) the amino acid sequence encoded by the cDNA insert of clone vc65_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:13;

(b) the nucleotide sequence of SEQ ID NO:13 from nucleotide 4 to nucleotide 261;

(c) the nucleotide sequence of SEQ ID NO:13 from nucleotide 124 to nucleotide 261;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc66_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc66_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc66_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc66_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:13.
23. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:14;

(b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and (c) the amino acid sequence encoded by the cDNA insert of clone vc66_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
24. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:15;

(b) the nucleotide sequence of SEQ ID NO:15 from nucleotide 135 to nucleotide 1227;

(c) the nucleotide sequence of SEQ ID NO:15 from nucleotide 216 to nucleotide 1227;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc68_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc68_1 deposited with the ATCC under accession number 361;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc68_1 deposited with the ATCC under accession number 361;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc68_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:15.
25. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:16;

(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and (c) the amino acid sequence encoded by the cDNA insert of clone vc68_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
26. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:17;

(b) the nucleotide sequence of SEQ ID NO:17 from nucleotide 79 to nucleotide 2424;

(c) the nucleotide sequence of SEQ ID NO:17 from nucleotide 145 to nucleotide 2424;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vk6_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vk6_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vk6_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vk6_1 deposited with the ATCC under accession number 361;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:17.
27. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:18;
(b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and (c) the amino acid sequence encoded by the cDNA insert of clone vk6_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
28. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:19;
(b) the nucleotide sequence of SEQ ID NO:19 from nucleotide 2 to nucleotide 733;
(c) the nucleotide sequence of SEQ ID NO:19 from nucleotide 71 to nucleotide 733;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo4_1 deposited with the ATCC under accession number 361;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo4_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo4_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo4_1 deposited with the ATCC under accession number 361;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:19.
29. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:20;

(b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and (c) the amino acid sequence encoded by the cDNA insert of clone vo4_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
30. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:21;
(b) the nucleotide sequence of SEQ ID NO:21 from nucleotide 151 to nucleotide 1323;
(c) the nucleotide sequence of SEQ ID NO:21 from nucleotide 217 to nucleotide 1323;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo8_1 deposited with the ATCC under accession number 361;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo8_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo8_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo8_1 deposited with the ATCC under accession number 361;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:22;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:21.
31. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:22;
(b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and (c) the amino acid sequence encoded by the cDNA insert of clone vo8_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
32. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:23;
(b) the nucleotide sequence of SEQ ID NO:23 from nucleotide 134 to nucleotide 613;
(c) the nucleotide sequence of SEQ ID NO:23 from nucleotide 215 to nucleotide 613;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo10_1 deposited with the ATCC under accession number 361;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo10_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo10_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo10_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:23.
33. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:24;
(b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and (c) the amino acid sequence encoded by the cDNA insert of clone vo10_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
34. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:25;
(b) the nucleotide sequence of SEQ ID NO:25 from nucleotide 102 to nucleotide 1163;
(c) the nucleotide sequence of SEQ ID NO:25 from nucleotide 156 to nucleotide 1163;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo20_1 deposited with the ATCC under accession number 361;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo20_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo20_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo20_1 deposited with the ATCC under accession number 361;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:26;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:25.
35. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:26;
(b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and (c) the amino acid sequence encoded by the cDNA insert of clone vo20_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
36. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:27;
(b) the nucleotide sequence of SEQ ID NO:27 from nucleotide 67 to nucleotide 702;
(c) the nucleotide sequence of SEQ ID NO:27 from nucleotide 157 to nucleotide 702;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo21_1 deposited with the ATCC under accession number 361;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo21_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo21_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo21_1 deposited with the ATCC under accession number 361;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:27.
37. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:28;

(b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and (c) the amino acid sequence encoded by the cDNA insert of clone vo21_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
38. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:29;
(b) the nucleotide sequence of SEQ ID NO:29 from nucleotide 57 to nucleotide 272;
(c) the nucleotide sequence of SEQ ID NO:29 from nucleotide 114 to nucleotide 272;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vp24_1 deposited with the ATCC under accession number 361;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp24_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vp24_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp24_1 deposited with the ATCC under accession number 361;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:30;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:29.
39. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:30;
(b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and (c) the amino acid sequence encoded by the cDNA insert of clone vp24_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
40. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:31;
(b) the nucleotide sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 757;
(c) the nucleotide sequence of SEQ ID NO:31 from nucleotide 137 to nucleotide 757;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo17_1 deposited with the ATCC under accession number 361;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo17_1 deposited with the ATCC under accession number 361;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo17_1 deposited with the ATCC under accession number 361;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo17_1 deposited with the ATCC under accession number 361;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:32;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:31.
41. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:32;
(b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and (c) the amino acid sequence encoded by the cDNA insert of clone vo17_1 deposited with the ATCC under accession number 361;
the protein being substantially free from other mammalian proteins.
42. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:33;
(b) the nucleotide sequence of SEQ ID NO:33 from nucleotide 93 to nucleotide 263;
(c) the nucleotide sequence of SEQ ID NO:33 from nucleotide 174 to nucleotide 263;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq11_1 deposited with the ATCC under accession number PTA-367;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq11_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq11_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq11_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:34;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:33.
43. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:34;
(b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and (c) the amino acid sequence encoded by the cDNA insert of clone vq11_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
44. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:35;
(b) the nucleotide sequence of SEQ ID NO:35 from nucleotide 43 to nucleotide 1125;
(c) the nucleotide sequence of SEQ ID NO:35 from nucleotide 85 to nucleotide 1125;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq12_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq12_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq12_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq12_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO0:36;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:35.
45. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:36;

(b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and (c) the amino acid sequence encoded by the cDNA insert of clone vq12_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
46. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:37;
(b) the nucleotide sequence of SEQ ID NO:37 from nucleotide 32 to nucleotide 904;
(c) the nucleotide sequence of SEQ ID NO:37 from nucleotide 77 to nucleotide 904;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq14_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq14_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq14_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq14_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:38;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;
(j) the nucleotide sequence of. a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:37.
47. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:38;
(b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and (c) the amino acid sequence encoded by the cDNA insert of clone vq14_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
48. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:39;
(b) the nucleotide sequence of SEQ ID NO:39 from nucleotide 384 to nucleotide 1193;
(c) the nucleotide sequence of SEQ ID NO:39 from nucleotide 642 to nucleotide 1193;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq15_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq15_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq15_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq15_1 deposited with the ATCC under accession number PTA-367;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:40;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:39.
49. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:40;
(b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and (c) the amino acid sequence encoded by the cDNA insert of clone vq15_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
50. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:41;
(b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 132 to nucleotide 503;
(c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 189 to nucleotide 503;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq17_1 deposited with the ATCC under accession number PTA-367;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq17_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq17_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq17_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:41.
51. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:42;
(b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and (c) the amino acid sequence encoded by the cDNA insert of clone vq17_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
52. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:43;
(b) the nucleotide sequence of SEQ ID NO:43 from nucleotide 69 to nucleotide 401;
(c) the nucleotide sequence of SEQ ID NO:43 from nucleotide 138 to nucleotide 401;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq18_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq18_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq18_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq18_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:44;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:43.
53. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:44;

(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and (c) the amino acid sequence encoded by the cDNA insert of clone vq18_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
54. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:45;
(b) the nucleotide sequence of SEQ ID NO:45 from nucleotide 65 to nucleotide 1180;
(c) the nucleotide sequence of SEQ ID NO:45 from nucleotide 149 to nucleotide 1180;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq22_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq22_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq22_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq22_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:46;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:45.
55. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:46;
(b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and (c) the amino acid sequence encoded by the cDNA insert of clone vq22_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
56. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:47;
(b) the nucleotide sequence of SEQ ID NO:47 from nucleotide 18 to nucleotide 1409;
(c) the nucleotide sequence of SEQ ID NO:47 from nucleotide 60 to nucleotide 1409;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vr3_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vr3_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:48;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:47.
57. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:48;
(b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and (c) the amino acid sequence encoded by the cDNA insert of clone vr3_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
58. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:49;
(b) the nucleotide sequence of SEQ ID NO:49 from nucleotide 690 to nucleotide 2570;
(c) the nucleotide sequence of SEQ ID NO:49 from nucleotide 765 to nucleotide 2570;
(d) the nucleotide sequence of SEQ ID NO:49 from nucleotide 1286 to nucleotide 2895;

(e) the nucleotide sequence of the full-length protein coding sequence of clone vb26_1 deposited with the ATCC under accession number PTA-367;
(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb26_1 deposited with the ATCC under accession number PTA-367;
(g) the nucleotide sequence of a mature protein coding sequence of clone vb26_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb26_1 deposited with the ATCC under accession number PTA-367;
(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:50;
(j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;
(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h);
and (1) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:49.
59. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:50;
(b) the amino acid sequence of SEQ ID NO:50 from amino acid 200 to amino acid 627;
(c) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and (d) the amino acid sequence encoded by the cDNA insert of clone vb26_1 deposited with the ATCC under accession number PTA-367;

the protein being substantially free from other mammalian proteins.
60. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:51;
(b) the nucleotide sequence of SEQ ID NO:51 from nucleotide 105 to nucleotide 1724;
(c) the nucleotide sequence of SEQ ID NO:51 from nucleotide 186 to nucleotide 1724;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc70_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc70_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc70_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc70_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:52;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50°lo formamide, to any one of the polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:51.
220 31. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:52;
(b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and (c) the amino acid sequence encoded by the cDNA insert of clone vc70_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
62. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:53;
(b) the nucleotide sequence of SEQ ID NO:53 from nucleotide 3 to nucleotide 239;
(c) the nucleotide sequence of the full-length protein coding sequence of clone vo28_1 deposited with the ATCC under accession number PTA-367;
(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo28_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:54;
(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;
(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d);
and (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:53.
63. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:54;
(b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and (c) the amino acid sequence encoded by the cDNA insert of clone vo28_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
64. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:55;
(b) the nucleotide sequence of SEQ ID NO:55 from nucleotide 49 to nucleotide 1452;
(c) the nucleotide sequence of SEQ ID NO:55 from nucleotide 109 to nucleotide 1452;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo29_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo29_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo29_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo29_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:56;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:55.
65. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:56;
(b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and (c) the amino acid sequence encoded by the cDNA insert of clone vo29_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
66. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:57;
(b) the nucleotide sequence of SEQ ID NO:57 from nucleotide 48 to nucleotide 866;
(c) the nucleotide sequence of SEQ ID NO:57 from nucleotide 114 to nucleotide 866;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vo30_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vo30_1 deposited with the ATCC under accession number PTA-367;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:58;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:57.
67. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:58;
(b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and (c) the amino acid sequence encoded by the cDNA insert of clone vo30_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
68. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:59;
(b) the nucleotide sequence of SEQ ID NO:59 from nucleotide 235 to nucleotide 510;
(c) the nucleotide sequence of SEQ ID NO:59 from nucleotide 316 to nucleotide 510;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vp25_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA-367;
the nucleotide sequence of a mature protein coding sequence of clone vp25_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:60;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:59.
69. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:60;
(b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and (c) the amino acid sequence encoded by the cDNA insert of clone vp25_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
70. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:61;
(b) the nucleotide sequence of SEQ ID NO:61 from nucleotide 177 to nucleotide 1626;
(c) the nucleotide sequence of SEQ ID NO:61 from nucleotide 219 to nucleotide 1626;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vq25_1 deposited with the ATCC under accession number PTA-367;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq25_1 deposited with the ATCC under accession number PTA-367;
(f) the nucleotide sequence of a mature protein coding sequence of clone vq25_1 deposited with the ATCC under accession number PTA-367;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq25_1 deposited with the ATCC under accession number PTA-367;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:62;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:61.
71. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:62;
(b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and (c) the amino acid sequence encoded by the cDNA insert of clone vq25_1 deposited with the ATCC under accession number PTA-367;
the protein being substantially free from other mammalian proteins.
CA002362538A 1999-02-19 2000-02-18 Secreted proteins and polynucleotides encoding them Abandoned CA2362538A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US12068099P 1999-02-19 1999-02-19
US29873399A 1999-04-23 1999-04-23
US14963999P 1999-08-17 1999-08-17
US15568699P 1999-09-23 1999-09-23
US15724799P 1999-10-01 1999-10-01
US16782399P 1999-11-29 1999-11-29
US16782299P 1999-11-29 1999-11-29
US18271100P 2000-02-15 2000-02-15
US60/182,711 2000-02-15
US60/167,822 2000-02-15
US09/298,733 2000-02-15
US60/167,823 2000-02-15
US60/149,639 2000-02-15
US60/120,680 2000-02-15
US60/157,247 2000-02-15
US60/155,686 2000-02-15
PCT/US2000/004340 WO2000049134A1 (en) 1999-02-19 2000-02-18 Secreted proteins and polynucleotides encoding them

Publications (1)

Publication Number Publication Date
CA2362538A1 true CA2362538A1 (en) 2000-08-24

Family

ID=27574855

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362538A Abandoned CA2362538A1 (en) 1999-02-19 2000-02-18 Secreted proteins and polynucleotides encoding them

Country Status (4)

Country Link
EP (1) EP1153121A2 (en)
JP (1) JP2002536973A (en)
AU (1) AU2883500A (en)
CA (1) CA2362538A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112662644B (en) * 2021-01-19 2022-04-22 华南理工大学 Diglycerol phosphate phosphodiesterase mutant and application thereof
CN117106627B (en) * 2023-07-05 2024-01-30 中国水产科学研究院珠江水产研究所 Bacillus subtilis and breeding method and application thereof

Also Published As

Publication number Publication date
AU2883500A (en) 2000-09-04
EP1153121A2 (en) 2001-11-14
JP2002536973A (en) 2002-11-05

Similar Documents

Publication Publication Date Title
US20020193567A1 (en) Secreted proteins and polynucleotides encoding them
CA2340616A1 (en) Secreted proteins and polynucleotides encoding them
WO1998017687A2 (en) Secreted proteins and polynucleotides encoding them
US5965397A (en) Secreted proteins and polynucleotides encoding them
US7344861B2 (en) Secreted proteins and polynucleotides encoding them
US20020065394A1 (en) Secreted proteins and polynucleotides encoding them
WO1998055614A2 (en) Secreted proteins and polynucleotides encoding them
WO1998040486A2 (en) Secreted proteins and polynucleotides encoding them
US6312921B1 (en) Secreted proteins and polynucleotides encoding them
CA2306457A1 (en) Secreted proteins and polynucleotides encoding them
CA2328489A1 (en) Secreted proteins and polynucleotides encoding them
WO1998046757A2 (en) Secreted proteins and polynucleotides encoding them
CA2327551A1 (en) Secreted proteins and polynucleotides encoding them
CA2324492A1 (en) Secreted proteins and polynucleotides encoding them
EP0971950A2 (en) Secreted proteins and polynucleotides encoding them
US6706869B1 (en) Map kinase phosphatases and polynucleotides encoding them
WO1998040404A2 (en) Secreted proteins and polynucleotides encoding them
CA2362538A1 (en) Secreted proteins and polynucleotides encoding them
CA2322732A1 (en) Secreted proteins and polynucleotides encoding them
CA2311683A1 (en) Secreted proteins and polynucleotides encoding them
EP0996721A2 (en) Secreted proteins and polynucleotides encoding them
CA2309782A1 (en) Secreted proteins and polynucleotides encoding them
CA2281015A1 (en) Secreted proteins and polynucleotides encoding them
EP0948620A2 (en) Secreted proteins and polynucleotides encoding them
WO1998031802A2 (en) Secreted proteins and polynucleotides encoding them

Legal Events

Date Code Title Description
FZDE Discontinued